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ABSTRACT	  	  
Sixty-eight percent of human solid tumors are aneuploid, which is classically associated 
with poor patient prognosis. Several mouse models disturbing the spindle assembly 
checkpoint (SAC) have been developed to study the consequences of chromosome 
instability (CIN) and aneuploidy in vivo. Current knowledge suggests that aneuploidy 
can promote tumorigenesis or act as a tumor suppressor.  
Mad2 is found over-expressed in human tumors, and Mad2 over-expression in mice 
induces the development of aneuploid tumors and facilitates KrasG12D lung tumor 
relapse. A proposed mechanism of tumor acceleration by CIN is the facilitation of 
tumor suppressor loss of heterozygosity. In how far Mad2 over-expression influences 
Kras driven lung tumorigenesis in a p53 heterozygous background, remains hitherto 
unclear. 
In this thesis, I show that Mad2 over-expression increases p53(+/–);KrasG12D mice 
survival by delaying tumor initiation and progression. Different tumor populations 
(expressing low, intermediate and high levels of Mad2) have co-evolved from an 
original population of Mad2-expressing type 2 pneumocytes. My data suggest that high 
Mad2-expressing lung nodules are selected against during early tumorigenesis and are 
mainly composed of instable aneuploid cells.  
Using time-lapse microscopy on mouse embryonic fibroblasts, I analyzed the effect of 
Mad2 over-expression in the context of p53 heterozygosity. Upon Mad2 over-
expression, the inactivation of one copy of p53 rescued mitotic cell death by inducing 
mitotic slippage and polyploid cells. 
In vivo, high Mad2 levels impaired S phase entry in tumor cells. Moreover, p53(+/–
)KM high nodules strongly induced p21 in a p53-dependent manner. This data suggests 
that one copy of p53 can induce G1 cell cycle arrest in tumors. Although Mad2 over-
expression generates aneuploidy, it does not accelerate p53 loss of heterozygosity 
(LOH), since Mad2 down-regulation occurs prior to LOH. Importantly, Mad2 over-
expression together with p53 heterozygosity also delayed EFGRL858R-induced lung 
cancer.  
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ZUSAMMENFASSUNG	  
Achtundsechzig Prozent aller soliden Tumoren enthalten einen abnormalen 
Chromosomensatz. Der Aneuploidie-Status eines Tumors korreliert in den meisten 
Fällen zudem mit schlechter Krankheitsprognose. Um die Folgen von chromosomaler 
Instabilität (CIN) und Aneuploidie in vivo zu untersuchen, wurden zahlreiche 
Mausmodelle auf der Basis eines veränderten Spindel-Kontrollpunktes entwickelt. Nach 
derzeitigem Wissensstand kann hier CIN sowohl tumorfördernd als auch 
tumorinhibierend wirken. Als Mechanismus für die Tumorstimulation wurde der  
Verlust von Heteroyzgotie eines Tumorsupressorgens wie beispielsweise TP53 durch 
unausgegliche Verteilung von Chromosomen vorgeschlagen. 
Die künstliche Überexpression von Mad2, einer zentralen Komponente des mitotischen 
Kontrollkomplexes, im Mausmodel führte zur Entstehung aneuploider Tumoren und 
verstärkte das Rezidiv KrasG12D verursachter Lungentumoren nach Onkogenentzug. 
Bislang ist jedoch nicht bekannt, inwiefern sich die Überexpression von Mad2 auf 
Tumorsuppressoren und die Tumorentwicklung im p53 heteroyzgoten Kontext 
auswirkt. 
In meinem Projekt habe ich einen positiven Effekt von Mad2 Überexpression auf das 
Überleben von p53(+/–);TetO-KrasG12D;CCSP-rtTA Mäusen aufgrund einer 
Verzögerung der Tumorentwicklung nachweisen können. Aus der ursprünglichen 
Population Mad2 überexprimierender Typ 2 Pneumozyten entwickelten sich 
verschiedene Subpopulationen mit unterschiedlichen Mad2 Leveln (hoch, mittel, 
niedrig). Tumorknoten mit hoher Mad2 Expression werden während der frühen Stadien 
der Tumorentwicklung gegenselektiert und bestehen aus instabilen aneuploiden Zellen. 
Mit Hilfe von Zeitraffer-Mikrokopie analysierte ich den Einfluss von Mad2 
Überexpression of embryonale Mausfibroblasten im p53 heterozygotem Hintergrund. 
Zusätzlich zur teilweisen Normalisierung der Mitosedauer, förderte die p53 
Heterozygotie hier das Entkommen aus dem mitotischen Zelltod durch sogenannte 
“mitotic slippage” und damit die Entstehung polypoider Zellen.  
In vivo Analysen zeigten, dass hohe Mad2 Level in Tumorzellen den Eintritt in die S-
Phase erschweren. Zudem induzierten p53(+/–)KM Knoten mit hohen Mad2 Level die 
Expression von p21, welche höchstwahrscheinlich auf die verbleibende Kopie von p53 
zurückzuführen ist. Eine Kopie von p53 kann somit zum G1-Arrest von Tumorzellen 
	   6	  
führen. Zusammenfassend führt Mad2 Überexpression somit zur Entstehung 
aneuploider Tumoren, fördert jedoch nicht den Verlust von p53 Heterozygotie, da die 
Herunterregulierung der Mad2 Expression dem zuvorkommt. Eine Verzögerung der 
Tumorentwicklung konnte zudem im Model von EGFRL858R-induzierten Lungenkrebs 
beobachtet werden. 
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1	  INTRODUCTION	  	  
1.1	  BRIEF 	  HISTORY	  OF	  CANCER	  
 Cancer is a phenomenon that results in a large group of diseases, which begins in the 
smallest unit of living systems: the cell. It relies on uncontrolled cellular growth and 
ultimately kills the organism. Cancer occurred before modern humans appeared on the 
earth; in fact, metastatic cancer has been found in the fossilized bone of a Jurassic 
dinosaur (Rothschild et al., 1999). Although it was not named at the time, evidence of 
cancer has been found in mummies and the first description of cancer appeared in an 
Egyptian papyrus (Breasted and New York, 1930). The Greek physician Hippocrates 
(460-375 BC) gave the disease the term “karkinos”, which later was translated to 
“cancer” in Latin, by the Roman physician Celsus (25 BC-50 AD). The Greek physician 
Galen (130-200 AD) proposed the term “oncos”, which is still used by specialists today. 
At that time, surgeries already existed for the treatment of cancer and methods 
continually improved over time (Hajdu, 2011).  
Christopher Columbus (1451–1506) introduced tobacco leaves in Europe and, thus, 
introduced the smoking habit to the Western world. By the end of the 16th century, the 
consumption of tobacco was common among celebrities and several cases of tobacco-
induced cancer were reported (Hajdu and Vadmal, 2010). Johannes Muller drew for the 
first time cancer cells (Muller, 1838) and Herman Lebert postulated that enlarged nuclei 
and poly-nucleation are hallmarks of malignant cells (Lebert, 1845). In 1895, Wilhelm 
C. Rontgen discovered the X-ray, which was immediately used for cancer diagnostics. 
At a later stage, the tumor-suppressing effects of X-rays were employed in radiation 
therapies. Further development included the use of radium based on the discovery of 
radioactivity by Antoine H. Becquerel and by Pierre and Marie Curie (Hajdu, 2012). 
Another finding of the 19th century was the link between hormones and cancer, which is 
now utilized in hormonal therapies (Hajdu, 2012). In 1914, Theodor Boveri 
demonstrated that mutations can lead to cancer and postulated that cancer cells may 
arise from single cells with abnormal chromosome content (Boveri, 1914).  
In the 1930s and 1940s, the establishment of in vitro cancer cell culture and animal 
experimentations stimulated the search for carcinogens (Hajdu and Darvishian, 2013). 
Otto H. Warburg discovered that cancer cells have a different metabolism, with high 
glucose consumption (Warburg, 1956), a property that is now used for cancer 
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diagnostics (PET scan) (Hajdu and Darvishian, 2013). In terms of the background of the 
discovery of the structure of DNA (Watson and Crick, 1953), Renato Dulbecco, 
Howard M. Temin and David Baltimore discovered the interaction between tumorigenic 
viruses and the genetic content of a cell (Baltimore, 1970; Dulbecco, 1967; Temin and 
Mizutani, 1970). In 1951, researchers grew for the first time neoplastic cells of a unique 
human cancer, adenocarcinoma of the uterine cervix (Gey GO, 1952); 64 years later, 
the HeLa cells are still used in laboratories (Landry et al., 2013). In 1966, the first case 
of familial cancer (Lynch syndrome) was reported, and this highlighted the importance 
of heredity in cancer development (Lynch et al., 1966). In the 60s, Sidney Farber 
launched the modern use of chemotherapy by developing the first national cancer 
chemotherapy protocols.  
In the 70s, Bishop and Varmus discovered that the retroviral proto-oncogene had a 
cellular origin, and when re-introduced in a cell would act as an oncogene, giving rise to 
tumors (Stehelin et al., 1976). In the 80s, Weinberg isolated the first human oncogene 
ras and tumor suppressor Rb (Der et al., 1982; Dryja et al., 1986). A study suggested 
that genes required the modification of both alleles to extinguish the tumor-suppressive 
function (Knudson, 1971). However, mutation in one tumor’s suppressor allele, such as 
p53, can be sufficient to drive tumorigenesis (Li and Fraumeni, 1969). Similar to proto-
oncogenes, the genetic mutation occurring in one of the alleles produces dominant 
proteins (Dittmer et al., 1993). Nowell introduced “the tumor stage” concept; 
specifically, in the first stage cells would proliferate without control allowing, in a 
second stage, additional mutations and subsequently the selection of tumor cells. In 
addition, he speculated that genomic instability could fuel the generation of variants 
with a growth advantage (Nowell, 1976). A study proposed that at least five mutational 
hits are required for the stepwise clone selection responsible for malignant tumor 
progression (Fearon and Vogelstein, 1990).  
The improved understanding of tumor biology and the identification of oncogenes 
led to targeted therapies. To gain access to oxygen and nutrients, tumors create new 
blood vessels; the 70s concept of blocking angiogenesis is now being used in clinics 
(Kerbel and Folkman, 2002). In some cases, the over-activated growth signaling is the 
target of novel drugs (Lynch et al., 2004). Studies on transmissible cancers suggest that 
cancer can break free and metastasize in other organisms; for example, a facial cancer 
appeared on a female Tasmanian devil about 20 years ago. The now-evolved clone 
	   12	  
populations keep hopping from one individual to another through bite-mediated cell 
inoculation (Murchison et al., 2012). Other transmissible cancers in the animal kingdom 
are the canine transmissible venereal tumor via copulation (Murgia et al., 2006) and the 
contagious reticulum cell sarcoma in the Syrian Hamster via mosquito bite (Banfield et 
al., 1965). In the future, a novel transmissible cancer might even appear in humans. In 
fact, this has already been observed following accidental inoculation by medical 
professionals (Gartner et al., 1996). 
Nowadays, cancer is a leading cause of death worldwide, with 8.2 million deaths in 
2012, and the global burden of cancer is expected to further increase during the next 
twenty years. In the last report by the World Health Organization (WHO), lung cancer 
was listed as the most diagnosed cancer type, accounting for 13% of new cases. This 
fact is not surprising considering that tobacco use is responsible for 22% of cancer 
deaths (Stewart et al., 2014). Furthermore, the increasing incidence with age and the 
impact of cancers due to environmental and social influences made it the most prevalent 
disease in developed countries (Stewart et al., 2014).  The world population is growing 
along with the adoption of cancer-causing behaviors (Jemal et al., 2011).  In 2010, the 
costs of cancer care in the United States were estimated at $124.57 billion, and the total 
cost in 2020 is projected to be $173 billion, a dramatic 39% increase in 10 years 
(Mariotto et al., 2011).  
1.2	  HALLMARKS	  OF	  CANCER	  
Scientists Hanahan and Weinberg have simplified knowledge on cancer biology. 
Their description of tumorigenesis as a stepwise progression of genetic changes leading 
to the consequent events of immortalization, malignant progression and metastasis 
became one of the most cited and known theories in the field of cancer (Hanahan and 
Weinberg, 2000). Like in Darwinian evolution, cells through multiple rounds of 
mutation will be selected for growth and will ultimately generate tumors. In this 
context, six hallmarks of cancer cells were identified: 
- Self-sufficiency in growth signal. In adult physiological tissues, most cells are 
quiescent. Under certain circumstances, they receive external signals such as growth 
factors that instruct them to re-enter the cell cycle and divide. A cell receives signals via 
their trans-membrane receptors that transduce the message into the cell and activate 
down-stream signaling pathways, most of the time by the action of kinases and 
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phosphorylation. To reduce this dependency, the cancer cells can modulate these 
signals. Cancer cells can produce their own ligands, stimulating autocrine feedback 
loops. In addition, cells can increase the amount of receptors, hence its chance of 
activation. An alternative is to produce a constitutive active form of the receptor or its 
down-stream effectors. 
- Insensitivity to anti-growth signal. Similar to the growth, the anti-growth signals are 
transduced from the outside to the inside of the cells via trans-membrane receptors and 
down-stream effectors. As a result, the cell can exit the cell cycle and enter the 
quiescent state or acquire a differentiated state. Cancer cells have many ways to impair 
anti-growth signals such as, for example, the inactivation of the retinoblastoma (Rb) 
protein (Dryja et al., 1986). The tumor suppressor Rb can sequester the E2F 
transcription factors, which become incapable of launching the production of proteins 
required for the transition from G1 to S.  
- Evading apoptosis. The homeostasis of tissues is normally regulated by proliferation 
and apoptosis. Apoptosis is a form of programmed cell death through the equilibrium of 
anti-apoptotic and pro-apoptotic proteins within the mitochondria. Molecular sensors 
can detect triggers such as DNA damage or hypoxia and, in response, activate molecular 
effectors that lead to apoptosis. The action of the pro-apoptotic proteins (Bax, Bak, 
Bim, Bid) within the mitochondria leads to the release of Cytochrome C, which 
activates caspases that destroy the genome and cellular organelles. The phenomenon is 
characterized by morphologic changes such as cellular blebbing, nuclear fragmentation, 
chromatin condensation and DNA fragmentation.  Professional phagocytic cells 
complete the elimination of the cell from the tissues. A common way of perturbing this 
process is the mutation of the TP53 gene; p53 acts as a DNA damage sensor and 
regulator of pro-apoptotic proteins. 
- Limitless replicative potential. In addition to the external signals, cells have an 
internal clock that limits their proliferation. The telomeres are located at the end of the 
chromosomes and during every S phase of the cell cycle they are shortened. When 
chromosomes become unprotected, cells die or enter a state of senescence. The main 
mechanism by which a tumor cell avoids the replicative limit is by over-expressing the 
enzyme telomerase, which is capable of increasing the length of telomeres.  
- Sustained angiogenesis. A possible limit for tumor growth would be the lack of 
oxygen and nutrient supply. The ability to generate and sustain new blood vessels is 
usually acquired at a later stage of tumorigenesis. To add to the complexity, many 
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different mechanisms promote angiogenesis. TP53 mutations are also implicated in this 
process by reducing the inhibitory signals for angiogenesis. 
- Tissue invasion and metastasis. Explorer cells that escape the primary tumor and 
travel to a new fertile tissue can initiate metastasis. Almost all fatal disease outcomes 
are attributed to metastatic cancer. When a cell finds itself in a new territory, it will 
resume all the previously described characteristics. The molecular processes leading to 
metastasis involve the deregulation of extracellular molecules required for cell-to-cell 
and extracellular matrix interactions. 
Ten years after the first publication of the hallmarks of cancer, the authors revisited the 
publication; they integrated the latest concepts and highlighted the importance of the 
tumor environment such as, for example, innate immunity. Two emerging and two 
enabling hallmarks were added to the previous list (Hanahan and Weinberg, 2011). 
- Deregulation cellular energetics. Tumors require many resources for their growth; to 
cope with their needs, tumor cells adjust their energy production. Healthy cells use 
aerobic metabolism: the glucose is transformed into pyruvate in the cytosol and further 
reactions requiring oxygen occur within the mitochondria. Cancer cells are able to 
increase their glucose intake and extensively use glycolysis, especially in the case of 
hypoxia. This phenomenon is known as the Warburg effect (see section 1.1). A possible 
reason for the metabolic switch is that in addition to providing energy, it also provides 
substrates for the synthesis of new cellular components.   
- Avoiding immune response. In an organism, the immune system is constantly 
monitoring and eliminating aberrant cells, blocking the generation of tumors. Thus, 
tumors must find a way to avoid this surveillance. It is possible that in the process of 
selection, only clones that do not trigger the immune system survive or that highly 
immunogenic cancer disables the hostile response.  
- Tumor promoting inflammation. Apart from the protective function of invading 
immune cells, the process of inflammation has also been linked to tumor enhancement. 
Cells involved in the inflammatory response involve macrophages, mast cells, 
neutrophils, and T and B cells. An example of the tumor promotion mechanism is the 
recruitment of inflammatory cells (co-expressing the macrophage marker Cd11b and the 
neutrophil marker Gr1), which are able to suppress the anti-tumoral activity of other 
immune cells (e.g. natural killer cells). 
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- Genome instability and mutation. In order to acquire the previously described 
hallmarks, tumor cells undergo a succession of mutations or genome modification. Like 
a cycle, every mutational step will confer a growth advantage to a cell that will 
ultimately give rise to tumors. Additionally, epigenetic changes can modify gene 
expression and be part of clone selection. The increased mutational potential of tumor 
cells is due to the dysfunction of proteins. As an example, the frequent p53 mutations 
increase the probability for more mutations. Functionalities such as detection and repair 
of DNA damage and mutagen neutralization are reduced. Alternatively, the loss of the 
protective telomeres at the chromosomal extremities can lead to chromosomal 
breakages and unstable karyotypes. Chromosomal instability is a form of genomic 
instability and will be introduced at a later stage (section 1.7). 
1.3	  LUNG	  CANCER	  
Lung cancer is the leading cause of cancer-induced death worldwide (Jemal et al., 
2011) and has a very low survival rate of five years (6.5-16% (Jemal et al., 2011)). It is 
known to be induced by smoking and predictions suggest that its incidence will increase 
(see section 1.1).	  Histologically, lung cancers have been classified into small-cell lung 
carcinoma (15%, SCLC) and the non-small-cell lung carcinoma (85%, NSCLC). The 
NSCLC are further separated into squamous cell carcinomas (SCC), large cell 
carcinomas and 55% are adenocarcinomas (Shames and Wistuba, 2014). The most 
common driving mutations include the proto-oncogene Kras mutated in about 20% of 
lung adenocarcinomas, and the oncogenic EGFR is present in 10%. Kras and EGFR 
mutations are mutually exclusive. Furthermore, the tumor suppressor p53 is mutated in 
50% of the adenocarcinomas (Chen et al., 2014; Imielinski et al., 2012).  
- EGFR: epidermal growth factor receptor. EGFR is a trans-membrane receptor 
(Figure 1.1). When activated by its ligand or constitutively activated in cancer, it 
induces proliferation via the RAS/MAPK, PI3K/AKT and STAT3/STAT5 signaling 
pathways. EGFR and its ligands can either be over-expressed in NSCLC or the kinase 
domain is over-activated. Kinase over-activation can be the result of the deletion of 
exon 19 or by a point mutation in the exon 21, L858R (Lynch et al., 2004). Because of 
its importance in lung cancer and its extracellular localization, targeted therapies 
affecting EGFR were developed and have been proven effective in patients (Pao et al., 
2004). Unfortunately, secondary mutation of EGFR confers treatment resistance.  
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- Kras. Ras proteins are small GTPases downstream of EGFR (Figure 1.1), and are part 
of the Ras/MAPK signaling pathway that transduces proliferative signals from the 
extracellular environment to the nucleus. Ras is one of the first discovered oncogenes 
(Pulciani et al., 1982) and the most common in lung adenocarcinomas (Mills et al., 
1995). The Ras genes codes for different splicing variants:  Nras, Hras, and Kras, which 
interact with similar down-stream effectors but differ in their post-transcriptional 
modifications. The mutated Ras variants appear be tumors specific and Kras mutations 
are predominant in NSCLC. Genetic mutations can be found in codon 12: G12D, G12C 
and G12V, or, in codon 13 and 21. These genetic mutations lead to the constitutive 
activation of GTPase and they are no therapy targeting Ras mutations. 
- P53. I would like to start this part with the following citation: “I worry a lot about p53. 
I’m paid to do it, but perhaps we all should, as the correct functioning of this 393 amino 
acid nuclear protein is apparently all that lies between us and an early death from 
cancer” (Lane, 1992). P53 is known as the guardian of the genome (Lane, 1992) and 
functions as a transcription factor after homo-tetramerization. p53 regulates the cell 
cycle and induces G1 arrest upon DNA damage (Kastan et al., 1992). Furthermore, p53 
regulates apoptosis, and acts as a backup for Rb inactivation (Morgenbesser et al., 
1994). At the beginning of the 80s, p53 was mistaken for an oncogene because of its 
promotion of cellular transformation (Parada et al., 1984). When the first mutations in 
the p53 gene were discovered, research on the topic became popular (Koshland, 1993). 
To date, over 20.000 mutations of p53 have been reported, of which very few lead to 
p53 disappearance. Most genetic alterations of the p53 gene are missense mutations, 
leading to the production of a stable protein with an inactive DNA-binding site and to 
its accumulation in the nucleus. From the mutated gene, the dominant-negative p53 
protein can form hetero-dimers with the wild-type p53 produced by the remaining allele 
and impairs transactivation and cell cycle and apoptosis control (Soussi and Beroud, 
2001). Moreover, some mutations can lead to a gain of function (Dittmer et al., 1993).  
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Figure 1.1: Frequent mutations in NSCLC.  The binding of the ligands (L) to the EGFR 
receptor leads to a conformational change of the receptor and its dimerization, preceding the 
trans-activation of the tyrosine kinase domain by trans-phosphorylation. The activated receptor 
initiates a signaling cascade including the PI3K/AKT (green), the STAT (pink) pathways and 
the Ras/Raf/MAPK pathway (blue) orchestrated by the ras GTPase (blue and yellow) and a 
series of phosphorylations. The cascades lead to genes transcription regulating proliferation, 
cell survival and angiogenesis.  In lung cancer, the EGFR receptor and its ligand can be 
amplified increasing the chance for receptor dimerization. The EGFR receptor can be mutated 
and constitutively activated. This is also the case for the Ras GTPase. The transcription factor 
p53 (red) can regulate proliferation, cell survival and angiogenesis via regulation of its gene 
targets and it is mutated in cancer. Ligand is shown in orange, ATP in yellow, phosphorylation 
in green. A red star indicates tumorigenic action points. 
 
 
1.4	  MOUSE	  MODELS	  OF	  NSCLC	  	  
There is amplitude of mouse models and possible transgenic mouse crosses 
recapitulating human lung cancer. In this section, I will focus on a subset of relevant 
findings for this thesis.  
1.4.1	  FIRST-­‐GENERATION	  MOUSE 	  MODELS	  
Lung cancer modeling started with spontaneous tumors in specific inbred-mouse 
stains or via induction by carcinogens. The first generation of transgenic mouse models 
constitutively over-expressed transgenes: oncogenes or inactive tumor suppressors. In 
the lung, this was done using cell-type-specific promoters. Initially, the promoter of 
SPC (lung surfactant protein C) was used to initiate transgene expression in type II 
pneumocytes and CCSP (Clara cells secretory protein) in Clara cells. The two systems 
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induced similar lung tumors, though the CCSP promoter is being used extensively since 
it was actually found active in both cell types (Meuwissen and Berns, 2005).  
1.4.2	  SECOND-­‐GENERATION	  MOUSE 	  MODELS	  
The next generation of mouse models includes knock-in strategies; Kras being an 
important oncogene in NSCLC was induced at endogenous levels and successfully 
induced tumors. In fact, the expression at endogenous levels appeared more tumorigenic 
than Kras over-expression, though the tumors were not restricted to the lung in this 
model (Johnson et al., 2001). The knock-in Lox-Stop-Lox-KRASG12D model overcomes 
this issue. The tracheal delivery of a recombinant adenovirus expressing Cre 
recombinase removes the Stop codon; it induces the expression of Kras and lung 
adenocarcinomas (Jackson et al., 2001). In addition, many Cre recombinase-carrying 
lines have been created for the removal of Stop codons in a cell-type-specific manner. 
Moreover, Cre recombinase expression can be controlled in a timely manner using 
inducible systems such as the Cre-RT2, where DNA excision is only possible in the 
presence of Tamoxifen (Brocard et al., 1997).  
1.4.3	  TET-­‐ON	  SYSTEM	  
The Tet-On (Figure 1.2) and Tet-off bi-transgenic models allow transgene de-
induction (Gossen and Bujard, 1992). These systems consist of a first transgene where a 
tissue-specific promoter controls the expression of the tetracycline-controlled trans-
activator (tTA) or reverse tTA (rtTA). In the absence of the regulator doxycycline 
(Dox), tTA activates the transcription of the second transgene by binding the tetO 
repeats, which are cloned upstream of the gene of interest. In these cases, the delivery of 
doxycycline leads to repression of the trans-activator and the transgenic system. On the 
contrary, the rtTA, being a mutated form of tTA, requires doxycycline for the induction 
of one or several target genes. The Tet-On-oncogene, CCSP-rtTA, allows transgene 
induction and de-induction in a temporal manner in the type II pneumocyte specifically 
and recapitulates human lung adenocarcinomas. An additional asset of the Tet-On 
system is that Dox bound to rtTA can induce more than one transgene at a time in the 
cell type of interest. Thus, the Tet-On system reduces the number of transgenes required 
for multi-parameter study. The CCSP-rtTA, TetO-KrasG12D, and CCSP-rtTA, TetO-
EGFRL858R mouse lines successfully developed lung adenocarcinomas (Fisher et al., 
2001; Politi et al., 2006) when doxycycline was administered and will be used in this 
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thesis in combination with other mouse models (see section 1.8.3). 
1.4.4	  P53	  
Due to the extensive interest in the role of p53 (e.g. dominant negative, gain of 
function or loss) in tumorigenesis, many mouse models have been generated targeting 
p53 or its regulators. One of the first mouse models with deficient p53 was a knockout 
(KO). Homozygotic p53 mice showed a very fast onset of tumorigenesis. 
Heterozygosity on the other hand aided tumor development (Jacks et al., 1994). This 
mouse model has been extensively crossed with other over-expressing oncogenes 
(Fisher et al., 2001). In this thesis, in a similar way, I am using the p53KO model by 
combining the TetO-KrasG12D (Fisher et al., 2001) or TetO-EGFRL858R (Politi et al., 
2006) mouse models.  
At a later stage, more sophisticated models have been created such as the “super p53” 
mice. In this model, one additional allele of p53 is added. This extra p53 allele leads to 
a better response to stress (e.g. cell cycle arrest and apoptosis) and mice are protected 
against cancer (Garcia-Cao et al., 2002). A knock-in model replacing the wild-type p53 
by the R175H mutant found in human cancer has shown to be prone to fast tumor onset 
and metastasis (Liu et al., 2000). Further knock-in models with specific mutations in 
post-transcriptional modification sites, such as phosphorylation, do not generate 
spontaneous tumors (Chao et al., 2003; MacPherson et al., 2004). Liu et al. showed that 
the over-expression of p53 induces cell cycle arrest, but impairs apoptosis, and mice 
show a late tumor onset (Liu et al., 2004). 
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Figure 1.2: The tet-on system.  The tetracycline-controlled reverse-transactivator (rtTA) 
consists of a mutated chimeric construct of the Escherichia coli Tn10 tetR gene (blue) and the 
VP16 transactivation domain from the herpes simplex VP16 protein (purple). In the presence of 
the inducer, doxycycline (Dox, Green), rtTA dimers bind to seven tandem repeated tetO 
sequences (tetO7), thereby activating transcription from a minimal promoter (TATA) and 
simultaneously driving expression of transgenes of interest. The CCSP promoter produces rtTA 
in lung epithelial cells. pA: polyadenylation 
 
1.5	  EUKARYOTE	  CELL 	  CYCLE	  	  
1.5.1	  DEF IN IT IONS 	   	  
The cell cycle consists of the execution of consequent events in one cell resulting in 
the production of two daughter cells. Importantly, cell division has three purposes for an 
organism: reproduction, growth and maintenance. Deregulation of the cell cycle 
underpins the onset of cancer. 
The cell cycle is divided into four phases (Figure 1.3).  DNA replication occurs in 
the S phase. Segregation of the replicated genetic material occurs in mitosis (M phase), 
which is considered the end of the cell cycle. The Gap phases, G1 and G2, are before 
the S phase and the M phase, respectively. In contrast to mitosis, during the G1, S and 
G2 phases, the cell does not change its morphology. These three phases are also defined 
as interphase. The majority of cells in an adult organism is neither in mitosis nor in 
interphase, but is quiescent. Specialized cells are an exception to this rule and continue 
dividing throughout life to replace cells that have a high rate of turnover (e.g. gut 
epithelium, hematopoietic cells).  
In the late 80s, it was hypothesized that the events taking place in the cell cycle are 
connected; the cycle progression depends on the success of the previous phases 
(Hartwell and Weinert, 1989). Hartwell and Weinert introduced the concept of cell 
cycle checkpoints and demonstrated the existence of the DNA damage checkpoint in 
yeast (Hartwell and Weinert, 1989). The three eukaryotic cell cycle checkpoints 
maintain the integrity of the genome and viable nucleo-cytoplasmic ratio. The first 
checkpoint occurs in G1, the second in G2 and the last one during mitosis. During the 
G1 phase, a cell can commit to cell division or arrest and eventually leave the cell cycle. 
The restriction point, also called the G1 checkpoint, defines the time where the fate of 
the cell has been decided. To re-enter the cell cycle, a cell needs to receive sufficient 
growth signals between the previous cycle of mitosis and the restriction point. These 
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signals ensure the synthesis of the tools necessary for future DNA synthesis and S phase 
(Foster et al., 2010). Alternatively, the cell can enter a quiescent state when received 
signals are insufficient. The quiescent state is when a cell is not preparing to divide or 
dividing; it is also called Gap 0 (G0). The first purpose of quiescence is to support cell 
survival in extreme conditions such as nutrient deprivation, and its physiological role is 
to stop the growth of complex mammalian organisms (O'Farrell, 2011; Pardee, 1974). 
When triggered, most cells can re-enter the cell cycle in G1 and resume proliferation 
with the exception of terminally differentiated cells (cardiac muscle cells, neurons 
(Pardee, 1974)). This is in contrast with the term senescence, which defines the end of 
replicative life and a physiologically irreversible state. It is the final state of our 
molecular clock determined through the erosion of telomeres with each cellular division 
(Sedivy, 1998). The fact that MEFs harboring deletion of p53 and p21 can become 
immortal indicates that senescence can be reversible upon appropriate mutations (Deng 
et al., 1995; Jacks, 1996). During G2, the cell undergoes rapid growth, synthetizes 
proteins and prepares for the next phase of mitosis. The checkpoint at the G2/M 
transition, also known as the DNA damage checkpoint, ensures the repair of DNA 
damage experienced during the S phase prior to mitosis.  
1.5.2	  REGULATIONS 	   	  
The key components of the cell cycle are the cyclin-dependent kinases (CDKs) and 
their regulatory sub-units, the cyclins. In humans, twenty-nine cyclins have been 
identified from which nine appear to control the cell cycle. The CDKs are 
serine/threonine kinases and eleven out of the twenty members of the family have cell 
cycle-related activities (Malumbres, 2014). The CDKs can be regulated in three major 
ways. First, the fluctuation of cyclin gene expression and the degradation by the 
ubiquitin-mediated proteasome pathway induces oscillation in CDK activity. This 
oscillation regulates the transition of one phase to the next (Evans et al., 1983; Glotzer 
et al., 1991; Nurse, December 9,2001). Second, the activity of the CDKs can be 
enhanced by the CDK-activating kinase by phosphorylating the pre-formed CDK-cyclin 
complex (Pavletich, 1999). On the other hand, phosphorylation of the complexes can 
also have inhibitory effects. Third, proteins from the INK4a and Cip/Kip families (e.g 
p21) inhibit the CDKs. They bind the CDKs alone or those already in complexes with 
the cyclins (Harper et al., 1995; Malumbres, 2014; Pavletich, 1999). P21 is 
transcriptionally activated by p53 and can inhibit Cdk2, Cdk3, Cdk4, and Cdk6, and 
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increased levels of p21 induce G1 arrest (Harper et al., 1995).  Moreover, these 
regulated transductions are tightly controlled by feedback loops responsible for the 
stable phases of the cell cycle.  
 
Figure 1.3: Simple view of the cell cycle.  The cell cycle is composed of four phases: Gap 1 
(G1), S phase (DNA synthesis), Gap 2 (G2) and mitosis (in white). Together G1, S and G2 
constitute the interphase (in gray).  When the conditions are not favorable for cell division the 
cell can reversibly escape in Gap 0 (G0) and become quiescent. Three checkpoints control for 
the genome integrity and cellular growth (red boxes): G1, G2 and mitotic checkpoints. The cell 
cycle progression is due to the CDKs enzymatic activity; CDKs operate when bound to the 
cyclins.  The cyclins availability fluctuates during the cell cycle, hence the dominant complex 
forms. CDKs 4 and 6 are active when bound to cyclin D in G1. The CDK2-cyclin E complex 
controls the progression to the S phase. In S phase, cyclin A slowly replaces cyclin E and peaks 
in G2 to form the CDK1-cyclin A complex. The mitotic cyclin B binds to CDK1, the complex 
is called the mitosis-promoting factor (MPF). Its activity rises during the cell cycle and 
provokes entry into mitosis; the degradation of cyclin B is required for mitotic exit. The protein 
from the Cip family, p21 can directly (black line) inhibit CDK 2, 4 and 6 and produce a G1 
arrest. The CDK1-Cyclin A complex is indirectly (dashed line) inhibited by p21 and contributes 
to a G2 arrest. 
 
 
 
 	  
 
 
G0
G1
S
G2
Mitosis
Interphase
G1 
Checkpoint
G2/M 
Checkpoint 
Mitotic
Checkpoint
CDK4 Cyclin D
CDK6 Cyclin D
CDK2 Cyclin ECDK2 Cyclin A
CDK1 Cyclin A
CDK1 Cyclin B
p21
p21
p21p21
p21
	   23	  
1.6	  MITOSIS 	  AND	  THE	  SPINDLE	  ASSEMBLY	  CHECKPOINT	  
1.6.1	  MITOSIS 	  
Mitosis is the phase of the cell cycle in which the previously replicated chromosomes 
are equally separated in two nuclei, a process followed by cytokinesis, leading to the 
production of two generally identical daughter cells. Walther Flemming was the first to 
publish extensive work on the process that he called mitosis (Flemming, 1878). 
Altogether, mitosis is divided into five phases in animals, while plants have an 
additional sixth phase: in pre-prophase, the nuclei have to migrate to the cell center. The 
first phase is prophase: the previously replicated pairs of centrioles (centrosome) 
migrate at the opposite poles of the mother cell and form the spindle via elongation of 
microtubules from each pole of the cell. The previously replicated DNA condensates, 
sister chromatids are associated by cohesin at their centromeres (kinetochores) and the 
nuclear envelop dissolves. In metaphase, the duplicated chromosomes (sister 
chromatids) align at the equatorial or metaphase plate of the mother cell. The 
microtubules connect the kinetochores of the sister chromatids to opposite poles of the 
cell. In anaphase, the chromosomes have lost cohesion and are pulled by the 
microtubules to their respective poles. In telophase, the chromatin decondenses, the 
spindle disappears, the two nuclear envelops form and the physical cell division begins. 
Finally, in cytokinesis, the cytoplasm divides through a contracting ring at the midbody, 
forming the cleavage furrow, which divides two daughter cells, thus ending mitosis. 
The purpose of the mitotic checkpoint, or the spindle assembly checkpoint (SAC), is to 
ensure proper chromosome segregation during anaphase by preventing the premature 
separation of sister chromatids. 
1.6.2	  THE 	  SP INDLE 	  ASSEMBLY 	  CHECKPOINT 	  (SAC)	  D ISCOVERY 	   	  
The SAC is activated in pro-metaphase, it controls the alignment of chromosomes at 
the metaphase plate and proper attachment of the sister chromatids to the microtubules 
coming from opposite poles. The centromeric chromatin and the cohesins comprise the 
inner part of the kinetochores. The chromosome passenger complex is localized at the 
inner kinetochore in metaphase. It is composed of inner centromere protein (INCENP), 
Survivin, Borealin, and Aurora B. Aurora B oversees chromosome bi-orientation by 
ensuring the enzymatic function of the complex, which is responsible for the removal of 
improper microtubule-kinetochore attachments. At the outer part, there are, 
	   24	  
respectively, binding and docking sites for the microtubules and SAC members 
(Sullivan et al., 2001).  
Members of the SAC gene family were discovered in two screens in budding yeast 
for genes, which, when mutated, confer sensitivity to depolymerizing microtubule drugs 
(Hoyt et al., 1991; Li and Murray, 1991). Among the mitotic arrest-deficient genes are 
Mad1, Mad2, and Mad3 (BubR1 in humans). Mad2 was the first to be identified in 
humans (Li and Benezra, 1996). Budding inhibited by benzimidazole genes belong to 
Bub1 and Bub3. Bub2 was later excluded from SAC composition since it monitors the 
spindle position, not the interaction between microtubules and kinetochores (Bloecher et 
al., 2000). In addition, the SAC components were responsible for the delay of 
metaphase entry when the chromosomes have mutant centromeres (Spencer and Hieter, 
1992). The Mps1 kinase was identified in an experiment where mps1 mutants did not 
arrest mitosis upon spindle disruption (Weiss and Winey, 1996). Many more proteins 
were identified as part of the SAC gene family, for example Spc105, MIS12, HEC1, 
and MCM21, which bind to the outer kinetochores. The impairment of kinetochore 
assembly by acting on the microtubule motor protein CENP-E and dynein can activate 
the SAC.  
1.6.3	  THE 	  SAC	  MECHANISM	   	  
Two proteins must be eliminated in order for mitosis to be completed. First, the 
degradation of Securin allows the separation of sister chromatids. Second, the 
destruction of Cyclin B inactivates the mitotic kinase CDK1 and promotes mitotic exit. 
At the molecular level (Figure 1.4), the kinase Mps1 phosphorylates proteins found at 
the microtubule-free kinetochores, allowing the recruitment of the Bub1-Bub3 complex.  
Mps1 phosphorylates Bub1, which interacts with Mad1. Mad1 at the un-attached 
kinetochores attracts Mad2 and changes its conformation from an open to closed form. 
The closed Mad2 sequesters Cdc20 in the cytoplasm and, as a result, Cdc20 becomes 
unavailable for the anaphase-promoting complex/cyclosome (APC/C). In addition to the 
sub-complex Mad2-Cdc20, the mitotic checkpoint complex (MCC) includes BubR1 and 
Bub3.  With increased complexity, the effector of the SAC has more affinity for Cdc20. 
When available, Cdc20, together with the APC/C, have ubiquitin ligase activity and 
target Securin and Cyclin B for proteolysis. Securin inhibits the enzyme Separase, 
which when free contributes to the separation of the sister chromatids by cleavage of the 
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cohesins. In summary, the recruitment of the SAC at the un-attached kinetochores leads 
to the change of Mad2 conformation, the sequestration of Cdc20, the inhibition of the 
APC/C complex, the inhibition of sister chromatid separation, the maintenance of 
CDK1 activity, and a pro-metaphase block. 
It is intuitive to think that the SAC is inactivated when all the kinetochores are 
attached. However, it remains unclear how it can distinguish between correct and 
incorrect attachments. Since the microtubules are pooling chromosomes, the SAC might 
be able to sense inadequate tension due to incorrect binding and remain active, or, 
alternatively, become inactive upon bi-polar attachment or both. 
 
 
Figure 1.4: The mitotic checkpoint or SAC. Figure taken from Geert JPL Kops, Frontiers in 
Bioscience 13, 2606-3620, May 1, 2008. “Schematic model of molecular aspects of mitotic 
checkpoint signalling. Unattached kinetochores (1) specifically recruit proteins that participate 
in production of the Mitotic Checkpoint Complex (MCC) (2), an inhibitory complex that 
prevents poly-ubiquitination (pUb) and subsequent degradation of cyclin B and Securin (3) by 
the APC/C. Integrity of the MCC is further maintained by Usp44, a de-ubiquitinating enzyme 
that counteracts Cdc20 multi-ubiquitination (mUb) by the APC/C and its E2 co-enzyme 
UbcH10 (4).” 
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1.7	  GENOMIC	   INSTABIL ITY, 	  CHROMOSOME	  INSTABIL ITY, 	  AND	  ANEUPLOIDY	  
1.7.1	  GENOMIC 	   INSTABIL ITY 	  
Genome instability (GI) has been recently associated with the acquisition of initial 
cancer hallmarks (Hanahan and Weinberg, 2011). Genomic instability can be divided 
into two categories: microsatellite instability and chromosome instability. 
Microsatellites are composed of large sequences of tandem repeats and ((CA)n is the 
most frequent) at the chromosome centromere (Ellegren, 2004). During DNA 
replication, the DNA polymerase is prone to slippage at the microsatellites, producing 
insertion-deletion loops and inactivating frame-shift mutations. DNA mismatch repair 
proteins normally correct these errors. Thus, microsatellite instability is a result of 
mutation or silencing of DNA mismatch repair. An example of microsatellite instability 
is found in a colon carcinoma cell line, where the DNA mismatch repair gene MSH2 is 
mutated as well as the pro-apoptotic protein BAX, the latter due to a frame-shift 
mutation (Zhivotovsky and Kroemer, 2004).  
1.7.2	  CHROMOSOME	   INSTABIL ITY: 	  STRUCTURAL	  
Among the different forms of GI, chromosome instability (CIN) is the most 
prevalent (Lengauer et al., 1997). Structural and numerical are the two types of 
chromosome instability. Structural instability can be promoted by dysfunction of the 
DNA damage sensor and repair mechanisms such as DNA damage checkpoint, DNA 
double strand breakage, non-homologous end-joining and homologous recombination. 
Moreover, structural instability can be a consequence of telomere attrition and end-to-
end chromosome fusion. As a result, chromosomes can break and enter chromosomal 
break-fusion-bridge cycles (Zhivotovsky and Kroemer, 2004). Chromosome 
translocations are the most common form of structural changes (Mitelman et al., 1997). 
The first example of a translocation was discovered in myeloid leukemia. The reciprocal 
translocation between chromosome 9 and 22 led to the fusion of two genes (BCR and 
Abl). This fusion led to the production of an oncogenic protein, a structural anomaly 
known as the Philadelphia chromosome (Look, 1997; Nowell P, 1960). Tumors are not 
always the result of one structural modification; in fact, they appear to have a high rate 
of chromosomal rearrangements (Abdel-Rahman et al., 2001). This frequent 
chromosome re-configuration confers instability and heterogeneity to tumors and 
supports the selective advantage of the cancerous population. 
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1.7.3	  CHROMOSOME	   INSTABIL ITY: 	  NUMERICAL, 	  ANEUPLOIDY	  
Where whole chromosomal instability relates to the dynamic rate of chromosomal 
changes, aneuploidy relates to a state: non-diploid DNA content. Physiological 
aneuploidy exists in the liver, skin, and brain (Duncan et al., 2010; Gandarillas and 
Freije, 2014; Rehen et al., 2005), and the stable karyotype can be transmitted to the 
cells. The majority of human solid tumors are aneuploid (Storchova and Kuffer, 2008) 
and generally continue to evolve throughout tumor cell generation. Such evolution is 
classically associated with poor patient prognosis (Choi et al., 2009; Lengauer et al., 
1997). As mentioned for structural changes, whole chromosomal instability or the 
constant change of karyotype might fuel the selection of transformed clones. Examples 
of mechanisms leading to numerical chromosome instability are merotelic attachments 
and mitotic checkpoint defects. Interestingly, these mechanisms can induce each other. 
- Merotelic attachments consist of the simultaneous attachment of a kinetochore by the 
microtubules from the two opposite poles. If the merotelic attachments are not resolved, 
it results in lagging chromosomes. Although Aurora B-dependent mechanisms can 
correct the placement of the wrongly attached microtubules, their removal seems to be a 
limiting factor (Bakhoum et al., 2009; Thompson and Compton, 2011). For this reason, 
the hyper-stabilization of the microtubule at the kinetochore can be a cause of 
aneuploidy. In fact, over-expression of Mad2 increases kinetochore-microtubule 
stability and leads to aneuploidy and tumorigenesis in mice (Kabeche and Compton, 
2012; Sotillo et al., 2007). Additionally, the mitotic checkpoint is not efficient in 
sensing the merotelic attachments enabling the dividing cell to proceed through the end 
of mitosis, resulting in aneuploid daughter cells (Thompson and Compton, 2008). 
Cohesion dysfunction in between two sister chromatids can also be a source of 
merotelic attachments since it can increase kinetochore accessibility for the 
microtubules. Another known cause of merotelic attachments is an abnormal 
centrosome number, which is common in cancer cells (Nigg, 2002) and can lead to the 
formation of a multi-polar spindle. In an environment with microtubules emerging from 
many poles, it is very likely that a kinetochore will find several attachments. In the 
context of structural modification, a chromosome can have multiple attachment sites 
and will trigger numerical instability. 
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- Mitotic checkpoint defects. On the one hand, a weak SAC does not arrest the cells 
when the microtubules are not properly attached to the kinetochores. This can lead to 
premature anaphase and aneuploid progeny. Alternatively, an over-activated SAC alters 
the mitotic timing by blocking cells in mitosis and might be overcome by mitotic 
slippage or mitotic catastrophe. The two outcomes are accidental mitotic exit where the 
first one leads to viable progeny and the second one to cell death. How this choice is 
made remains largely unclear. The outcome seems to depend on the balance between 
apoptotic signals and SAC-independent gradual degradation of Cyclin B (Gascoigne 
and Taylor, 2008). Deficient (too weak or too strong) SAC function, in the majority of 
cases, results in improper chromosomal segregation and aneuploidy. Depending on the 
severity of the damage to and the status of p53, the cell might arrest in G1 or undergo 
apoptosis in interphase. In the absence of functional p53, the aneuploid cell could 
continue cycling and increase the levels of aneuploidy. Several mouse models 
disturbing the SAC have been developed to study the consequences of CIN and 
aneuploidy in vivo (Schvartzman et al., 2010).  
1.8	  ANEUPLOIDY	  MODEL	  ORGANISMS	  AND	  ANEUPLOIDY	  PARADOX	  
Although representing a common feature in cancer, aneuploidy has been shown to 
have detrimental effects on cell growth and fitness. The contradictory findings together 
with the lack of consensus in studies has led to the concept of “aneuploidy paradox”, 
describing its beneficial or detrimental effects on tumorigenesis, depending on context. 
In this section, I am summarizing the results relevant for this thesis. It is important to 
remember that aneuploidy corresponds to a stable state of non-diploid karyotype.  On 
the contrary, chromosome instability (CIN) corresponds to the dynamic rate of 
karyotype changes, meaning that CIN cells can also be aneuploid. 
1.8.1	  ANEUPLOIDY 	  WITH 	  OUT 	  TRANSGENIC 	  MOUSE 	  MODELS	  
At the cellular level, in vitro studies indicate that aneuploidy impairs cellular fitness. 
Yeast strains and mouse cell lines carrying extra chromosomes have impaired growth 
and immortalization. As a consequence of the increase in gene products, cells need an 
enhanced metabolism; this phenomenon is called proteotoxic stress (Pavelka et al., 
2010; Torres et al., 2007; Williams et al., 2008). In people, aneuploidy is the leading 
cause of miscarriage. Only autosomal trisomies of chromosomes 13, 18 and 21 are 
compatible with human life, though these result in phenotypes with severe 
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developmental problems such as mental retardation and reduced survival (Hassold et al., 
2007). Despite the development of a phenotype at puberty, aneuploidy of sex 
chromosomes is better tolerated in childhood. In healthy tissues, mitosis leading to 
aneuploid progeny can occur (Hartwell and Smith, 1985), though with the control 
mechanisms being intact, the cells are eliminated or kept in rare physiological cases 
(e.g. skin). On the contrary, 68% of the pathologic human solid tumors are aneuploid 
(Duijf et al., 2012). The constant evolution of tumor karyotypes has been linked to 
tumor heterogeneity, resistance to therapy and poor prognosis including lung 
adenocarcinomas (Choi et al., 2009; Gao et al., 2007; Kuukasjarvi et al., 1997).  
1.8.2	  FIRST-­‐GENERATION	  MOUSE 	  MODELS: 	  WEAKENED	  SAC	   	  
Initial in vivo studies on the effect of aneuploidy addressed whether aneuploidy by 
itself is sufficient to induce tumorigenesis. Alternatively, aneuploidy could be a 
“passenger” accompanying selected mutations. Since the complete abrogation of the 
mitotic checkpoint and the deletion of its components are lethal (Hassold et al., 2007; 
Kalitsis et al., 2000; Michel et al., 2004), the first mouse models were aimed solely at 
weakening the checkpoint. In this weakened condition, the aneuploidy is induced by 
premature separation of the sister chromatids, and many models display an increase in 
susceptibility to spontaneous tumors with late latencies, especially in the lung. The 
mouse embryonic fibroblasts derived from the mouse models were aneuploid and 
disabled. In most cases, however, no correlation could be found between the in vitro 
levels of aneuploidy with the in vivo disease outcome. As examples, Mad2, CENP-E, 
Mad1 heterozygous and Bub1 hypomorphic mice showed an increase in the incidence 
of spontaneous lung tumors (Iwanaga et al., 2007; Jeganathan et al., 2007; Michel et al., 
2001; Weaver et al., 2007). On the contrary, Bub1 and Bub3 haplo-insufficiency and 
consequent CIN did not affect spontaneous tumorigenesis (Jeganathan et al., 2007; 
Kalitsis et al., 2005).  These results indicate that a weakened SAC can induce 
aneuploidy and tumorigenesis, and for undetermined reasons the lung tissue is 
particularly prone to tumors. 
1.8.3	  SECOND-­‐GENERATION	  MOUSE 	  MODELS: 	  SAC	  OVER-­‐ACT IVAT ION	  
Gene down-regulation leading to a weakened checkpoint is extremely rare (e.g. 
mosaic variegated syndrome), especially in human tumors (Haruki et al., 2001). In fact, 
the over-activation of the SAC is more likely to cause of aneuploidy in tumors. 
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Accordingly, a study extrapolated a 70 gene-expression signature corresponding to 
aneuploid human tumors, in which most SAC genes were up-regulated (Carter et al., 
2006). Furthermore, the commonly lost tumor suppressors Rb and p53 are critical 
negative regulators of the SAC, also leading to SAC component up-regulation 
(Schvartzman et al., 2011). These studies can be misleading since it is possible that 
equal up-regulation of the SAC components due to high proliferation or mutations does 
not affect SAC functionality. It would be interesting to analyze the SAC stoichiometry 
and confirm that it is unbalanced and hyper-activated in human tumors. Nevertheless, it 
appears that aneuploidy as a result of SAC over-activation is relevant for the human 
disease. Studies with Mad2, Hec1 or Bub1 over-expression have shown that hyper-
activation of the SAC induces CIN, which is sufficient for tumor initiation (Diaz-
Rodriguez et al., 2008; Ricke et al., 2011; Sotillo et al., 2007). Moreover, upon the de-
induction of the Mad2 transgene, the tumor persisted, indicating that Mad2 was not 
required for tumor maintenance. Mad2 over-expression leads to SAC hyper-activation 
and CIN (Sotillo et al., 2007). It is important to consider that phenotypes can be 
obtained by SAC-independent functions of the subject proteins. For instance, in 
addition to its effect on the SAC, Mad2 leads to Aurora B mis-localization and impairs 
the correction of merotelic attachments, leading to lagging chromosomes (Kabeche and 
Compton, 2012). These data shows that the over-activation of SAC induces aneuploidy 
and tumorigenesis.  
1.8.4	  MOUSE 	  MODEL 	  COMBINATIONS 	   	  
The effect of CIN and aneuploidy on tumorigenesis was further investigated through 
the combination of CIN and tumor-prone mouse models. The cumulative outcome was 
that CIN could both promote and impair tumorigenesis. Mad2 over-expression 
enhanced Myc-induced lymphomagenesis (Sotillo et al., 2007). Furthermore, Kras-
induced lung tumorigenesis increased relapse incidence after oncogene withdrawal 
when Mad2 was over-expressed during primary tumorigenesis (Sotillo et al., 2010). 
CENP-E heterozygosity impaired tumorigenesis in two different systems: carcinogen-
induced tumors together with tumor-suppressor knockout (Weaver et al., 2007). 
Moreover, BubR1 deficiency favored colon tumorigenesis, but inhibited intestinal 
tumors (Rao et al., 2005). Furthermore, Bub1 haplo-insufficiency, in the context of 
tumor-suppressor partial inactivation, had surprising outcomes. It accelerated 
tumorigenesis on two occasions (p53, APCmin) and inhibited tumor development once 
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(Pten) (Baker et al., 2009). A simple explanation for the tumor-promoting effect in the 
context of tumor-suppressor heterozygosity is that CIN promotes the loss of the 
remaining wild-type allele. Actually, Bub1 insufficiency promotes p53 loss of 
heterozygosity and the gain of the mutant allele (Baker et al., 2009). Nevertheless, it 
remains unclear how CIN inhibits tumorigenesis in tumor-prone models with impaired 
tumor-suppressor function. A recent study has revealed that the effect of CIN on 
tumorigenesis depends on the rate of chromosome mis-segregation (Silk et al., 2013). 
Tumor suppressors (e.g p53) are responsible for the elimination of aneuploid cells (Li et 
al., 2010). It is, therefore, possible that tumor-suppressor inactivation may increase the 
mis-segregation rate, shifting the balance towards tumor cell death. This hypothesis is 
tested in the present thesis.  
 
1.9	  AIM	  
 Lung cancer is the leading cause of cancer-related death. The lung tissue is particularly 
sensitive to aneuploidy, and lung tumors develop in many spontaneous mouse models 
of tumorigenesis with impaired SAC. It is known that aneuploidy can promote and 
inhibit tumorigenesis, though the decisive factors shifting the balance remain unclear. 
CIN can promote tumorigenesis by inducing tumor suppressor loss of heterozygosity; 
however, how CIN inhibits tumorigenesis remains unclear. Two points will be 
addressed in this thesis: 
- Weather Mad2 over-expression leads to p53 loss of heterozygosity in a model of lung 
cancer? 
- How aneuploidy inhibits lung tumorigenesis in lung cancer mouse models?   
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2.	  MATERIALS	  AND	  METHODS	  	  
2.1	  MOUSE	  MODELS	  
All transgenic mice were maintained in a mixed background (129-C57Bl/6-FvB) and 
were generated previously: TetO-HAMad2 (Sotillo et al., 2007), TetO-KrasG12D (Fisher 
et al., 2001), TetO-EGFRL858R (Politi et al., 2006) and p53KO (Jacks et al., 1994). Mice 
were kept in pathogen-free housing at EMBL Mouse Biology Unit, Monterotondo, in 
accordance with the Italian legislative decree on animal experiments Nr. 116/92 and 
approved by the Italian Ministry of Health (Decree nr. 233/2011-B).  Mice were 
monitored on a regular basis and sick animals were sacrificed humanely in accordance 
with the guidelines for Humane End Point for animal used in biomedical research. 
Animals were kept on 12h light, 12h night cycle with constant temperature (21 degrees 
Celsius) and humidity (55%). Animals were weaned at 3 weeks and house grouped with 
a maximum of five per cage with pellet food and water ad libitium. The Doxycycline 
was impregnated in the food pellet (625 mg/kg; Harlan-Teklan) and the experimental 
mice were switched to a doxycycline-enriched diet at 4 weeks. BrdU was dissolved in 
the drinking water (1g/L, Sigma), protected from light and was given to the mice for 
48h or 24h.  
For genotyping, DNA was extracted by incubating the tail with 200 µl 0.05M NaOH 
at 98°C degrees for 40 minutes and neutralized with 20µl 1M Tris HCL, pH 7.5. PCR 
reactions were used for transgene detection using 1µl of the supernatant coming from 
the tail digestion. The primers used for genotyping are indicated in table 2.1 and the 
PCR condition in table 2.2. PCR products were run on 1.5% agarose gel with ethidium 
bromide (Sigma), except for p53 with 2% agarose.   
	  	  	  	   	  
Table 1:PCR program p53 genotyping  Table2: PCR program for other genotypes
   
Step Temperature (°C) Time (min) Cycles
Denaturation 95 05:00 1X
Denaturation 94 00:30
Annealing 60 01:00
Elongation 72 01:30
Elongation 72 05:00 1X
Hold 10 for ever NA
28X
Step Temperature (°C) Time (min) Cycles
Denaturation 95 05:00 1X
Denaturation 94 00:30
Annealing 60 00:30
Elongation 72 00:30
Elongation 72 01:00 1X
Hold 10 for ever NA
29X
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Table 3: Genotyping primers 
 
2.2	  HISTOLOGY	  	  
2.2.1	  NECROPSY 	   	  
Mice were euthanized by CO2 suffocation and were perfused with PBS in the left 
ventricle of the heart and the liquid evacuated from the sectioned inferior vena cava.  In 
order to further clean the lungs, tracheal PBS perfusion was performed. For DNA and 
RNA, tumor and lung samples were snap frozen in liquid nitrogen and conserved at -
80°C. For immunofluorescence, healthy lung samples were embedded in O.C.T. 
compound (Tissue-Tek), and conserved at -80°C. For immunohistochemistry, lungs 
were fixed in 10% neutral buffered formalin solution over-night at room temperature. 
After PBS washing the sample were dehydrated in Leica ASP300S and embedded in 
paraffin. For both Cryo (Cryostat CM3050S, Lieca) and paraffin tissues (RM 1235 
microtome, Leica), the 8µm sections were put on Super-frost Glass slides (Thermo 
scientific).  
2.2.2	  HEMATOXYL IN 	  AND	  EOSIN 	  (H&E)	  
The paraffin tissue sections were de-paraffinized as follow: two times incubation 
with Xylene for 15 minutes, three time with 100% ethanol for 3 minutes, 3 minutes in 
96% ethanol, 3 minutes in 70% ethanol, two time washes in water for 5 minutes. For 
H&E staining, the sections were incubated for 1 minute with hematoxylin QS (Vector) 
and washed in water. The tissue was counter stained with eosin 1% (Bio optic) and 
washed. The section were dehydrated as follow: 3 minutes in 70% ethanol, 3 minutes in 
96% ethanol, two times 3 minutes is 100% ethanol, two times 15 minutes in xylene. 
DPX mounting media was used (VWR #360294H). Leica LMD 7000 mounted with the 
Leica CD310 digital camera and the Leica LASV3.7 software were used to acquire 
images. 
Genotypes Forward Reverse 
CCSP-rtTA AAGGTTTAACAACCCGTAAACTCG GTGCATATAACGCGTTCTCTAGTG
TetO-Kras GGGAATAAGTGTGATTTGCCT GCCTGCGACGGCGGCATCTGC
TetO-Mad2 CCATCCACGCTGTTTTGACCTC GGCTTTCTGGGACTTTTCTCTACG
p53 commun/  ATAGGTCGGCGGTTCAT WT/ CCCGAGTATCTGGAAGACAG
Mutant/ CCTCGTGCTTTACGGTATCGC
CMV-rtTA GTGAAGTGGGTCCGCGTACAG GTACTCGTCAATTCCAAGGGCATCG
TetO-EGFR ACTGTCCAGCCCACCTGTGT GCCTGCGACGGCGGCATCTGC
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2.2.3	   IMMUNOHISTOCHEMISTRY 	  ON	  PARAF IN 	  SECT IONS. 	   	  
Sample hydration was done as for H&E. Sections were subjected to antigen retrieval 
by steamed treatment for 30 min in 0.09% (v/v) antigen unmasking solution (Vector 
Lab). After cooling, endogenous peroxidases were inactivated by incubation is 3% H202 
for 15 minutes. After two PBS washes of 5 minutes each, sections were blocked with 
10% serum in PBS for 30 minutes (serum specie depend on the primary antibody, 
Vectastain ABC rat or rabbit kit, Vector laboratory). Primary antibodies were diluted in 
the previous blocking solution and incubated for 2 hours at room temperature. Primary 
antibodies included: anti-HA (1:200 dilution, #11867423001 Roche), anti-Prosurfactant 
Protein C (proSP-C, 1:400 dilution, #AB3786 Millipore), anti-Ki67 (1:500 dilution, # 
VP-K451, Vector laboratories), anti-BrdU (1:200, #ab6326, Abcam). After two PBS 
washes of 5 minutes each, sections were incubated for one hour with the appropriate 
Biotinylated secondary antibody diluted in blocking solution (Vectastain ABC rat or 
rabbit kit). Sections were washed twice 5 minutes with PBS and incubated with HRP 
conjugated antibody for 30 minutes and washed. Staining was reveled by peroxidase 
reaction using the DAB peroxidase substrate kit (Vector) and stopped when the stain 
comes visible, less than 2 minutes. After wash in water the section were counterstained 
with Hematoxylin for 10 seconds, de-hydrated, mounted and imaged as for H&E.  
Whole mount Senescence staining was done using Senescence β galactosidase 
staining Kit (#9860 Cell signaling). TUNEL assay was performed by Joana Passos 
using ApopTag® (#S7100, Millipore) and p21 staining was performed at the histology 
facility of the CNIO (Madrid, Spain). Aneuploidy was quantified by measuring nuclear 
volumes in tissues as described previously (Perez de Castro et al., 2013). Briefly, area 
of nuclei were measured using ImageJ, the radius was determined and the volume was 
calculated using the following sphere formula: 4/3*π *r3. 
2.2.3	   IMMUNOFLUORESCENCE 	  ON	  CRYO-­‐SECT ION	   	  
Cryo-section was chosen for immunofluorescence (IF) of healthy lung because the 
paraffin section together with the lung auto-fluorescence gave to much background for 
the detection of specific fluorescence. Cryo-samples are stored at -80°C and were left 
for 20 minutes to equilibrate to -20°C before cutting. After cutting sections were left for 
one hour at room temperature to dry and attach to the slides. Sections were briefly fixed 
with paraformaldehyde to avoid background (4%, 4 minutes) and incubated 30 min with 
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2M HCL at 37°C for 30 minutes for antigen retrieval. The section were washed three 
times 10 minutes in PBS and blocked for 1 hour with 5% goat serum in PBS (Jackson 
ImmunoResearch). Sections were incubated with primary antibodies in the previous 
blocking solution at 4°C over-night. Primary antibodies included: anti-Prosurfactant 
Protein C (proSP-C, 1:400 dilution, #AB3786 Millipore), anti-BrdU (1:100, #ab6326, 
Abcam). The next day the sections were washed three times 10 minutes and incubated 
with the conjugated secondary antibodies in blocking solution for one hour. Secondary 
antibodies were: Alexa 647 goat anti rat IgG, Alexa 488 goat anti rabbit IgG (1:1000 
dilution, # A21247, #A11034, Invitrogen). Sections were washed 3 times with PBS for 
10 minutes and the last wash included DAPI for nuclei counter staining. Leica TCS SP5 
confocal microscope was use to acquire and ImageJ to analyze the images. 
2.3	  LUNG	  FACS	  
After animals were sacrificed, tracheal PBS was used to clean the lungs. Auxiliary 
lymph nodes were dissected and single cell solution was obtained by mechanic 
dissociation and the use of 40µm filters. To make single lung cells suspension, 2ml of 
dispase (Roche) followed by 2ml of liquid low melting agarose (Promega) was 
delivered to the lungs via the trachea. After the agarose solidified the lungs were taken 
and further incubated in 2ml of dispase and incubated for 45 minutes under agitation. 
Auxiliary lymph nodes were dissected. To terminate the digestion DMEM (Life 
Technology) media was added and contained DNase I (5mg/ml Sigma, #D4527), to 
prevent the clamping of dead cells. The lung was mechanically dislocated and passed 
trough 70µm and 40µm nylon filters (Falcon). Red blood cells were eliminated by 
incubated with red blood cell lysis buffer (Sigma, #R7757) for 1 minute. The antibodies 
solutions were prepared according to the cell count.  
For cell death staining, the lung single cell suspension was washed with the 
apoptosis-staining buffer, incubated for 30 min in the dark with annexin V at RT and 
before analysis the live cell die Cytoxblue was added (Annexin apoptosis Detection kit 
FITC, eBioscience). For inflammation staining in the lung and in the lymph nodes, 
single cell suspensions were blocked with CD16/32 block (clone 93 eBioscience). T 
cells were excluded using their positivity for CD8 and CD4 (CD8-alexafluor 488 clone 
53-6.7 bd Farmigene, CD4-PE clone L3T4 eBioscience). B cells were eliminated using 
the marker B220 (B220-PE clone RA3-6B2 eBiosceince). Macrophage were further 
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identified based on CD11b high expression (Cd11b-APC clone M1/870, eBioscience) 
and activation was monitor with the CD54 marker (CD54 FITC clone yN1/.7.4 
Biolegend). For this procedure all the antibodies were added (1/50 dilution) in the same 
time and incubated for 10 minutes at RT, washed and cells were analyzed. PBS 
supplemented with 2% FBS was used for washes.  
2.3	  CELL 	  CULTURE	  
2.3.1	  MOUSE 	  EMBRYONIC 	  F IBROBLASTS: 	  MEFS	  
Mouse embryonic fibroblast (MEFs) was obtained from embryos of 12.5 after 
conception. The day of conception was known by the appearance of a white plug at the 
entry of the mouse genitals and the male was removed from the cage. Later, 12.5 days, 
the mouse was examined for pregnancy and in the positive case it was euthanized and 
the embryos dissected out. The visible liver or the embryo was mechanically removed 
and the head taken for genotyping. The body was incubated over night in 0.5 ml of 
0.05% trypsin (Life technology) at 4°C for digestion. During incubation the heads were 
digested and genotyped as it is done for the tails (section 2.1). The next day, the selected 
embryos were further mechanically dissociated and the cell suspension was plated in 
150 cm dish, with DMEM medium. The DMEM media was complemented with 10% 
Tet-free serum (FBS, Clontech Cat#631106), L-Glutamine for a final concentration of 
2mM (Life technology) and Penicillin/Streptomycin for a final concentration of 
100U/mL (Life technology). When the plate was confluent (about 3 days), the MEFs 
were divided in 4 vials and frozen. Freezing media consisted of 90% serum and 10% 
DMSO (Sigma).  For cell growth and immortalization experiments, MEFs vials were 
thawed and platted in two 10cm dish. After 3 days the MEFs have expanded and can be 
distributed in different plates for experiments. After being collected 20µl of MEFs 
suspension was inserted in cell counting chamber and counted automatically 
(Cellometer). For immortalization, one million MEFs was platted per dish with or with 
out doxycycline (1mg/ml), twice a week they were counted and one million was re-
plated until the end of the experiment. After platting the cells pellet was frozen for 
further analysis. For cell growth, 70.000 MEFs were plated in each well of a 6 well 
plate and one well was counted everyday, after counting the cells were frozen for 
protein samples. 
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2.3.1	  TIME	  LAPSE 	   IMAGING	   	  
In order to visualize the DNA with the time-lapse recording, and because primary 
MEFs do not get transfected, they were transduced with H2B-GFP (Yamamoto et al., 
2004). The construct containing H2B-GFP was a kind gift from Rocio Sotillo and 
amplified by bacterial transformation.  
Frozen competent cells were thawed on ice for 20 minutes and were incubated with 
1µl of the given preparation for 20 minutes on ice. The mixture was put at 42ºC for 1 
minute for heat shock and cells were allowed to recover for 2 minutes on ice. 500µl of 
LB media was added and the mixture placed at 37ºC for one hour allowing the bacteria 
to grow. 50µl was platted on a 10cm LB agar ampicillin plate and incubated at 37ºC 
over night. The day after, the transformed clone were further gown until enough 
bacteria were collected for maxi-prep, which was done using Qiagen Plasmid Maxi Kit. 
Transformed bacteria were also frozen for LB-ampicillin inoculation when more 
plasmid was needed.  
For the production of retrovirus containing H2B-GFP (Yamamoto et al., 2004), I 
used the Phoenix retrovirus packaging cell line. The phoenix cells were transfected with 
the H2B-GFP constructs using the calcium phosphate method (ProFection Kit, 
Promega). In brief 15ng of construct was first mixed with calcium 62µl 2M CaCl2 and 
sterile, deionized water for a total of 500µl. The mixture was slowly added to tube 
containing 500µl 2X HBS upon agitation. The combined solution was left at room 
temperature for 30 minutes and done in duplicate. The two mixtures were delivered 
drop wise onto two plates of 70% confluent Phoenix cells in normal DMEM media. 
After over-night incubation the media was replaced and Phoenix cells were transduced 
as seen by their Green fluorescence. Phoenix cells were producing retrovirus-containing 
H2B-GFP found in the media.     
As soon as MEFs vials were platted in two 10cm dish, they were incubated with the 
Phoenix filtered media (0.45 µM, Millex HA), which contains the H2B-GFP virus. In 
order to enhance the virus infection efficiency, Polybrene (Final concentration 4µg/ml, 
Sigma) was added to the media. MEFs were repetitively infected, twice a day for 4 
days. The transduction efficiency remaining low the MEFs were sorted for green 
fluorescence and directly platted in a 35mm high µ-plate (Ibidi). MEFs were left to 
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recover and attach to the plate for 5 hours. In order to synchronize their entry in mitosis 
they were serum starved (0.1% serum) for 72h. When the cells were released by adding 
media with 10% serum, the Doxycycline (1mg/ml) was also included to induce 
transgene expression. Release and Dox induction occurred 20h prior to imaging. To 
observe cell death TO-PRO-3 iodide (1:1000 dilution, #T3605, Molecular Probes) was 
added to the media just before the imaging started. Imaging was recorded on an inverted 
spinning disk confocal (Perkin Elmer Ultraview-Vox): 3µm stack across 27µm, 10 
minutes frames during 48 hours. Volocity version 6.2 (Improvision-Perkin Elmer) was 
used for image acquisition and analysis.  
2.4	  MOLECULAR	  METHODS	  
2.4.1	  PCR	  AND	  REAL 	  T IME	  PCR	  
DNA and mRNA were isolated from flash frozen nodules and from MEFs using the 
DNA/RNA Micro kit (Qiagen) and the pestle ruptor method was chosen to disrupt the 
tissues. For p53 PCR, 150ng of genomic DNA was used and the primers were the same 
as the one used for genotyping (see section 2.1). Band intensities were measured using 
the Chemidoc XRS+ with image lab software (Biorad).  
RNA from the extractions was measured using a Nanodrop (Thermo Scientific), 0.2 
to 0.5 µg of RNA was reversed transcribed into cDNA using Superscript III RT kit 
(Invitrogen). Quantitative PCR was done using LightCycler 480 SYBR Green I Master 
and Light Cycler 480 (Roche). The reaction program is indicated in table 2.4 and 
primers in table 2.5. The fold changes in gene expression were calculated using the 
ΔΔCt method. Reactions were run in triplicate, the fold changes were calculated using 
two references genes and normalized to reference sample.  
 
Table 2.4: Real time PCR program.  
Step Temperature (°C) Time (s) Cycles
Denaturation 95 300 1X
Denaturation 95 10
Annealing 60 15
Elongation 72 10
Denaturation 95 5 1X
Annealing 65 60 1X
Denaturation 95 N/A Continuous
Cooling 40 10 1X
45X
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Table 2.5: Real time PCR primers sequences.   
 
2.4.2	  WESTERN	  BLOT	  
Protein were obtained using RIPA buffer complemented with PMSF and complete 
mini protease inhibitor cocktails (Roche), half tablet for 12.5ml. Cell pellet were 
incubated for 10 minutes on ice and spin at the maximum speed for 10 minutes. 
Supernatant was collected and protein was measured using the Bradford method (Biorad 
protein Assay). Before leading the protein were denatured at 98°C for 2 minutes. 
Preparation of 12% SDS-PAGE and the stacking gel was done using a Biorad system. 
Isopropanol was used to ensure a strait 12% gel and removed before pouring of the 
stacking gel.  The composition of the 12% gel was as followed: 12% acrylamide, 0.1 M 
Tris (pH 8,8), 0.01% ammonium persulfate, and TEMED was added for fast 
polymerization. The composition of the stacking gel was as followed: 5% acrylamide, 
0.1 M Tris (pH 6,8), 0.01% ammonium persulfate, and TEMED was added for fast 
polymerization. After leading the samples and the molecular weight marker 
(Kaleidoscope, Biorad) the gels were submerged with running buffer and run at 100V 
for 1h30.  The composition of Tris-Glycine running buffer was as followed: 25mM 
Tris, 250 mM Glycine, and 0.1% SDS. For transfer, the nitrocellulose membranes were 
submerged in methanol for 2 min, washed with water and transfer buffer. Filters, the 
papers, and the pads were submerged in transfer buffer. All the components were 
mounted for wet transfer and submerged with transfer buffer, and run at 40V over-night 
at 4°C. The composition of transfer buffer was as followed: 48 mM Tris, 39 mM 
Glycine, 0.037% SDS, and 20% methanol. After transfer, blots were blocked for 1hour 
with 1% Bovine Serum Albumin (Sigma). Blots were probed with antibodies directed 
against, p44/42 MAP Kinase (Cell Signaling technology), HA (#H9658, Sigma), Kras 
(F234, SC-30, Santa-Cruz), Mad2 (BD Transduction Laboratories), and Actin (#A2066, 
Genes Forward Reverse 
LC37 TCTGTGGCAAGACCAAGATG GACAGCAGGGCTTCTACTGG
PPIa CGCGTCTCCTTCGAGCTGTTTG CGCGTCTCCTTCGAGCTGTTTG
HA-Mad2 GGCTTACCCATACGATGTTCC CGACGGATAAATGCCACG
Bax TGGAGCTGCAGAGGATGATTG TGGGATGCCTTTGTGGAACT
p21 CAGATCCACAGCGATATCCA GGCACACTTTGCTCCTGTG
PUMA GCGGCGGAGACAAGAAGA AGTCCCATGAAGAGATTGTACATGAC
GADD45 ATTACGGTCGGCGTGTACGA CAGCAGGCACAGTACCACGTTA
Mdm2 AGCAGCGAGTCCACAGAGA ATCCTGATCCAGGCAATCAC
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Sigma). HRP conjugated anti-mouse or rabbit were used as secondary antibodies and 
proteins were visualized and quantified using Chemidoc XRS+ with image lab software 
(Biorad). 
2.5	  STATISTICS 	   	  
Student t test, F analysis or log-rank tests were performed using Graph Pad Prism 5 
and error bars represent mean ± SEM. Statistical significance was concluded at p < 
0.05. Samples images were quantified using ImageJ (National Institutes of Health, 
Bethesda, Maryland). 
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3.	  RESULTS	  
3.1	   IN	   VIVO	   CHARACTERISATION	   OF	   THE	   P53(+/–)K	   AND	   P53(+/–)KM	  
COHORTS	  
3.1.1	   OVER-­‐EXPRESS ION	   OF 	   MAD2	   DELAYS 	   KRAS 	   INDUCED	   LUNG	   TUMORS	   WITH 	  
IMPAIRED 	  P53	  
It has previously been reported that Mad2 over-expression accelerates Kras induced 
lung tumorigenesis by inducing chromosome instability (Sotillo et al., 2010). Current 
knowledge supports a model where tumor suppressor inactivation may lead to Mad2 
over-expression that results in CIN and aneuploidy, which in turn may contribute to 
tumor progression. However, it remains unclear to what extent CIN can contribute to 
tumorigenesis since some tissues are more prone to tumor formation than others, 
pointing out the importance of the cellular context and genetic landscape in mice 
(Sotillo et al., 2007). p53 impairment is found in a majority of lung tumors and 
importantly it is a critical regulator of aneuploidy (Schvartzman et al., 2011; Thompson 
and Compton, 2010). My supervisor, Dr. Rocio Sotillo and I, hypothesized that Mad2 
over-expression would affect KrasG12D induced tumorigenesis -either further 
acceleration or via inhibition- when a copy of p53 is inactivated.  
To test this hypothesis, I monitored mice overexpressing tetracycline inducible Mad2 
(M) and KrasG12D (K) in a p53(+/–) background. The control cohort of p53(+/–)K mice 
died of lung tumors with a median latency of 33 weeks and the over-expression of 
Mad2 led to an significant increased lifespan of around 13 weeks (46 weeks; Figure 
3.1).  
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Figure 3.1: Mad2 over-expression delays p53(+/–)Kras driven lung tumorigenesis. Mice 
were feed doxycycline-impregnated food from 4 weeks of age and monitored for lung tumors. 
Tumor free survival of p53(+/–)Kras (black, median survival: 33.4 weeks, n=20) and p53(+/–
)Kras Mad2 mice (red, median survival: 46.65 weeks, n=12; Mantel-cox test *p<0.05). 
 
3.1.2	  KINET ICS 	  OF 	  TUMORIGENES IS 	  
Upon observation of the Mad2 inflicted delay on Kras driven lung tumorgenesis in 
the p53(+/–) background, I set out to determine the window in which Mad2 was 
exerting it’s influence. As in the absence of MRI qualifying mice as humane end point 
can be challenging with mouse models of lung cancer, I used an alternative approach 
that was originally utilized for the initial characterization of this Kras mouse models 
(Fisher et al., 2001). I analyzed the kinetics of tumorigenenes by histology, selecting 
different time points of doxycycline induction, and I calculated the percentage of tissue 
occupied by tumors.  
There was noticeably little tumor development during the first 10 weeks of 
doxycycline induced transgenes expression (Figure 3.2 A and B). At a later time point 
between 10 and 20 weeks - I observed that the tumors in the p53(+/–)KM lungs were 
occupying a significantly smaller surface than in the p53(+/–)K lungs (5.67% Vs. 
45.61%, Figure 3.2 A and B).  However, this difference diminished at longer induction 
times, from more that 20 weeks induction to humane end point (31.42% Vs. 51.68%, 
Figure 3.2 A and B). This is probably due the fact that in the control cohort (p53(+/–
)K), the lungs were soon saturated with tumors, with at 10-20 weeks time point the 
tumors occupied close to half of the lungs. The >20 weeks time point did not show 
significant increases beyond the 10-20 week time point for this cohort (Figure 3.2 A and 
B). Fifty percent of tumor in the lung is probably the maximum tolerated by the mice 
before they classify as humane end point. The cohort over-expressing Mad2 had only 
5.67% of tumors at the 10 to 20 weeks time point, and as the lungs were not yet 
saturated with tumors, it was possible to observe the their growth. At the >20 weeks 
time point, the tumors were occupying 31.42% of the lungs in the p53(+/–)KM cohort. I 
observed that the lungs over-expressing Mad2 initially have an impaired tumorigenesis 
however, the tumors eventually developed to occupy a significant portion of the lungs, 
albeit with slower kinetics (10-20weeks: 5.67%, >20 weeks: 31.42%, p<0.05, Figure 3.2 
B), suggesting a compensation mechanism for Mad2 over-expression.  
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Figure 3.2: Kinetics of tumorigenesis in the p53(+/–)Kras and p53(+/–)Kras Mad2 cohorts. 
A) H&E staining at 0-10 weeks, 10-20 weeks and >20 weeks after transgenes induction. Scale 
bar 200μm. B) Percentage of tumor area per lung section indicating a maximum delay in 
tumorigenesis between 10 and 20 weeks. Time point 0-10 weeks; p53(+/–)K= 1.47% n= 7 mice, 
p53(+/–)KM= 1.83% n= 9 mice.  Time point 10-20 weeks; p53(+/–)K= 45.61% n= 6 mice, 
p53(+/–)KM= 5.76% n= 6 mice, unpaired t-test ***p<0.001.  Time point >20 weeks; p53(+/–)K= 
51.68% n= 7 mice, p53(+/–)KM= 31.42% n= 17 mice. 
 
3.2	  EARLY	  EFFECT	  OF	  MAD2	  OVER-­‐EXPRESSION,	  PRIOR	  TUMORIGENESIS	  
3.2.1	   MAD2	   OVER-­‐EXPRESS ION	   INHIB ITS 	   THE 	   PROL IFERATION	   OF 	   TYPE 	   2	  
PNEUMOCYTES 	  PR IOR 	  TO 	  TUMORIGENES IS 	  
The observation that lung tumors arise in the p53(+/–)K and in the p53(+/–)KM mice 
cohorts at different times (Figure 3.1 and 3.2), suggested that over-expression of Mad2 
may have an inhibitory effect on p53(+/–)Kras-induced tumor initiation. The lung is a 
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very slowly proliferating tissue, therefore it is challenging to monitor it is physiological 
turnover: proliferation and cell death. To address the negative effect of Mad2 over-
expression on cell proliferation on pseudo-healthy lung, the mice were feed doxycycline 
for 4 days and pulsed with BrdU (a nucleotide analogue) in the drinking water for 
48hours. When new DNA is synthetized the BrdU is faulty incorporated; this method 
allows the cumulative labeling of cells that have entered S phase. First, Mad2 
expression at this early time point was confirmed by immunohistochemistry against the 
HA tag in the p53(+/–)KM samples (Figure 3.3 A). Importantly, samples with no trans-
activator did not show positive staining for HA-Mad2 confirming the tight control of 
transgenes induction. In a first step, I calculated the ratio of BrdU positive area per 
nuclei area (Magenta/DAPI). Since both marker are nuclear, the number reflects the 
percentage of BrdU positive cells per total lung cells and I observed a non-significant 
increase in the p53(+/–)K lungs (data not shown). The transgenic system induces the 
expression of the transgenes specifically in the type 2 pneumocytes (TIIPN). The TIIPN 
secrete pulmonary surfactant and can be visualized using the Surfactant protein C (SpC) 
as a marker. In a second step, I counted the percentage double positive cells (SpC and 
BrdU) from the total BrdU positive cells. Finally, I calculated the percentage of double 
positive cells per total lung cells using the BrdU values for conversion. As an example, 
if 5% of the total lung cells are BrdU positive and only 10% of the BrdU nuclei are also 
SpC, then 0.5% of the total cells are double positive cells (SpC and BrdU).  
In the lung physiological lung (mice lacking the transactivator rtTA), I found very 
few proliferating TIIPN: 0.5% double positive cells (SpC and BrdU). The TIIPN 
proliferation was significantly increased in the p53(+/–)K lungs and upon Mad2 over-
expression the percentage of proliferative TIIPN was significantly reduced: 1.9% Vs. 
0.6% double positive cells (Figure 3.3 D and E). These results suggest a very early 
negative effect of Mad2 over-expression on the TIIPN, at this stage it is more likely due 
to an over-activation of the mitotic checkpoint rather than a decrease of cell fitness due 
to aneuploidy. 
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Figure 3.3: Mad2 over-expression inhibits type 2 pneumocytes proliferation. Mice were feed 
doxycycline-impregnated food at 4 weeks of age and scarified after 4 days including 2 days with 
BrdU provided in the drinking water. A) HA IHC of lung samples confirming the induction of 
HA-Mad2 exclusively in p53(+/–)KM samples. Control is a p53(+/–)KM lung without the rtTA. 
Scale bar 50 μm. B) IF staining on lung sections induced for 4 days and pulsed with BrdU for 
48hours before sacrifice. Scale bar: 50μm. C) Quantification of double positive cells (BrdU, 
SpC). Mice that are lacking the trans-activator were used to measure the physiological lung 
proliferation (0.5% of proliferating TIIPN (0.5158 ± 0.1667 n=7 mice). This number was 
significantly increased in the p53(+/–)K lungs (1.951 ± 0.4266 n=9 mice, unpaired t-test, 
*p<0.05). Upon Mad2 over-expression the percentage of proliferative TIIPN was significantly 
reduced to 0,6% (0.6476 ± 0.1302 n=13 mice, unpaired t-test, **p<0.01).  
 
3.2.2	  CELL 	  DEATH	   IN 	  V IVO : 	   LACK 	  OF 	  EV IDENCE	  
To test whether the inhibition of proliferation induced by Mad2 over-expression 
(Figure 3.3) is due to cell death, I analyzed TUNEL immunohistochemistry performed 
by Joana Passos (Lab Technician) at different time point of transgenes induction. After 
4 days of induction, I could detect only sporadic positive cells. As the time point can be 
critical for in vivo observations, I also analyzed TUNEL at later stages of induction, 
which were also not conclusive (Figure 3.4 A), probably due to the rapid turn over 
apoptotic cells. Another possible limitation for the detection of apoptotic cells can be 
due to the small amount of tissue that can be quantified by immunohistochemistry.   
In order to detect more apoptotic cells, I decided to analyze the entire lung by FACS 
(fluorescence activated cell sorting). After preparing a single cell suspension from the 
lung on doxycycline for 4 weeks, I excluded the macrophages and followed cell death 
using Annexin V staining combined with a live cell dye (Figure 3.4 B). It allows 
measuring live, early and late apoptosis as well as necrotic cells; in this experiment I did 
not observe an increase of cell death upon Mad2 over-expression (Figure 3.4 C). 
However, this method might lead to a type II error: the amount of dying cells generated 
by the procedure could mask small variations between the genotypes. Overall, I did not 
observe the induction of apoptosis upon Mad2 over-expression, however this might be 
due to the in vivo condition.  
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Figure 3.4: Cell death in vivo. A) TUNEL staining showing occasional dead cells at 4 days, 2, 
4, 5 weeks time points. Scale bar 50 μm. B) Annexin V and cytoxblue staining showing live, 
early and late apoptotic cells, necrotic cells; from lung cell suspension depleted from its 
macrophages.  C) Quantification of the different population (n=3 mice) showing no difference 
across the genotypes (n=3 mice), p53(+/–) mice were used as control. 
 
3.2.3	   INFLAMMATION	   IN 	  V IVO : 	   LACK 	  OF 	  EV IDENCE	  
The detection of apoptotic cells is very challenging in vivo, to retain tissue 
homeostasis alveolar macrophages clear apoptotic and necrotic bodies. They are usually 
kept in a quiescent state in the lungs and can be classically or alternatively activated. The 
classic macrophages are the primary “killers” and induce inflammation, the alternative 
macrophages are involved in tissue repair and appear to promote tumor growth (Galdiero 
et al., 2013). Alveolar macrophages have been shown to transport pathogens to lymph 
nodes to trigger adaptive immunity, a feature that has been long consider exclusive to 
dendritic cells (Kirby et al., 2009). I hypothesized that if Mad2 would induce cell death 
in vivo, it could lead to the infiltration of macrophages in the lungs, their activation and 
possibly their migration to the axillary lymph nodes. After preparing a single cell 
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suspension from the lung, I isolated the macrophages (CD11b+, Figure 3.5 A) and 
followed their activation (CD54, Figure 3.5 B) by FACS.  
Using wild-type mice, I observed a high number of Cd11b+ cells populating the lung 
compare to the axillary lymph nodes (Figure 3.5 C) and on the contrary, activated 
Cd11b+ cells were the most represented in the axillary lymph nodes (Figure 3.5 D). 
These results are in accordance with the physiological function of macrophages. I then 
performed the similar analysis on mice fed with doxycycline during 4 weeks (Figure 3.5 
E-H) and I did not observe an effect of Mad2 over-expression on macrophage 
recruitment and activation in the lung or axillary lymph nodes.  These results indicates 
that none of the induced transgenes leads to the infiltration or activation of the alveolar 
macrophages in p53(+/–) mice after 4 weeks of induction. 
 
Figure 3.5: Inflammation. The B and T cells populations were excluded from the single cell 
suspension of lungs and lymph nodes. A) Macrophages population identified on the basis of the 
Cd11b expression and Side Scatter (SSC). B) Macrophages activation was followed on the basis 
of CD54 expression. A.B) Cd11b and Cd54 X-axis represent log fluorescence intensity. C) 
Percentages of Cd11b+ cells found in the lung and in the axillary lymph nodes in wild-type 
mice showing the abundance of macrophages in the lungs (n=3 mice paired t-test *p<0.05). D) 
Macrophages activation in the lung and in the axillary lymph nodes in wild-type mice showing 
activated macrophages in the axillary lymph nodes (n=3 mice paired t-test *p<0.05). E-H) 
Macrophages percentages and activation from control (p53(+/–)) and experimental mice 
showing no differences between the cohorts (n=3 mice except for E: n=1 mouse).  
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3.2.4	  MAD2	  OVER-­‐EXPRESS ION	   IMPAIRES 	  CELLULAR 	  GROWTH	   IN 	  V ITRO 	  
As it is very challenging to study the consequences of Mad2 over-expression at the 
cellular level in vivo. I utilized an alternative in vitro approach and generated murine 
embryonic fibroblast (MEFs) isolated from day 12.5 mouse embryos. To induce 
transgenes expression in MEFs the ubiquitous CMV promoter controls the rtTA 
expression as described previously (Sotillo et al., 2007).  I first tested the expression of 
the transgenes by western blot. At 24 hours post doxycycline induction there was no 
leakage in the transgenic system and the exogenous HA tagged Mad2 was produced in 
p53(+/–)KM cells (Figure 3.6 A). In order to test for activation of Kras signaling 
following doxycycline driven transgenes expression, I preformed a western blot for the 
downstream phospho-Erk, which I found elevated in both p53(+/–)KM and p53(+/–)K 
MEFs (Figure 3.6 A).  
I assessed the MEFs growth rate by plating a fixed amount of cells and following 
their proliferation for 6 days. Oncogenic Ras can induce cell cycle arrest and senescence 
(Serrano et al., 1997), which would render the use of MEFs for the study of cancer 
properties futile. Importantly, the p53(+/–) clones over-expressing Kras were able to 
grow in culture indicating that MEFs could be used for further experiments (Figure 3.6 
B).  The detrimental effect of Mad2 on MEF growth has previously been reported in the 
p53 wild-type background (Sotillo et al., 2007), I obtained similar results (Figure 3.6 C) 
as well as in the context of Kras over-expression (Figure 3.6 D). Moreover, Mad2 over-
expression impaired the MEFs growth with or without Kras over-expression in the p53 
heterozygote background (Figure 3.6 E and F). These results indicate that Mad2 over-
expression has a dominant detrimental effect on MEFs growth, independent of 
oncogene over-expression and partial tumor suppressor inactivation.  
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Figure 3.6: Mad2 over-expression impairs cellular growth in vitro. A) Western Blot from 
MEFs showing the specific expression of HA–Mad2 and the activation of the down-stream 
effector of Kras (p42-p44) after 24hours of doxycycline (Dox). Actin was used as loading 
control. Control 1; MEFs lacking the trans-activator, Control 2: MEFs lacking Kras and Mad2 
transgenes. B-F) Representative MEFs growth curves showing the dominant detrimental effect 
of Mad2 over-expression. Control with out Dox in black and with Dox in red. 70000 cells were 
platted at day 0 and the cells were counted during the 6 following days. The Y axis shows the 
doubling population normalized to day 0. B) p53(+/–)K, C) p53(+/+)M, D) p53(+/+)MK, E) 
p53(+/–)M,  F)p53(+/–)M. 
 
3.2.5	   INACT IVAT ING	   ONE	   COPY 	   OF 	   P53	   RESCUES 	   THE 	   MITOTIC 	   DEATH	   INDUCED	   BY 	  
MAD2	  OVER-­‐EXPRESS ION	  AND	  GENERATES 	  POLYPLOID 	  MEFS	  
Mad2 over-expression confers a growth dis-advantage to MEFs over-expressing 
Kras in the p53 wild-type and p53 heterozygote background (Figure 3.6). However the 
effect of Mad2 over-expression on Kras induced lung tumorigenesis differs depending 
on the p53 background, with an acceleration in the wild-type background (Sotillo et al., 
2010) and a delay when p53 is partially inactivated (Figure 3.1).  It is then possible that 
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the preliminary detrimental effect of Mad2 is mediated by two distinct mechanisms that 
would have different effects during the long process of tumorigenesis. High Mad2 
levels have been shown to induce aneuploidy and mitotic cell death when p53 is 
functional (Sotillo et al., 2007).  In an attempt to understand the effect of Mad2 over-
expression in the context of p53 heterozygosity, I used p53(+/+)KM, p53(+/–)K and 
p53(+/–)KM MEFs and time-lapse microscopy. To monitor the early effect of Mad2 
over-expression on the first mitosis and to visualize the DNA, I infected the cells with a 
retrovirus expressing Histone 2B fused to the green fluorescent protein (H2B-GFP). 
Because of the low efficiency of primary cell transduction, I cell sorted the positive 
cells using the GFP reporter. After allowing them to recover for 5 hours, I serum-
starved the cells for 3 days and released them 20 hours prior imaging allowing them to 
enter mitosis coincidentally with the beginning of imaging. Upon release doxycycline 
was added and the transgenes induced.  I first verified by western blot the maintenance 
of the transgenes expression at 72 hours post doxycycline (the endpoint of the imaging). 
I observed that Kras was induced upon doxycycline treatment in all the chosen 
genotypes and as expected the exogenous Mad2 was overexpressed in p53(+/+) and 
p53(+/–)KM MEFs (Figure 3.7 A).  
I followed the duration and the outcome of mitosis by imaging the cells for a total 
duration of 52 hours.  Control p53(+/–)K MEFs underwent a rapid mitosis (51 min) 
with 87% of the cells giving rise to two daughter cells and 13% becoming tetraploid 
(Figure 3.7 B upper panel, C and D). Over-expression of Mad2 in combination with 
Kras -p53(+/+)KM- led to a dramatic increase in the time spent in mitosis (5h48min) 
while having just one copy of wild-type p53 reduced this time to 3h10min (Figure 3.7 B 
and C). As expected, over-expression of Mad2 in p53(+/–)K cells increased the number 
of tetraploid cells by 2.5 fold (13.1% Vs. 32.6%; Figure 3.7 D). In addition to the partial 
rescue of the mitotic timing, p53 heterozygosity almost completely rescued the mitotic 
cell death of p53(+/+)KM MEFs (2.8% Vs. 32.7% Figure 3.7 D). Moreover, I failed to 
detect cell death in interphase during the time of imaging. These results are consistent 
with the previous in vivo data, where the over-expression of Mad2 did not induce cell 
death in the p53(+/–) background at early time points of transgene induction.  
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Figure 3.7: Mad2 over-expression induces aneuploidy in p53(+/–)Kras MEFs.  A) Western 
Blot from MEFs showing the specific over-expression of HA–Mad2 and Kras after 72hours of 
doxycycline (Dox). Actin was used as loading control. B) Time-lapse microscopy of MEFs 
showing the course of mitosis between 24 hours and 72hours after induction. Upper: p53(+/–)K 
cell entering mitosis at T=0 min and completing cytokinesis by 1hour. Middle: representative 
p53(+/+)KM cell arrested in mitosis for more than 6hrs and dying in mitosis indicated by the 
To-PRO staining (magenta). Lower: p53(+/–)KM cell completes mitosis after 6 hrs. C) 
Duration of mitosis, Y axis log2 scale. Control p53(+/–)K MEFs completed mitosis in 50 
minutes (0.8451 ± 0.01150 hours, n=624 mitosis); p53(+/+)KM MEFs ended mitosis in an 
average time of 5.8 hours (5.799 ± 0.4717, n=98 mitosis) and in p53(+/–)KM cells mitosis was 
completed in an average time of 3.2 hours (3.165 ± 0.2810 n=177 mitosis). P53(+/–)KM mitosis 
was longer than p53(+/–)K and shorter than p53(+/+)KM mitosis (unpaired t-test ****p<0.0001). 
D) Single cell analysis of the out come of mitosis showing an increased percentage of 
p53(+/+)KM cells dying compared to p53(+/–)KM and showing an increase of cells becoming 
tetraploid in the p53(+/–)KM compare to p53(+/–)K. 
 
It was surprising to find that the removal of only one copy of p53 was sufficient for 
rescuing the mitotic death induced by Mad2 over-expression. I next hypothesized that, 
in this settings, the p53(+/–) cells were similar to the true p53 Knock out (KO) and 
performed the experiment using p53(–/–)KM clones.  The effect of Mad2 over-
expression together with Kras in the p53 complete KO was similar to what we observed 
in the p53(+/–)KM cells: mitotic block but only rare mitotic death and the generation of 
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tetraploid cells (Figure 3.8 A). To rule out that the p53(+/–) cells lost the wild-type copy 
of p53, I verified the presence of the p53 wild-type allele during the experimental 
processing of the p53(+/–) MEFs (Figure 3.8 B). These results suggest that half of the 
p53 dosage is enough to allow mitotic slippage and the generation of aneuploid cells in 
the presence of high Mad2 levels. This permissiveness could explain the apparent tumor 
suppressor effect of Mad2 in the p53(+/–) background in vivo.  
 
Figure 3.8: Mad2 over-expression induces aneuploidy in p53(–/–)Kras MEFs. A) Mitotic 
timing and outcome of mitosis of single p53(–/–)KM cells after 24 hours on doxycycline 
(n=185 mitosis). B) PCR for mutant and wild-type p53 from MEFs at different steps before 
time-lapse imaging. p53(+/–) K and KM MEFs retained their wild-type copy of p53 after being 
transduced with H2B-GFP, cell sorted, plated, starved, released and induced for 24hours.   
 
3.5.6	  EARLY 	  S INGS 	  OF 	  P53-­‐P21	  MEDIATED	  G1	  ARREST 	   IN 	  V IVO 	  
I could not detect any sign of cell death in the p53(+/–)KM lungs, interestingly the 
time-lapse experiments indicated that two copies of p53 are required to trigger mitotic 
death. I decided to look again for cell death but this time I compared p53(+/+) and 
p53(+/–)KM early induction lung samples. Once again I failed to detect evidence of cell 
death (data not shown). I then explored the opposite situation, cell cycle arrest, by 
following the activation of the p53 target p21. I hypothesized that if the two copies of 
p53 are able to kill cells in mitosis they should be also more potent in inducing cell 
cycle arrest following a defective mitosis. This approach also had the advantage that 
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contrary to dead cells; arrested cells should remain for a while in the lung before 
clearance or cell cycle re-entry.  
I controlled for the HA-Mad2 and p21 induction by IHC after 4 days of doxycycline 
(Figure 3.9 A). I counted the number of p21 positive cells and normalized it by the 
quantity of tissue present on the images. In general I found a very low average of p21 
positive cells per tissue area, further analysis should focus on the cell type on interest, 
the type II pneumocytes. I observed p21 positive cells with very large nuclei in the 
p53(+/+)KM lungs, this phenomenon was less frequent in in the samples with only one 
copy of p53 (Figure 3.8 B and C).  Cell type specific analysis and the use of more 
samples could confirm the primary observations. In addition to the slight increase in the 
number of p21 cells, the fact that half of the p21 positive cells in the p53(+/+)KM have 
enlarged nuclei suggest a p53-p21 mediated G1 arrest due to Mad2 over-expression. 
These results support the hypothesis that at a very early time point (4days), the removal 
of one copy of p53 reduces the control of a defective mitosis in vivo. Additionally these 
data suggest that the inhibitory effect of Mad2 on type II pneumocyte described earlier 
(Figure 3.3) is most likely due to the mitotic block and not the activation of p53.      
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Figure 3.9: Early sings of p53-p21 mediated G1 arrest in vivo. Mice were feed doxycycline-
impregnated food at 4 weeks of age and scarified after 4 days. A) HA and p21 IHC of lung 
samples. Black scale bar 50 μm. B) Quantification showing the normalized number of p21 
positive cell per lung tissue surface. p53(+/–)K lungs were used as negative control (1.1±0.4 
positive cells, n=4 mice). The p53(+/+)KM were variable however seem to have more p21 
positive cells than p53(+/–)KM lungs (15.0 ± 8.7 n=6 Vs. 2.4 ± 1.2 n=9, n.s). C) Classification 
of the nuclear size of p21 positive cells and their distribution in the different genotypes, normal 
nuclear size in gray and large nuclei in purple. p53(+/–)K: normal 97%, large 3 %, n=31 p21 
nuclei. p53(+/+)KM: normal 53%, large 47 %, n=183 p21 nuclei. p53(+/–)KM: normal 80%, 
large 20 %, n=54 p21 nuclei. Red scale bar 10 μm. 
 
3.3	  EFFECT	  OF	  MAD2	  OVER-­‐EXPRESSION	  ON	  P53(+/–)K	  TUMOR	  
3.3.1	  MAD2	  OVER-­‐EXPRESS ING	  NODULES 	  ARE 	  SELECTED	  AGAINST 	  
I observed that Mad2 over-expression delays lung tumorigenesis induced by Kras in 
the p53(+/–) background (Figure 3.1). Moreover, in the p53 wild-type background, I 
found a high incidence of cell death in vitro whereas the p53(+/–) background was more 
permissive to Mad2 over-expression (Figure 3.7). I then suspected that high levels of 
Mad2 are generally detrimental for tumorigenesis in vivo but to different extents 
depending of the p53 background. To address this question, I verified the expression of 
the Mad2 transgene in lung nodules, taking advantage of an HA tag upstream of the 
initiation codon.  
I described that both low and high HA-Mad2 expressing nodules (Figure 3.10 A) 
were present within the same lung. A population with intermediate levels of Mad2 was 
consistently found across genotypes (Figure 3.10 A), probably due to the difficulty of 
classifying some nodules in one category using this empirical method. Control 
p53(+/+)KM lungs had an average of 46.6% of high Mad2 (HA-Mad2) expressing 
nodules whereas the removal of one copy of p53 reduced the incidence to 14.4% 
(Figure 3.10 B). These data demonstrate the evolutionary disadvantage of high Mad2 
expressing tumors in the context of p53 partial inactivation. Yet, these results are 
intriguing since the removal of one copy of p53 initially enhanced cell survival in vitro.  
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Figure 3.10: Mad2 over-expressing tumors are selected against. A) Representative staining 
of HA-Mad2 lung nodules indicating different levels of Mad2 expression: low, intermediate and 
high. Mice were selected for having at least 10 tumours and transgenes were induced at 
different time points. B) Percentage of nodules with low, intermediate (Int.) or high Mad2 levels 
shows a decrease in high expressing nodules in p53(+/–)KM mice compared to p53(+/+)KM 
(p53(+/–)KM: 14.4%, n=13 mice Vs. p53(+/+)KM: 46.6% n=13 mice, t-test ****p<0.0001) and 
similar percentage of nodules with Ha-Mad2 intermediate levels in the 2 genotypes. 
 
3.3.2	  MAD2	  OVER-­‐EXPRESS ING	  NODULES 	  ARE 	  COMPOSED	  OF 	  ANEUPLOID 	  CELLS 	  
The removal of one copy of p53 rescued the mitotic death induced by Mad2 over-
expression and lead to the generation of polyploid cells in vitro (Figure 3.7), 
paradoxically, high Mad2 nodules were most selected against in the p53(+/–) 
background (Figure 3.10).  Since chromosomal instability and aneuploidy have been 
shown to have tumor promoting and tumor suppressor effects (Weaver et al., 2007), I 
hypothesized that the initial permissiveness produced by the removal of one copy of 
p53 was generating highly instable tumors, which in turn was detrimental to 
tumorigenesis. It has previously been reported that increased chromosome copy number 
correlates with an increase in nuclear size (Knouse et al., 2014). To confirm that cells 
overexpressing Mad2 in p53(+/–) animals had undergone chromosome mis-segregation, 
I measured the nuclear size and converted to nuclear volumes in the different tumor 
sub-categories, the normal nuclear volumes of type II pneumocytes were used for 
	   57	  
normalization.  
Generally tumors cells showed very large nuclei compare to healthy cells (Figure 
3.11 A and B), it is not surprising since 68 % of solid tumors are aneuploidy (Duijf and 
Benezra, 2013). It has been previously shown that Mad2 over-expression induces 
aneuploidy in Kras induced tumors (Sotillo et al., 2010), accordingly, Mad2 over-
expression in this study led to the generation of polyploid cells as indicated by the 
dramatic increase in the tumor cell nuclear size, in both p53 backgrounds (Figure 3.11 
A and B). However the nuclear volume variability was significantly higher in the 
p53(+/–) background (Figure 3.11 B), reflecting the diverse DNA contents thus the 
increased instability. Moreover, p53(+/–)KM low tumors had larger and variable nuclei 
size compared to p53(+/–)K nuclei (Figure 3.11 B), suggesting persistent low over-
expression of Mad2 or an earlier transient Mad2 over-expression in this population. 
These data are compatible with the possibility that sustained high levels of Mad2 over-
expression may lead to an evolutionary disadvantage in p53(+/–) KM mice due to 
increased aneuploidy and chromosomal instability. 
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Figure 3.11: Mad2 over-expressing tumors are mainly composed of aneuploid cells. A) 
SpC staining of healthy wild-type type II pneumocytes or tumorigenic cells from p53(+/–)K 
mice and mice over-expressing Mad2 in the p53(+/+) or (+/–) backgrounds. E) Quantification 
of the nuclear size relative to wild-type control cells, Y axis log2 scale, indicating an increase of 
the nuclear size (unpaired t-test) and increase of size variability (F test) upon Mad2 over-
expression. Average volumes were: healthy TIIPN: 1 (0.9988 ± 0.01975, n=256 nuclei), 
p53(+/+)KM low: 4.7 (4.678 ± 0.2475 n=126 nuclei), p53(+/+)KM high: 6.2 (6.181 ± 0.2864 
n=125 nuclei), p53(+/–)KM low: 5.4 (5.423 ± 0.2415, n=129 nuclei), p53 (+/–)KM high: 6.5 
(6.535 ± 0.3584, n=118 nuclei), p53(+/–)K: 3.8 (3.842 ± 0.1641, n=147 nuclei). Scale bar 20 
μm. 
	  
3.3.3	  MAD2	  OVER-­‐EXPRESS ION	   INDUCES 	   P21	   AND	   INHIB ITS 	   P53(+/–)KRAS 	   TUMOR	  
PROL IFERATION	  
I reasoned that if Mad2 over-expressing cells were first selected against (Figure 3.10 
and 3.11), the detrimental effect of Mad2 may be eventually lost during malignant 
transformation. To test this hypothesis I analyzed early tumors coming from p53(+/–)K 
and p53(+/–)KM mice, at 15 weeks post-transgenes induction. Using 
immunohistochemistry, I first classified the tumors depending on their genotype and 
their HA-Mad2 expression (Figure 3.12 A) and I stained the sections with markers of 
cell death, proliferation and cell cycle arrest.  
Once again, I observed very few cell death events in all subtypes (Figure 3.12 B) and 
I failed to detect any differences in the amount of proliferating cells assessed by Ki67 
staining (Figure 3.12 C). Ki67 stains the cells at any phase of the cell cycle, including 
cells arrested in G1 and G2, for this reason it might not be the best marker for 
measuring tumor proliferation in this thesis. I next used BrdU labeling; I started by 
giving a BrdU pulse to the mice via injection 2 hours before sacrifice, in this experiment 
only few tumors cells were labeled in comparison to the control intestinal tissue (data 
not shown). It is relatively intuitive to think that tumors are highly proliferative but in 
fact they are relatively slow compared to other normal tissues (e.g intestine data not 
shown). Furthermore, using the 2hours BrdU labeling I did not observe differences 
between the tumors subtypes (data not shown), I hypothesized that the difference of 
proliferation between tumor subtypes could not be seen because of the small amount of 
labeled tumor cells.  With two hours BrdU pulse, only cells that enter S phase in the two 
hour window will be stained. Increasing the pulse of BrdU to 24hours will cumulatively 
stained cells entering S phase, and importantly, cells completing cell division will give 
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arise to two BrdU positive cells and amplify the proliferation signal. By increasing the 
labeling to 24 hours, I observed a significant decrease in the number of BrdU positive 
cells in High Mad2 nodules compared to the control tumors (Figure 3.12 D), thus Mad2 
over-expression impairs proliferation.  
Moreover, p53(+/–)KM high nodules had a very high number of p21 positive cells 
compared to the other nodule types (Figure 3.12 E). This result was surprising since 
p53(+/–)KM and p53(–/–)KM MEFs showed similar behavior (Figure 3.7 and 3.8) 
where the removal of only one copy of p53 rescued the mitotic death induced by Mad2. 
In this experiment, at an early tumor stage, the cells with only one copy of p53 are able 
to activate the down stream effector p21. Importantly, these result indicate that the 
p53(+/–)K tumors over-expressing Mad2 are arrested in G1.  
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Figure 3.12: Mad2 expression in early p53(+/–)Kras lung nodules induces p21 and inhibits 
proliferation. A) HA immunostaining of early tumors after 15 weeks of transgenes induction. 
Scale bar 50 μm. B) TUNEL staining showing occasional dead cells (p53(+/–)K n=18 tumors 
from 6 mice, p53(+/–)KM Low n= 9 tumors from 3 mice, p53(+/–)KM High n=10 tumors from 
4 mice). C) KI67 staining showing similar number of cycling cells in all the tumors sub-types 
(p53(+/–)K n=23 tumors from 5 mice, p53(+/–)KM Low n=15 tumors from 3 mice, p53(+/–
)KM High n=15 tumors from 4 mice). D) BrdU staining after 1day of labelling showing the 
reduced number of BrdU positive cells in High Mad2 tumors indicating the decrease of 
proliferation upon Mad2 over-expression (p53(+/–)K: 68.16 ± 2.174 n=96 tumors from 11 mice, 
p53(+/–)KM Low: 65.04 ± 3.342 n=38 tumors from 7 mice, p53(+/–)KM High : 38.00 ± 4.559  
n=24 tumors from 8 mice, unpaired t-test ****p<0.0001). E) P21 staining showing the high 
number of p21 positive cells in High Mad2 tumors indicating a G1 arrest upon Mad2 over-
expression (p53(+/–)K: 23.30 ± 3.517 n=44 tumors from 6 mice, p53(+/–)KM Low: 18.12 ± 
4.575 n=22 tumors from 4 mice, p53(+/–)KM High : 41.98 ± 6.624 n=24 tumors from 3 mice,  
unpaired t-test **p<0.01).  
 
The previous results indicated that p53(+/–)K tumors cells over-expressing Mad2 are 
able to activate the p53 target p21 (Figure 3.12), however previous experiments 
suggested that p53(+/–)KM MEFs are similar to p53(–/–)KM, it is then possible that the 
activation of p21 in the tumors is independent of p53. To test whether the activation of 
p21 was due to p53 activation, I took advantage of the rare p53(–/–)KM mice that 
survived long enough to develop tumors. I observed equal amounts of p21 positive cells 
in p53(–/–)K, p53(–/–)KM low and high tumors. These data demonstrate that the p21 
induction in p53(+/–)KM high nodules was due to the remaining wild-type copy of p53, 
since p53(–/–)KM nodules did not induce p21 despite expressing high levels of Mad2 
(Figure 3.13). 
 
Figure 3.13: Mad2 expression in p53(–/–)Kras early lung nodules doesn’t induces p21. 
Upper panel) HA immunostaining of early p53 null tumors, around 13 weeks of transgenes 
induction. Scale bar 50 μm. Lower panel) p21 staining of early p53 null tumours showing that 
the activation of p21 is p53 dependant (p53(–/–)K: 7.037 ± 1.225 n=27 tumors from 6 mice, 
	   61	  
average induction time =13.8 weeks, p53–/–)KM Low: 4.252 ± 0.8074  n=20 tumors from 4 
mice, average induction time =13.2 weeks, p53(–/–)KM High: 6.231 ± 3.099 n=13 tumors from 
6 mice, average induction time =13 weeks).  
 
At early stage, the fact that p53(+/–)KM high tumors had reduced BrdU and 
increased p21 suggests that Mad2 over-expression remained detrimental in these tumors 
by preventing cell proliferation (Figure 3.12). At later stage of tumorigenesis, I 
observed that the proportion of lungs occupied by the tumors in p53(+/–)KM lungs 
became close to the tumor proportion found in the p53(+/–)K control lungs (more than 
20 weeks, Figure 3.2). Therefore, I hypothesized that the growth repression induced by 
p21 could be released at later stages during tumor growth. Immunohistochemistry 
staining against p21 on aged-tumors (humane end point) from p53(+/–)KM animals 
remained positive for p21 upon Mad2 over-expression (Figure 3.14) however, it was 
decreased in the p53(+/–)KM high aged-tumors compare to the early ones (42 Vs. 21 
positive cells per tumor area, Figure 3.12 E and 3.14). At the contrary to early tumors, I 
was not able to assess proliferation-using BrdU labeling in the late stage tumors (data 
not shown). It is important to keep in mind that at this stage around 50% of the lungs 
are occupied by tumors in the p53(+/–)K cohort and it appeared that the BrdU was un-
evenly distributed in the lungs probably due to their general obstruction, or that the 
large tumors have reached a physiological limit. All together these results suggest that 
one wild-type copy of p53 is sufficient to activate p21 and at later tumor stages high 
Mad2 expressing nodules might have lost the control of p21 expression, probably due to 
the loss of the wild-type copy of p53. 
 
Figure 3.14: Mad2 expression in late stage p53(+/–)Kras lung nodules induces p21. Upper 
panel) HA immunostaining of late tumors, more than 20 weeks after transgenes induction. 
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Scale bar 50 μm. Lower panel) Representative images of p21 immunostaining in late stage 
tumors showing a p21 induction upon Mad2 over-expression (p53(+/–)K: 5.815 ± 0.9184 n=42 
tumors from 6 mice, p53(+/–)KM Low: 5.649 ± 0.9188 n=37 tumors from 6 mice, p53(+/–)KM 
High : 21.30 ± 2.835 n=36 tumors from 6 mice, unpaired t-test ****p<0.0001).  
 
3.3.4	  MAD2	  OVER-­‐EXPRESS ION	  DOES 	  NOT 	   INDUCE 	  SENESCENCE	  
In remained unclear to me how high levels of Mad2 can induce p21 and cell cycle 
arrest but does not lead to cell death (Figure 3.12). A possible explanation would be that 
after a long arrest the cells would re-enter the cell cycle or enter senescence; at the 
contrary to cell cycle arrest and similar to cell death, in theory senescence is 
irreversible. Using a conditional mouse model with an oncogenic Kras-V12 allele that is 
activated by Cre recombinase, a study has shown that Kras induces senescence in pre-
malignant tumors called adenomas (Collado et al., 2005). The progression of these 
tumors toward a more aggressive form; adenocarcinomas is characterized by the fact 
that the tumors overcome senescence. Thus the authors claim that lung adenomas are 
composed of many senescence cells seen by an intense senescence associated β-
galactosidase blue staining (β-gal), whereas adenocarcinomas show only rare positive 
cells.  I have observed activation of p21 in the tumors over-expressing Mad2 in the 
p53(+/–) background (Figure 3.12-14), and p21 is increased in senescent human 
fibroblast (Tahara et al., 1995). To test whether the activation of p21 and the G1 arrest 
would push the tumors cells into senescence, I performed a β-gal staining on p53(+/–)K 
with out Mad2,  Mad2 low and high tumors.  
I did not observe the previously described intense blue staining at the center of the 
tumors characteristic of adenomas in any of the tumors category suggesting that in this 
p53(+/–)Kras model of cancer the tumors were all adenocarcinomas (Figure 3.15). 
Accordingly, the MEFs over-expressing did not shown evidence of senescence as 
suggested by their growth in culture (Figure 3.6). Initially adenomas were chemically 
induced in mouse, however, adenocarcinomas are one of the lung cancer sub-types 
frequently found in humans, thus some genetically engineered models were developed 
which could directly give rise to adenocarcinomas (Kazushi Inoue, 2013). Moreover, I 
observed senescent cells only at the periphery of the tumors, where they appear to form 
an external layer that encapsulates the heart of the tumors. In the center, where the p21 
or BrdU positive cells were found I saw occasional senescent cells (Figure 3.15).  This 
pattern was very consistent across the different tumors type. It is been previously shown 
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that p21 is not required for the induction of senescence (Pantoja and Serrano, 1999), 
thus, p21 induction in high Mad2 expressing tumors doesn’t mean that cells will enter 
senescence.  In fact, it appears that senescence is not the route taken by the cells after 
being p21 positive and arrested in G1, it could be because in this model of cancer the 
tumors have already bypassed this difficulty to arise. The reduction of arrested cells 
over-time in the tumor over-expressing Mad2 can be due to 2 non-mutuality exclusive 
possibilities. The p21 positive cells can be progressively eliminated, or they can by-pass 
the arrest and re-enter the cell cycle.  
 
Figure 3.15: Mad2 expression doesn’t induce senescence in early lung nodules. Upper 
panel) HA immunostaining of early tumors after 15 weeks of transgenes induction, showing he 
different types of tumors: p53(+/–)K with out, low or high Mad2. Scale bar 200μm. Lower 
panel) β-galactosidase staining showing senescent cells at the tumor peripheries, independently 
of the tumor type.  
	  
3.4	  P53	  LOSS	  OF	  HETEROZYGOCITY	  
3.4.1	  MAD2	  OVER-­‐EXPRESS ION	  DOES 	  NOT 	   INCREASE 	  P53	  LOH	  
P53 loss of heterozygosity normally occurs in human lung cancer. It has been shown 
that p53 heterozygosity in human cancers is achieved via mutation of one copy of p53, 
which correlates with the removal of corresponding intact copy. This phenomenon is 
called p53 loss of heterozygosity (p53 LOH) and leads to the inactivation of both copies 
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of the tumor suppressor (Mallakin et al., 2007; Zienolddiny et al., 2001).  Because it 
was unclear how chromosome instability can drive tumorigenesis, a study addressed the 
possibility that chromosome instability promotes tumor suppressor loss of 
hetorozygosity. The study shows that reduced levels of the mitotic checkpoint protein 
Bub1 induce p53 LOH, however, it doesn’t induce the LOH of other tumor suppressors 
(Baker et al., 2009).  The previous results show that Mad2 over-expression impairs Kras 
induced lung tumors in the context of partial p53 inactivation (Figure 3.1 and 3.2). 
However, when I screened by immunohistochemistry the p53(+/–)KM lungs, I observed 
that 15% of tumors were able to develop with very high levels of Mad2 (Figure 3.10) 
and the p53 mediated induction of p21 decreased over-time (Figure 3.12-14). I therefore 
looked into possible compensatory mechanisms and tested whether Mad2 over-
expression induces p53 LOH. I explored this possibility by performing PCR for the two 
alleles of p53 (Figure 3.16 A upper panel), and I calculated the ratio between the mutant 
and wild-type bands, I used control healthy lungs to normalize (Figure 3.16 A lower 
panel). A ratio with a value of 1 corresponds to the normal genotype p53(+/–),  more the 
value is close to zero more the wild-type copy of p53 is underrepresented compare to 
the mutant one in the sample (Figure 3.16 A and C).  
The results indicated that both Kras and Kras/Mad2 genotypes could give rise to 
tumors with p53 LOH and Mad2 over-expression has no influence on p53 LOH (Figure 
3.16 A). To better understand the significance of p53LOH, I performed qPCR analysis 
for the Mad2 transgene on the same nodules. As expected, p53(+/–)K tumors did not 
express exogenous Mad2 and the pattern of Mad2 expression on p53(+/–)KM nodules 
was very heterogeneous as previously seen by imunohistochemistery (Figure 3.16 B and 
3.10). Since the p53(+/+)KM cohort was not originally included in this thesis, I 
obtained fewer p53(+/+)KM nodules. In the case of the p53(+/+)KM, late stage nodules 
were over-expressing the Mad2 transgene (Figure 3.16 B). I hypothesized that the Mad2 
low expressing nodules could mask a relationship between Mad2 over-expression and 
p53LOH. The correlation between the two parameters indicated that although LOH was 
not a prerequisite for high expressing Mad2 nodules, the p53 wild-type allele was 
under-represented in the most high expressing nodules (Figure 3.16 C).  In this model 
p53LOH is the result of selection pressure, an opportunistic way to adapt to the 
detrimental effect of Mad2. Yet, it is not Mad2 induced chromosome instability that is 
responsible for p53LOH since it occurs with the same frequency in the control tumors. 
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Figure 3.16: Mad2 over-expression doesn’t induce p53 LOH. A) PCR example of p53(+/–) 
and p53 LOH (upper panel); lower panel: quantification of p53 LOH in nodules: a value of 1 
corresponds to p53(+/–) and 0 to p53 LOH. B) qPCR analysis of Mad2 transgene in individual 
nodules from p53(+/+)KM n=6 tumors from 3 mice (blue) p53(+/–)K n= 5 tumors from 3 mice 
(black) and p53(+/–)KM n=19 tumors from 7 mice (red). Ref. used was a p53(+/–)KM lung 
without the rtTA and p53(+/–)M healthy lung on doxycycline was used as positive control. C) 
Regression analysis showing that Mad2 over-expression and p53LOH in p53(+/–)KM nodules 
do not correlate. On the Y axis: values used in A and on the X axis: Mad2 over-expression. Red 
square: nodules with p53(+/–) and high Mad2 levels. Green square: p53 LOH and high Mad2 
levels.  
 
3.4.2	  MAD2	  OVER-­‐EXPRESS ION	   INDUCES 	  THE 	  EXPRESS ION	  OF 	  P53	  TARGET 	  GENES	  
To functionally confirm the complete p53 loss in the different nodules I performed 
real time PCR for some p53 target genes. P53(+/–)K nodules were used as a negative 
control and p53(+/+) nodules expressing Mad2 were used as positive controls. I defined 
two groups of nodules in p53(+/–)KM mice: those that expressed high Mad2 which 
remained p53(+/–) and the ones that underwent p53 LOH (Figure 3.16  C). It has been 
shown that p53 can negatively regulate Cdc20 and positively p21 (Kidokoro et al., 
2008; Macleod et al., 1995). I observed that Mad2 over-expression led to down 
regulation of Cdc20 and induction of p21 in the p53 heterozygous background and the 
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regulations were similar to the one in the p53 wild-type samples (Figure 3.17 A and B). 
As expected, p53LOH suppressed these p53-mediated regulations. These results 
confirm that high Mad2 levels induce cell cycle arrest in nodules with only one 
functional copy of p53. It was challenging to reliably quantify cell death on tumor 
sections using TUNEL due to the physiological clearance of the lung tissue. Therefore, I 
took an alternative approach and I analyzed the expression of the two pro-apoptotic 
genes PUMA and Bax and observed their up-regulation upon Mad2 over-expression 
that was abolished upon p53LOH (Figure 3.17 C, D). Similar results were obtained with 
GADD45, an effector of the DNA damage-signaling pathway that is regulated by p53 
(Figure 3.17 E). Importantly, GADD45 is able to induce a G2 arrest. Since G1 and G2 
arrest are not distinguishable and cell death is rare in vivo it is possible that the nodules 
over-expressing high levels Mad2 are arrested in the two phases of the cell cycle and 
ultimately dying. Moreover, the p53 negative regulator Mdm2 was found down 
regulated upon p53LOH (Figure 3.15 F) indeed, it is no longer needed in the absence of 
functional p53. In summary, Mad2 over-expression induces the expression of p53 
targets when one or two copies of p53 are functional while the p53 mediated regulation 
is abolished in the p53(+/–) tumors that experienced p53LOH. The fact that Mad2 
delays tumorigenesis (Figure 3.1) shows that the late stage random occurrence of 
p53LOH in Mad2 expressing nodules was not sufficient to restore tumorigenesis.  
 
Figure 3.17: Mad2 over-expression induces the up-regulation of the p53 targets in the p53 
heterozygote background and it is abolished upon p53LOH. A-F) qPCR analysis of p53 
target genes in p53(+/+)KM (blue), p53(+/–)K (black), p53(+/–)KM high (red) and p53(+/–)KM 
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LOH high (green) (At least n=4 nodules per group were analysed, unpaired t-test *p<0.05 or 
**p<0.01). For all expect Cdc20, p53(+/+)KM n=4 tumors from 3 mice, p53(+/–)K n= 4 tumors 
from 4 mice, p53(+/–)KM high n=4 tumors from 4 mice, p53(+/–)KM LOH high n=8 from 4 
mice. For Cdc20, p53(+/+)KM n=5 tumors from 3 mice, p53(+/–)K n= 5 tumors from 2 mice, 
p53(+/–)KM high n=4 tumors from 4 mice, p53(+/–)KM LOH high n=6 from 3 mice. A) Cdc20 
B) p21 C) PUMA D) Bax E) Gadd45 F) MDM2 
 
3.4.3	   MAD2	   OVER-­‐EXPRESS ING	   CELLS 	   ARE 	   SELECTED	   AGAINST 	   IN 	   THE 	   P53(+/–) 	  
AND	  P53(–/–) 	  KRAS 	  BACKGROUND	   IN 	  V ITRO 	  
To better understand the sequence of events during lung tumorigenesis, I followed 
p53(+/–)KM MEFs during immortalization after continuous passage, twice a week as 
described previously (Sotillo et al., 2001). Contrary to the results obtained previously 
(Figure 3.6 F), Mad2 over-expression had no effect on the MEFs growth (Figure 3.18 
A). This is due to the two very distinct goals and settings of the two experiments. In the 
previous experiment (Figure 3.6), I assed the initial cell fitness by following their short-
term growth (day 0 to day 6), when the cells were counted it was the end of the 
experiment. In the long-term immortalization experiment, the one described in this part, 
the continuous passage promotes the growth and selection of the fittest, mimicking the 
phenomenon of transformation in vivo, where only one transformed cell needs to make 
it through the initial selection for a tumor to form. Even if Mad2 has been previously 
shown to have a detrimental effect on cellular growth (Figure 3.6), the cells that do not 
find a compensatory mechanism in this experiment will be eliminated early allowing the 
culture to be overtaken by low or non-expressing clones.  
Previous results indicated that p53LOH might help restoring tumorigenesis (Figure 
3.13 and 3.17), to test this hypothesis I followed the immortalization of p53(–/–)KM 
and p53(+/–)KM MEFs. The growth curves showed no differences between the two 
genotypes or to MEFs grown in the absence of doxycycline (Figure 3.18 A). In fact, 
with and without doxycycline p53(+/–)KM MEFs became immortal by losing the wild-
type copy of p53 around passage 8 (Figure 3.18 B). Interestingly, doxycycline induced 
p53(+/–)KM cultures were quickly over-taken (at passage 4) by low Mad2 expressing 
cells before LOH took place (Figure 3.18 C). These results correlates with the situation 
in vivo where low expressing nodules were found as early as 15 weeks of transgenes 
induction (Figure 3.12) and at a later time point, the high Mad2 expressing nodules 
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show sign of p53LOH (reduced p21 activation, Figure 3.14). Interestingly, p53(–/–) 
MEFs were able to sustain high levels of Mad2 for a longer time in comparison to 
p53(+/–) MEFs (until passage 10, Figure 3.16 C). In this setting, p53LOH was again not 
a consequence of Mad2 induced aneuploidy since non-induced p53(+/–)KM cells lost 
the wild-type allele at similar frequencies compared to induced cells (Figure 3.16 B).  
These results indicates that complete p53 inactivation slightly increases the tolerance for 
Mad2 over-expression in vitro. 
 
 
Figure 3.18: p53LOH is independent of Mad2 over-expression in vitro. A) Growth curve of 
p53(+/–)KM or p53(–/–)KM MEFs in culture with and without doxycycline from two 
experiments. B) PCR analysis of p53 LOH at different passages showing that LOH is 
independent of Mad2. C) Western blot analysis of HA-Mad2 shows reduction of Mad2 levels 
relative to control (Actin) prior to p53 LOH. The analysis shows that p53(–/–)KM MEFs keep 
higher Mad2 levels longer than p53(+/–)KM, indicating that p53 loss tolerate better Mad2 over-
expression. 
 
3.4.4	   P53	   COMPLETE 	   INACTIVAT ION	   DOES 	   NOT 	   RESTORE 	   KRAS 	   TUMORIGENES IS 	  
UPON	  MAD2	  OVER-­‐EXPRESS ION	  
The fact that the remaining wild-type copy of p53 in the p53(+/–)KM mice is 
sufficient to induce the regulation of the p53 targets in the tumors over-expressing 
Mad2 (Figure 3.12-14 and 3.17) suggests that the complete inactivation of p53 from the 
beginning of the transgenes induction could restore the normal course of tumorigenesis.  
To test this hypothesize, I analyzed the size and the incidence of the tumors appearing 
in the rare p53(–/–)K mice and compared it to the herein previously described p53(+/–
)K tumors, with or with out Mad2. Because the p53 null mice die very early in 
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comparison to the other lung tumor models used here, I used early time points of 
transgene induction in this experiment, about 15 weeks.  
In both p53 backgrounds I found again that the Mad2-high expressing nodules were 
smaller than the low expressing ones (Figure 3.19 A and B). Contrary to the p53(+/–) 
mice,  the majority of nodules in p53(–/–) mice were expressing high levels of Mad2 
(Figure 3.19 C) at 15 weeks. The results indicate that the maximum detrimental effect 
of Mad2 during p53(+/–)K tumorigenesis occurs prior tumorigenesis, where Mad2 high 
expressing cells are selected against due to their increased aneuploidy and remaining 
p53 activity. The fact that low expressing nodules are generated in the p53(–/–)K 
background together with the fact that high Mad2 nodules remain smaller suggest that 
even if complete loss of the p53 tumor suppressor helps tolerating high levels of Mad2, 
it would not be enough to restore the normal course of tumorigenesis.  Previous results 
indicated that the inactivation of the two copies of p53 first led to the generation of 
polyploid cells (Figure 3.8) and then suppressed rescuing mechanisms (e.g. cell cycle 
arrest, Figure 3.13 and 3.17). In the absence of p53, it is possible that the double 
tolerance (in mitosis and in G1) for Mad2 over expression turn out to be harmful. It 
would be interesting to study what are the molecular mechanisms impairing the 
development of aneuploid tumors in the absence of p53.  
 
 
Figure 3.19: High Mad2 nodules are smaller than control nodules in the complete p53 
knock out. A) HA-Mad2 staining showing the size of p53(+/–)K , p53(+/–)KM low and high,  
p53(–/–)K and p53(–/–)KM low and high nodules. Scale bar: 200μm B) Graph representing the 
decreased nodules size (arbitrary unit) upon Mad2 over-expression independently of the p53 
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background (p53(+/–)K n=103 tumors from 6 mice, p53(+/–)KM low n=45 tumors from 4 mice,  
and high n=52 tumors from 4 mice; p53(–/–)K n=63 tumors from 5 mice, p53(–/–)KM low 
n=24 tumors from 4 mice and high n=27 tumors from 4 mice, unpaired t-test *p<0.05 or 
***p<0.001) C) Graph showing reduced incidence of high Mad2 nodules compared to the low 
ones in p53(+/–) lungs and an increased incidence of high Mad2 nodules in the complete null 
p53 background (p53(+/–)KM n=24 lung fields from 6 mice, p53(–/–)KM n=26 lung fields 
from 7 mice, unpaired t-test *p<0.05).  
	  
3.5	   IN	   VIVO 	   CARACTERIZATION	   OF	   THE	   EGFR	   COHORTS	   OVER-­‐EXPRESSING	  
MAD2	  
3.5.1	  MAD2	   OVER-­‐EXPRESS ION	   DELAYS 	   EGFR	   DRIVEN	   LUNG	   TUMORIGENES IS 	   UPON	  
P53	  PARTIAL 	   INACT IVAT ION	  BUT 	  NOT	   IN 	  THE 	  P53	  WILD-­‐TYPE 	  BACKGROUND	  
Mad2 over-expression together with the Kras oncogene has been shown to accelerate 
tumorigenesis (Sotillo et al., 2010) while the similar combination in the context of 
partially impaired p53 delays tumorigenesis (Figure 3.1). In the field, whether 
aneuploidy is promoting or suppressing tumorigenesis is often attributed to the cellular 
context since all the studies aiming to better understand this opposite behavior have yet 
to reach a consensus. I hypothesized that regardless of the oncogene driving 
tumorigenesis Mad2 is detrimental in the context of a partially inactivated p53. After 
Kras, EGFR is the second most common oncogene found in lung cancer (Imielinski et 
al., 2012). I took advantage of mice expressing an inducible a human EGFR oncogene: 
EGFRL858R (Politi et al., 2006) (E) and crossed them with the inducible Mad2 mice in a 
wild-type or p53 heterozygous background.   
I observed that the EGFR mice had a very fast onset of tumorigeneis in comparison 
to the Kras model (Figure 3.1 and 3.20 A).  Here again, the combination of Mad2 over-
expression in the p53(+/–) background delayed lung tumorigenesis (Figure 3.20 A). 
However, contrary to what was described in the Kras model, Mad2 over-expression 
seem to have no impact on EGFR driven tumorigenesis in a p53-wild-type background 
(Figure 3.20 B).  A possible explanation for this finding is that the EGFR tumor onset is 
so fast that it cannot be further accelerated by Mad2 over-expression, or, that the EGFR 
cells are highly proliferative and thus do not tolerate an hyper-active mitotic checkpoint. 
In other words, the treading of aneuploidy for the cost of a mitotic block is no longer 
producing benefits in the EGFR model. I speculate that aneuploidy could accelerate 
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EGFR tumorigeneis in the p53 wild-type background, only with a permissive mitotic 
checkpoint.  
 
Figure 3.20: Mad2 delays lung tumorigenesis in the EGFR lung cancer models. A) Tumor 
free survival of mice expressing EGFRL858R oncogene (E) in the p53(+/–) background. Median 
survival time of p53(+/–)E: 11.57 weeks, n=17 (black) and p53(+/–)EM: 18.05 weeks, n= 41 
(red) (Mantel-cox test **p<0.01). B) Tumor free survival of mice expressing EGFRL858R 
oncogene (E) in the p53 wild-type background. Median survival time of p53(+/+)E: 12.43 
weeks, n=21 (gray line), p53(+/+)EM: 17.86 weeks, n=41 (blue). 
 
3.5.2	   MAD2	   OVER-­‐EXPRESS ING	   NODULES 	   ARE 	   SELECTED	   AGAINST 	   IN 	   THE 	   EGFR	  
MODEL	  
I have seen that in the Kras model different types of tumors appeared in the cohorts 
over-expressing Mad2 (Figure 3.10). I performed the same analysis in the EGFR 
cohorts; by immohistochemistry I classified the incidence of low, intermediate and high 
Mad2 expressing nodules (Figure 3.21 A and B). The induction of EGFR led to the 
generation of a different type of tumors, bronchioloalveolar carcinoma (BAC or diffuse 
tumors) that contrary to confined nodules colonizes the entire lung. I also noticed 
variable levels of Mad2 in this tumor type (Figure 3.21 C and D).  Independent of the 
p53 background, the high Mad2 expressing tumors sub-type was extremely under-
represented (Figure 3.21). I speculate that in a perfect mouse model where only high 
Mad2 nodules would be generated, the tumorigenesis of EGFR in the p53 wild-type 
background would also be delayed. The advantage of this model, at the contrary to the 
Kras one, is that the different types of tumors are equally represented in both p53 
backgrounds with very rare high Mad2 expressing nodules (Figure 3.10 and 3.21). In 
this case, it is possible to affirm that it is the low expressing Mad2 nodules that are 
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responsible for the death of the animals in the two p53 backgrounds.  
 
Figure 3.21: Mad2 High nodules are selected against in the EGFR models. A) 
Representative staining for HA-Mad2 showing low Mad2 nodules in the EGFR model. Scale 
bar 500 μm. B) Quantification of nodule incidence depending on Mad2 expression (p53(+/+) 
n=10 mice; p53(+/–) n=13 mice). C) Representative staining of a low, intermediate and high 
HA-Mad2 in bronchioalveolar carcinomas (BAC) of p53(+/–)EM mice. Scale bar 500μm. D) 
Percentage of BAC tumors depending of HA-Mad2 levels. 
 
3.5.3	  MAD2	   OVER-­‐EXPRESS ING	   NODULES 	   ARE 	   MAINELLY 	   COMPOSED	   OF 	   ANEUPLOID 	  
CELLS 	  
Previous results indicate that the removal of one copy of p53 predisposed Kras cells 
to high aneuploidy and instability due to their in-efficiency to die during prolonged 
mitosis (Figure 3.7). In fact high expressing Mad2 tumor cells in the Kras, p53(+/–) 
background showed an increased nuclear size suggesting higher levels of aneuploidy, 
additionally the nuclear sizes were highly variable reflecting the increased chromosomal 
instability (Figure 3.11). Similar analysis in the EGFR tumors indicated that once again 
the size of the nuclei and the variability in size were increased upon Mad2 over-
expression, especially in the cohort where one copy of p53 was lacking (Figure 3.22). 
These results support the hypothesis that Mad2 over-expression and the removal of one 
copy of p53 increases chromosomal instability and the level of aneuploidy, which is 
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selected against very early in tumorigenesis.  Further analysis on this model remains 
challenging mainly due to two reasons: the generation of diffuses tumors and the low 
incidence of nodules over-expressing Mad2, it impairs tumor measurement and staining 
quantifications in tumors sub-categories.  
 
 
Figure 3.22: Mad2 High nodules are mainly composed aneuploidy cells. Quantification of 
the nuclear size relative to wild-type control cells, Y axis log2 scale, indicating an increase on 
the nuclear size and size variability upon Mad2 over-expression (unpaired t-test and F test: ****p 
<0.0001). The average volumes: p53(+/+)EM low: 2 (2.030 ± 0.06550 n=259 nuclei), 
p53(+/+)EM high: 4.9 (4.851 ± 0.1750 n=204 nuclei), p53(+/–)EM low: 4.6 (4.579 ± 0.1746 
n=247 nuclei), p53 (+/–)EM high: 6.8 (6.757 ± 0.3193 n=276 nuclei), p53(+/–)E: 3.3 (3.337 ± 
0.1752 n=101 nuclei).  
 
3.6	   HIGH	   LEVELS	   OF	   MAD2	   IMPAIRS	   KRAS	   LUNG	   TUMOR	   GROWTH	   IN	   THE	  
P53	  WILD-­‐TYPE	  BACKGROUND.	  
3.6.1	   KINET ICS 	   OF 	   KRAS 	   TUMORIGENES IS 	   IN 	   P53	   WILD-­‐TYPE 	   COMPARE 	   TO 	   P53	  
HETOROZYGOTE, 	  WITH 	  OR 	  WITH 	  OUT 	  MAD2	  OVER-­‐EXPRESS ION	  
It appeared to me that the combination of Mad2 over-expression together with 
impaired p53 is detrimental in the EGFR model (Figure 3.20) and Mad2 is detrimental 
for p53(+/–)Kras tumorigenesis (Figure 3.1). Detailed analysis of the p53(+/–)Kras 
model suggested that the detrimental effect of Mad2 is predominantly exerted prior to 
tumorigenesis, as a result very few nodules with high levels of Mad2 were generated in 
the p53 heterozygote background (Figure 3.10 and 3.19). This particular fatal 
combination seems to be due to permissiveness produced by the inactivation of one 
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copy of p53 towards the aneuploidy generated by Mad2 (Figure 3.7). However, since 
one copy of p53 is able to induce cell cycle arrest in the Mad2 expressing tumors, it 
remained unclear to me how Mad2 over-expression benefits Kras tumors progression in 
the p53 wild-type background, in which they are two functional p53 copies. For these 
reasons, I decided to compare the effect of Mad2 over-expression on Kras 
tumorigenesis in the p53 wild-type and p53(+/–) backgrounds simultaneously.  
Because the method is faster and commonly employed than survival curves for 
monitoring lung tumorigenesis, I followed the kinetics of tumorigenisis by histology in 
the four following mice cohorts: p53(+/+)K, p53(+/+)KM, p53(+/–)KM, and p53(+/–
)KM at two time points of transgene induction, 15 weeks and more than 20 weeks 
(Figure 3.23 A). In this experiment the more than 20 weeks time point has a sharper 
time window (25 to 29 weeks) than in the figure (Figure 3. 2). In the previous 
experiment the mice were humane end point and exceeded this time window. First I 
observed that at 15 weeks of transgenes induction, the tumorigenesis in the p53(+/–)K 
was more advanced than in the p53(+/+)Kras lungs, until the lungs reached saturation in 
both cohorts (at >20 weeks, 50% of the lungs were occupied by tumors, Figure 3.23 B 
and C). Furthermore, Mad2 over-expression delayed p53(+/–)K induced tumorigenesis  
at 15 weeks and this difference faded over time (Figure 3.23), these results confirms 
previous findings (Figure 3. 2). In the p53 wild-type background, Mad2 over-expression 
delayed Kras tumorigenesis (Figure 3.23 B and C) however, it remains unclear what 
would be the long-term effect on mice survival. In fact, Mad2 over-expression in the 
p53 wild-type EGFR background appeared to be detrimental since high Mad2 
expressing nodules were selected against however; the mice survival was not 
significantly prolonged. Therefore, it is possible that Mad2 over-expression in the p53 
wild-type background would have no effect or could increase the Kras tumor free 
survival of the mice. Importantly at 15 weeks, the detrimental effect of Mad2 was more 
visible in the p53(+/–)K cohort, since the default tumorigenesis was more potent 
(Figure 3. 23 B). In a simple model where tumor would grow exponentially, the earlier 
and the strongest Mad2 detrimental effect is, the later mice will succumb of lung 
tumors.  
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Figure 3.23: Mad2 delays Kras driven lung tumorigenesis at two time points. A) Kinetics 
of tumorigenesis in p53(+/+)K and p53(+/+)KM, p53(+/–)K and p53(+/–)KM mice. H&E 
staining at 15 weeks and >20 weeks after transgene induction. Scale bar 500μm. B) Percentage 
of tumor area per lung section after 15 weeks of transgenes induction. Data indicating a delays 
in tumorigenesis upon Mad2 over-expression, that is more evident in the p53(+/–) than in the 
p53(+/+) background (p53(+/+)K= 18.42% n=10 mice, p53(+/+)KM= 5.84% n=19 mice, 
p53(+/–)K = 37.69 % n=10 mice, p53(+/–)KM = 14.95% n=16 mice;  unpaired t-test *p<0.05,  
**p<0.01). C) Percentage of tumor area per lung section after >20 weeks of transgenes 
induction. Data indicating a delays in tumorigenesis upon Mad2 over-expression (p53(+/+)K= 
38.81% n=6 mice, p53(+/+)KM= 19.63% n=16 mice, p53(+/–)K = 43.90 % n=11 mice, p53(+/–
)KM = 25.29% n=9 mice;  unpaired t-test **p<0.01). 
 
3.6.2	  MAD2	  OVER-­‐EXPRESS ION	   INDUCES 	   P21	   AND	   INHIB ITS 	   P53(+/+)KRAS 	   TUMOR	  
PROL IFERATION	  
I reasoned that if one copy of p53 and Mad2 over-expression can induce p21, it is 
also probably the case in the presence of two copies of p53. In fact, I observed similar 
induction of the p53 targets in aged tumors with high levels of Mad2 with one or two 
copies of p53 (Figure 3.17). To confirm the induction of p21 at an early time points and 
analyze the effect on tumor proliferation, I analyzed tumors coming from p53(+/+)K 
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and p53(+/+)KM mice. Similarly to the previous analysis tumors were generated by 15 
weeks of transgenes induction. Using immunohistochemistry I classified the tumors 
depending on their genotype and their HA-Mad2 expression (Figure 3.24 A), I analyzed 
the tumors for p21 induction and BrdU incorporation.  
In early stage tumors, I observed a significant increase of p21 positive cells and 
decrease of BrdU positive cells in High Mad2 nodules compared to the control tumors 
(Figure 3.24 B and C), suggesting a G1 mediated arrested also in this background. The 
fact that the control p53(+/+)Kras tumors appears to have more p21 induction than the 
p53(+/–)K at early time point (23 Vs. 48 positive cells per tumor area, Figure 3.12 E  
and 3.24) together with the fact that p53(+/+)Kras tumors are smaller than p53(+/–)K at 
15 weeks (Figure 3.23) suggests that having only one copy of p53 accelerates Kras 
tumorigenesis in this thesis. I speculate that Kras cells over expressing Mad2 have a 
reduced chance to accumulate instability compare to the p53(+/–)K cells. With two 
copies of p53 the Kras cells seem to have a better control of the cell cycle (e.g mitotic 
block, transformation) than the p53(+/–)K cells. However, even if Kras and Mad2 
produces moderate instability compare to the tumors in the p53 heterozygote 
background, all the tumors over-expressing Mad2 are arrested in G1.  
 
Figure 3.24: Mad2 expression in p53 wild-type Kras lung nodules induces p21 and inhibits 
proliferation. A) HA immunostaining of early tumors after 15 weeks of transgenes induction. 
Scale bar 50 μm. B) BrdU staining after one day of labelling showing the reduced number of 
BrdU positive cells in High Mad2 tumors, indicating the decrease of proliferation upon Mad2 
over-expression (p53(+/+)K: 71.40 ± 4.528 n=42 tumors from 6 mice, p53(+/+)KM Low: 86.16 
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± 4.358 n=18 tumors from 4 mice, p53(+/+)KM High : 53.19 ± 3.098 n=24 tumors from 8 mice,  
unpaired t-test ****p<0.0001). C) P21 staining showing the high number of p21 positive cells in 
High Mad2 tumors indicating a G1 arrest upon Mad2 over-expression (p53(+/+)K: 47.73  ± 3. 
748 n=37 tumors from 5 mice, p53(+/+)KM Low: 53.84 ± 4.382 n=19 tumors from 4 mice, 
p53(+/+)KM High : 104.9 ± 10.90  n=20 tumors from 5 mice,  unpaired t-test ***p<0.001).  
 
I observed that the difference in tumor area in aged p53(+/+)K and p53(+/+)KM 
remained visible over-time (Figure 3.23 C). I hypothesized that the growth repression 
induced by p21 could be maintained at later stages during tumor growth. As expected, 
immunostaining against p21 on aged-tumors (from 25 weeks to 34 weeks of induction) 
from p53(+/+)KM animals remained positive for p21 upon Mad2 over-expression 
(Figure 3.25) however, it was also decreased in the p53(+/+)KM high aged-tumors in 
comparison to the early ones (105 Vs. 71 positive cells per tumor area p<0.01 , Figure 
3.24 C  and 3.25). I observed that p53 (+/–) tumors loose the wild-type copy of p53 that 
reduce the expression of p21, however it is unlikely that the tumors loose the two alleles 
of p53. How the p53 wild-type tumors expressing high levels of Mad2 are able to 
reduce the p21 induction remains unknown and could be addressed in the future. 
 
 
Figure 3.26: Mad2 expression in late stage p53 wild-type Kras lung nodules induces p21. 
Upper panel) HA immunostaining of early tumors after at least 20 weeks of transgenes 
induction. Scale bar 50 μm. Lower panel) P21 staining in aged tumors showing the activation 
of p21 upon Mad2 over-expression (p53(+/+)K: 41.21 ± 3.129 n=29 tumors from 5 mice, 
p53(+/+)KM Low: 36.98 ± 2.188 n=31 tumors from 7 mice, p53(+/+)KM High : 70.74 ± 6.204 
n=23 tumors from 8 mice, unpaired t-test ****p<0.0001).  
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4	  DISCUSSION	  	  
4.1	  CONSTRUCTION	  OF	  A	  MODEL	  	  
The results of my work indicate that Mad2 delays Kras and EGFR tumorigenesis in 
the context of p53 partial inactivation. Work from my colleagues, who are studying 
similar combinations of oncogenes together with Mad2 in the breast, supports the fact 
that Mad2 over-expression is detrimental to tumorigenesis. Specifically, in the p53 
wild-type mouse model, Mad2 delays Kras-induced breast cancer (in preparation, 
Konstantina Rowald). Furthermore, Mad2’s detrimental effect on Her2 and on Myc-
induced breast cancer was previously described in Martina Mantovan’s PhD thesis 
(Autonomous University of Madrid). In addition, my results suggest that the negative 
effects of Mad2 are exacerbated in the context of p53 partial inactivation in lung tumors 
driven by the Kras or EGFR oncogene, however it remains unclear if this is the case in 
other cancer types. 
In this thesis, I classified tumorigenesis in three stages (Figure 4.1). Initially, Mad2 
over-expression impairs proliferation in both p53 backgrounds due a primary mitotic 
block. However, the cell fate outcomes differ depending on the p53 background. I 
hypothesize that, prior to tumorigenesis, the inactivation of one allele of p53 results in a 
less stringent control of the cell cycle. Firstly, cancer is the result of uncontrolled cell 
growth and Kras tumorigenesis is enhanced upon p53 partial inactivation. Second, early 
passage MEFs challenged by Mad2 over-expression do not succumb to mitotic death in 
the p53 (+/–) background and do not die in interphase during imaging. Reduction of p53 
leads to weak cell cycle control, and together with Mad2 over-expression generates 
highly instable cells, which, in turn, impairs cellular transformation (Figure 4.1 A). The 
clearance of cells with high levels of aneuploidy in the p53 wild-type tissues may 
attenuate the detrimental effect of Mad2 on tumorigenesis. The elimination of defective 
type two pneumocytes could fuel their re-generation and increase the chance for a clone 
transformation with high levels of Mad2.  
In the context of simultaneous Mad2 and Kras over-expression, the p53 background 
influences the selection of clones, giving rise to tumors. At the tumor stage, one copy of 
p53 is sufficient to induce G1 arrest. Mad2 over-expression induces the expression of 
p21 in the p53(+/+) and p53(+/–) tumors, but not in the p53(–/–)tumors. Furthermore, 
the response to Mad2 over-expression was not restricted to p21, but also included other 
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p53 targets, confirming the p53-mediated response. As a consequence, the tumors over-
expressing Mad2 had decreased proliferative potential with one or two copies of p53 
(Figure 4.1 B). At a later stage of tumorigenesis, Mad2 did not influence the loss of the 
remaining copy of p53. However, complete inactivation of p53 served as a 
compensatory mechanism to the few nodules expressing high levels of Mad2. In 
general, the late spontaneous loss of p53 was not sufficient for counteracting the strong 
selection occurring prior to tumorigenesis in the p53(+/–)KM lung tissues (Figure 4.1 
C). A hypothesis for the strong selection in the p53(+/–)KM lung is that the defective 
type II pneumocytes are not being eliminated due to the impaired p53 function, 
reducing their chance for transformation. In the p53 wild-type background it remains 
unclear how the tumors expressing Mad2 compensate for the cell cycle arrest, they 
could mutate one p53 allele and generate a dominate negative p53 form that would 
reduce the induction of p21 or act down stream of p21.  
 
 Figure 4.1: Findings model:  Tumorigenesis is divided in 3 stages after doxycycline induction 
(Dox), prior tumorigenesis (orange, A): early tumorigenesis (green, B), and late tumorigenesis 
(blue, C) until humane end point (HE). The gray shapes represent the intensity of Mad2 
detrimental effect on lung tumorigenesis over time. Upper part in the p53 wild-type 
background, Lower part in the p53(+/-) background. The blebbing cell represents cell death 
and the 2 times 2N cell and its size represents the amount of aneuploid cells, always in the 
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context of Mad2 over expression (bleu round shape). The traffic light signs indicate the effect of 
p53 dosage in mitosis in A, B and C, and in G1 in B and C. The left dashed line symbolizes the 
cell malignant transformation and the right one the tumor progression and it is qualified by the 
signs STOP or SLOW. A) Even if Mad2 induces a mitotic arrest in both conditions Mad2 
produces more aneuploid cells in the p53 (+/–) background and impairs cellular transformation, 
most of the cells arrested in mitosis are eliminated in the p53 wild-type background. B) The 
remaining wild-type copy of p53 activates its target p21 to arrest aneuploidy cells in G1. The 
Mad2 detrimental effect on tumor progression is more pronounced in the p53 (+/–) since it 
produces more aneuploidy cells. C) Loss of the p53 wild-type copy suppresses the G1 arrest but 
increase aneuploidy leading to slow tumor progression. It remains unclear how tumor 
progression occurs in the in the p53 wild-type background and how the G1 arrest is by-passed. 
	   	   	  
4.2	  NEW	  MOUSE	  MODELS?	  	  
In this thesis, the partial inactivation of p53 was achieved by inactivation of one 
allele from the day of conception modeling of the Li-Fraumeni syndrome, which is 
characterized by germ-line mutations of p53, for which rare sufferers have 
predisposition to cancer (Li and Fraumeni, 1969). Because tumorigenesis in mouse 
models can be time-consuming, the p53(+/–) mouse model (Jacks et al., 1994) has 
become a tool for the acceleration of tumorigenesis. Additionally, human tumors are 
more instable than the murine tumors, so model-increasing CIN was used to faithfully 
mimic the instability of human tumors (Janssen and Medema, 2013). The combination 
of Mad2 and Kras over-expression in fact led to instable tumors (Sotillo et al., 2010). 
However, combining the two mouse lines for accelerating tumorigenesis failed and 
resulted in a further delay. Since partial inactivation of p53 is not directly relevant for 
lung cancer, the work should be complemented using inducible forms of modified p53 
(see section 1.4).  
Whether aneuploidy is a cause or a consequence of cellular transformation is 
frequently debated. The fact that chromosome abnormalities do not occur in isolation 
together with the fact that mutations of the SAC genes are extremely rare in cancer 
(Carter et al., 2006), made it challenging to identify aneuploidy as the initiating event. 
The over-expression of SAC components found in cancer could be the result of tumor-
increased proliferation and the inactivation of tumor suppressors (Schvartzman et al., 
2011). It is also possible that over-expression of SAC components does not result in 
SAC over-activation. It would be interesting to determine the stoichiometry of the SAC 
components in human tumors. Nevertheless, it appears that aneuploidy leads to late 
latency murine tumors (see section 1.8), though this has been done in extreme settings 
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such as SAC gene knockdown or over-expression. Importantly, the results could also 
come from additional SAC-independent protein functions. All together, these findings 
support the hypothesis that aneuploidy is the result of a deregulated cell cycle by driver 
oncogenes and tumor-suppressor inactivation. Thus, it might be of interest to decouple 
tumor generation and the induction of CIN in mouse models. In this thesis, it was not 
possible since Mad2 and Kras or EGFR were induced simultaneously by doxycycline. 
To closely simulate human disease, if would be of interest to combine relevant p53 
modifications with a mouse model in which transgenes can be induced independently.  
4.3	  SELECTION	  
The modulation of the expression of SAC components leads to genomic instability, 
but has variable effects on tumorigenesis: spontaneous late latency tumors (see section 
1.8) or various degrees of delayed tumorigenesis (this thesis). Using the Tet-On 
transgenic system, I noticed that different tumor populations (expressing low to high 
levels of Mad2) have co-evolved from an original population of Mad2 expressing type 2 
pneumocytes. In vivo, low Mad2-expressing nodules were over-represented in almost 
all mouse models analyzed, suggesting that high Mad2 levels are selected against during 
tumorigenesis. In addition, MEFs over-expressing Mad2, if not dead, are quickly over-
taken in culture by low expressing cells. The use of a moderate over-expression 
transgenic system would be more appropriate for further in vitro experiments.  
I propose that co-evolution of the Mad2 tumor types is the result of selection 
mechanisms occurring prior to tumorigenesis (Figure 4.2). Considering that 
spontaneous models of tumorigenesis have tissue in quasi-homeostasis (Sotillo et al., 
2007) and that transgenic cancer models undergo rapid tumorigenesis, it is possible that 
different selective pressures take place. In reference to evolution and organisms 
development, a crucial step during the process of Darwinian evolution is genetic 
stabilization, making the new species (or tumor) independent of its environment. This 
requirement is indeed compromised in the models with a rapid onset of cancer. In late 
latency tumors, the amount of CIN has probably been ‘shaped’ and ‘stabilized’ to a 
certain degree. Importantly, a slow proliferation rate and putative stabilization have 
been linked to tumor aggressiveness (Anjomshoaa et al., 2009).  
If genetic stabilization is precluded, it is possible for an organism or a tumor cell to 
adapt to its environment. If Mad2 over-expression is initially normally distributed, the 
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cells expressing the lowest amount of Mad2 were directionally selected prior to tumor 
formation (Figure 4.2). Mad2-expressing tumors in the p53(+/–) background were 
extremely under-represented, suggesting that they persisted until a random event 
produced the required modification for their development; such as p53 loss of 
heterozygosity. In other words, implementing strong constraints on organism/cell that 
preclude stabilization in their environment will frustrate its reproduction/growth and its 
survival. Random selection is being considered as the mechanism in which cancer 
clones are generated, with each round of mutation giving growth advantages to a 
random cell. Genomic instability by means of random selection could benefit the Mad2 
opportunistic cells resistant to cancer therapies, giving rise to relapse (Sotillo et al., 
2010). Moreover, these scenarios could explain the frequent differences between in vivo 
and in vitro observations. 
 
 
 
 
 
 
 
 
 
 Figure 4.2: Putative selection mechanisms. Assuming that Mad2 is normally distributed 
among the equipped transgenic cells, some cells should express less Mad2 than average. In 
systems with slow growth, high Mad2 levels could be integrated and stabilized giving rise to 
late tumors. In system with high population doubling, Mad2 over-expression is selected against 
but it can eventually be maintain if a random event allows its tolerance.  
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4.4	  ANEUPLOIDY	  LEVELS	  
The generation of low Mad2-expressing tumor can be due to an initial variability of 
induction, or to mechanisms reducing transgene expression. A hypothesis could be that 
the transgene promoters have been methylated. In this study, Kras and Mad2 are 
induced by the same rtTA.  Even if I did not verify rtTA and Kras expression, it is very 
likely that they are expressed in tumors since Kras is required for tumorigenesis (Fisher 
et al., 2001). A probable explanation in the context of an instable genome is that the 
Mad2 transgene has been eliminated. However, I verified the presence of the Mad2 
transgene by PCR in the low expressing tumors analyzed in section 3.16 (data not 
shown). It is likely that the mosaic nature of the Tet-On system resulted in low 
expressing cells from the beginning of the induction. In fact, cells would benefit twice 
from the low induction of the transgenes given that high levels of Kras would push cells 
into senescence. The pattern of Kras expression could not be followed due to the lack of 
reliable antibodies for IHC. In a recent study using the Tet-On system, the over-
expression of the two types of Cyclins B produced tumors; whether the tumors 
maintained transgene expression was not shown (Nam and van Deursen, 2014). In vivo, 
I have analyzed tumors from the opposite spectrum of expression and noticed the 
detrimental effect of Mad2 in the tumors expressing the most. The impact of low levels 
of Mad2 over-expression on tumorigenesis remains unclear and, thus, a model inducing 
uniform lower levels of Mad2 should be used.   
The hypothesis that the amount of aneuploidy is responsible for the switch between 
tumor suppression and promotion has prompted labs to look for a critical aneuploidy 
threshold. Experiments aimed at determining the extent to which CIN or aneuploidy can 
be tolerated and affect tumorigenesis are not straightforward since quantitative detection 
of aneuploidy in tissue samples remains challenging. Often the interpretations on this 
matter come from extrapolation of results from cells derived from the mouse models 
(e.g MEFs, splenocytes) and the in vitro result does not always reflect the in vivo 
phenotypes. In addition, the multitude of ways in which to induce cancer in a mouse 
adds a layer of complexity when one decides to harmonize the findings. As an example, 
mice over-expressing Mad2 using the CMV (ubiquitous (Sotillo et al., 2007)) develop 
lung tumors, but it is not the case when the transgene is over-expressed under the 
influence of the CCSP promoter (lung epithelium (Sotillo et al., 2010)). Furthermore, 
the side effects of the transgenic systems could make it difficult to compare studies with 
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different inducible strategies. If fact, a recent study has shown that doxycycline disturb 
mitochondrial function in model organisms including mice (Moullan et al., 2015). 
Harmonization of the “amount of aneuploidy” data could be beneficial to clarify the role 
of aneuploidy on murine tumorigenesis. One approach could be via centralized 
pipelines similar to the methodology championed at the International Knockout Mouse 
Consortium (Bradley et al., 2012). Another way could be to order studies’ key 
experiments from an external platform. Nevertheless, a recent report has suggested that 
the rate of chromosome mis-segregation was the relevant parameter and not the amount 
of aneuploidy per se. The authors suggested that low rates of chromosome mis-
segregation promote tumorigenesis, while increased mis-segregation leads to tumor 
suppression (Silk et al., 2013). An additional insight coming from the tumor analysis in 
this thesis is that the faster the tumorigenesis is, the higher the inherent CIN, and the 
less Mad2 is tolerated. In light of the previous study (Silk et al., 2013), I hypothesize 
that p53(+/-)K increased the proliferation rate and leads to an increase of mis-
segregation rate upon Mad2 over-expression.  
4.5	  REPLICATIVE	  STRESS	  
A simple explanation for the CIN increase in cells with a high proliferation rate with 
over-activated SAC is that cells are undergoing frequent defective mitosis. 
Alternatively, but not exclusively, in fast cycling cells, the lack of preparation before 
replication could result in replicative stress and additional CIN. A study has shown that 
supplying extra nucleotides to a CIN cell line reduced the segregation errors (Burrell et 
al., 2013). In line with this, a study has shown that aneuploidy leads to the over-
expression of nucleic acid metabolism genes (Torres et al., 2007), suggesting the 
possibility of replicative stress. Furthermore, lagging chromosomes can be encapsulated 
in micronuclei and are a major source of DNA damage after mitotic failure (Terradas et 
al., 2010). Moreover, micronuclei have been shown to be replicating in G2 (Crasta et 
al., 2012) and their fate is still open to debate. When micronuclei break (Hatch et al., 
2013), the DNA can be re-incorporated into the genome, leading to catastrophic DNA 
rearrangements, a phenomenon called Chromothripsis likened to p53 mutations (Rausch 
et al., 2012). I noticed the formation of micronuclei during a time-lapse microscopy 
experiment (data not shown), though this line of research was not investigated. I 
hypothesize that Mad2-induced failure of mitosis in the context of partially impaired 
p53 produces micronuclei and might exacerbate the CIN phenotype by inducing 
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replicative stress. Moreover, the removal of p53 in mouse prone to replicative stress was 
expected to rescue the DNA damage and the opposite happened (Murga et al., 2009), 
demonstrating the role of p53 in limiting replicative stress. The expression of the p53 
target GADD45a is linked to DNA damage (Walmsley and Tate, 2012); in this thesis, I 
show the up-regulation of GADD45a in Mad2-expressing tumors. However, I did not 
observe the induction of DNA damage in pilot experiments (data not shown). 
Nonetheless, further experiments could investigate the effect of replicative stress on 
SAC function and mitotic fidelity.  
4.6	  P53	  CELL 	  CYCLE	  ARREST	  
Inactivation of one copy of p53 was sufficient to rescue mitotic cell death induced by 
high levels of Mad2 and leads to the generation of polyploid MEFs after slippage. It is 
generally accepted that aneuploidy results in gene dosage imbalance and proteotoxicity 
and impairs cellular fitness and growth (Pavelka et al., 2010; Segal and McCoy, 1974; 
Tang et al., 2011; Torres et al., 2007; Williams et al., 2008). How aneuploid cells cope 
with the unbalanced gene dosage remains unclear.  Polyploidization has been proposed 
as a mechanism to reduce the negative effect of aneuploidy (Varetti et al., 2014). 
Multiple copies of the genome could rescue the loss of single chromosomes. 
Accordingly, whole-genome doubling was found in 37% of cancers and was associated 
with p53 mutations (Zack et al., 2013). However, polyploidization induces endoplasmic 
reticulum stress, which is recognized by an immune-surveillance mechanism for ploidy 
(Senovilla et al., 2012). It remains unclear in this thesis whether the p53 background 
altered immune surveillance and impinged on tumor development. The survival of p53 
heterozygote MEFs in response to Mad2 over-expression is consistent with previous 
observations in cell lines. The deletion of the p53 gene enhances mitotic slippage 
(Marxer et al., 2014), it enhances CIN upon Mad2 deletion, and it is required to 
generate a CIN phenotype (Burds et al., 2005; Li et al., 2010; Thompson and Compton, 
2010). Using high-throughput time-lapse microscopy, a study proposed a model where 
cell fate after mitotic arrest (death or slippage) depends on what threshold is breached 
first: apoptotic activity or Cyclin B1 degradation (Gascoigne and Taylor, 2008). Current 
knowledge indicates that mitotic death is due to the reduction of anti-apoptotic proteins 
(Harley et al., 2010; Shi et al., 2011), and the fact that cytoplasmic p53 is capable of 
regulating them (Kim et al., 2014) could explain why p53(+/–)KM MEFs are resistant 
to mitotic death. Nevertheless, this hypothesis still remains to be addressed, although 
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information on the role of the cytoplasmic p53 in mitotic death is very limited. Research 
on the role of p53 in mitotic catastrophe could be further developed using MEFs derived 
from different p53 mouse models (see section 1.4) together with the use of biosensors 
that would report its activities in real time. 
Increasing evidence from several mouse models have underscored the tumor-
suppressor effect of aneuploidy on late-stage tumorigenesis (Varetti et al., 2014). 
However, the consequences of aneuploidy on tumor progression have not yet been fully 
addressed. Here, I show that Mad2 over-expression leads to cell cycle arrest by inducing 
the p53 target gene p21. These results are in line with a previous study, showing that 
p21 contributes to the maintenance of chromosome stability and prevents 
lymphomagenesis (Barboza et al., 2006). It is likely that in an impaired p53 context, 
Mad2 over-expression increases the level of CIN that can be later counteracted by p21 
induction in lung tumors. It is unclear whether cell cycle arrest has been induced 
directly after one or several mitotic blocks given that tetraploid cells can go through 
mitosis but also arrest in G1 (Kuffer et al., 2013). At an early stage of tumorigenesis, 
nodules expressing Mad2 in p53(+/–) animals rely on one wild-type copy of p53 to 
induce G1 arrest. The fate of the arrested cells, since pro-apoptotic genes were up-
regulated, remains unclear, and it is possible that they die. However, I did not observe 
cell death in vivo; another alternative is that the cells re-enter the cell cycle. 
Analysis of late stage tumors showed that complete loss of p53 increases the 
tolerance for Mad2 over-expression. This result is not surprising since a study using 
mitotic drugs on human cell lines has shown that aneuploidy-induced cell cycle arrest 
mediated by p21 does not occur in p53-deficient cells (Thompson and Compton, 2010). 
However, lung tumors over-expressing Mad2 in the complete p53 KO model remained 
smaller. These data show that p53 complete KO would not be sufficient to restore the 
detrimental effect of Mad2 on lung tumorigenesis. The van Deursen lab has shown that 
in p53 heterozygous mice, CIN leads to p53 loss of heterozygosity (LOH) and 
accelerates lymphomagenesis. However, it remains unclear how CIN delayed prostatic 
cancer in a model heterozygote for the tumor suppressor Pten (Baker et al., 2009). In 
this thesis, Mad2 over-expression failed to increase p53 LOH because high levels of 
Mad2 were first selected against. CIN is proposed to actively induce loss of 
chromosomes containing tumor-suppressor genes (Sotillo et al., 2009). My thesis 
suggests a rather passive mechanism where clones are selected for LOH to counteract 
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the negative effect of CIN. This hypothesis should be further confirmed with other 
tumor suppressors. 
 
4.7	  THE	  SAC	  AS	  A	  THERAPEUTIC	  TARGET	  
The result of this study supports the hypothesis that in the long term, mitotic slippage 
and enhanced instability impairs lung tumor development and growth. Since only 30% 
of patients with NSCLC show a partial response to taxane-based therapy, a recent study 
using NSCL cancer cell lines has shown that increasing the duration of mitotic arrest 
increases the efficacy of the chemotherapeutic agent Paclitaxel (Sinnott et al., 2014). 
Moreover, the inhibition of the SAC Mps1 kinase increased the sensitivity of cancer 
cells to chemotherapeutic agents (Tannous et al., 2013). In human breast tumor samples, 
the clinically relevant concentration of Paclitaxel was low and induces chromosome 
mis-segregation (Zasadil et al., 2014). Moreover, a low dosage of Paclitaxel induces 
aneuploidy in cell lines and is sufficient to induce G1 arrest (Giannakakou et al., 2001). 
Interestingly, using intra-vital imaging in mice has shown that the chemotherapeutical 
agent Docetaxel had anti-tumor effects by means other than mitotic perturbation 
(Janssen et al., 2013), suggesting the need for improving the efficacy of 
chemotherapeutic agents. Kras mutations and p53 dysfunction can initially induce 
mitotic stress (Luo et al., 2009) and CIN (Burds et al., 2005; Thompson and Compton, 
2010). The results of this thesis suggest a therapeutic strategy for lung adenocarcinomas 
by combining anti-mitotic agents (targeting microtubules or mitotic spindle) with drugs 
that increase CIN. Determining if and how the SAC is over-activated in tumor would 
help to find the best strategy.  
 
 
 
 
 
	  
	   88	  
LITERATURE	  	   	  
Abdel-Rahman, W.M., Katsura, K., Rens, W., Gorman, P.A., Sheer, D., Bicknell, D., Bodmer, 
W.F., Arends, M.J., Wyllie, A.H., and Edwards, P.A. (2001). Spectral karyotyping suggests 
additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement. 
Proc Natl Acad Sci U S A 98, 2538-2543. 
Anjomshoaa, A., Nasri, S., Humar, B., McCall, J.L., Chatterjee, A., Yoon, H.S., McNoe, L., 
Black, M.A., and Reeve, A.E. (2009). Slow proliferation as a biological feature of colorectal 
cancer metastasis. British journal of cancer 101, 822-828. 
Baker, D.J., Jin, F., Jeganathan, K.B., and van Deursen, J.M. (2009). Whole chromosome 
instability caused by Bub1 insufficiency drives tumorigenesis through tumor suppressor gene 
loss of heterozygosity. Cancer Cell 16, 475-486. 
Bakhoum, S.F., Thompson, S.L., Manning, A.L., and Compton, D.A. (2009). Genome stability 
is ensured by temporal control of kinetochore-microtubule dynamics. Nature cell biology 11, 
27-35. 
Baltimore, D. (1970). RNA-dependent DNA polymerase in virions of RNA tumour viruses. 
Nature 226, 1209-1211. 
Banfield, W.G., Woke, P.A., Mackay, C.M., and Cooper, H.L. (1965). Mosquito Transmission 
of a Reticulum Cell Sarcoma of Hamsters. Science 148, 1239-1240. 
Barboza, J.A., Liu, G., Ju, Z., El-Naggar, A.K., and Lozano, G. (2006). p21 delays tumor onset 
by preservation of chromosomal stability. Proc Natl Acad Sci U S A 103, 19842-19847. 
Bloecher, A., Venturi, G.M., and Tatchell, K. (2000). Anaphase spindle position is monitored 
by the BUB2 checkpoint. Nature cell biology 2, 556-558. 
Boveri, T. (1914). Frage der Entwicklung maligner Tumoren. (Jena, Germany: G. Fischer). 
Bradley, A., Anastassiadis, K., Ayadi, A., Battey, J.F., Bell, C., Birling, M.C., Bottomley, J., 
Brown, S.D., Burger, A., Bult, C.J., et al. (2012). The mammalian gene function resource: the 
International Knockout Mouse Consortium. Mammalian genome : official journal of the 
International Mammalian Genome Society 23, 580-586. 
Breasted, J.H., and New York, h.s. (1930). The Edwin Smith surgical papyrus (Chicago, Ill.,: 
The University of Chicago press). 
Brocard, J., Warot, X., Wendling, O., Messaddeq, N., Vonesch, J.L., Chambon, P., and 
Metzger, D. (1997). Spatio-temporally controlled site-specific somatic mutagenesis in the 
mouse. Proc Natl Acad Sci U S A 94, 14559-14563. 
Burds, A.A., Lutum, A.S., and Sorger, P.K. (2005). Generating chromosome instability through 
the simultaneous deletion of Mad2 and p53. Proc Natl Acad Sci U S A 102, 11296-11301. 
Burrell, R.A., McClelland, S.E., Endesfelder, D., Groth, P., Weller, M.C., Shaikh, N., Domingo, 
E., Kanu, N., Dewhurst, S.M., Gronroos, E., et al. (2013). Replication stress links structural and 
numerical cancer chromosomal instability. Nature 494, 492-496. 
	   89	  
Carter, S.L., Eklund, A.C., Kohane, I.S., Harris, L.N., and Szallasi, Z. (2006). A signature of 
chromosomal instability inferred from gene expression profiles predicts clinical outcome in 
multiple human cancers. Nat Genet 38, 1043-1048. 
Chao, C., Hergenhahn, M., Kaeser, M.D., Wu, Z., Saito, S., Iggo, R., Hollstein, M., Appella, E., 
and Xu, Y. (2003). Cell type- and promoter-specific roles of Ser18 phosphorylation in 
regulating p53 responses. J Biol Chem 278, 41028-41033. 
Chen, Z., Fillmore, C.M., Hammerman, P.S., Kim, C.F., and Wong, K.K. (2014). Non-small-
cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 14, 535-546. 
Choi, C.M., Seo, K.W., Jang, S.J., Oh, Y.M., Shim, T.S., Kim, W.S., Lee, D.S., and Lee, S.D. 
(2009). Chromosomal instability is a risk factor for poor prognosis of adenocarcinoma of the 
lung: Fluorescence in situ hybridization analysis of paraffin-embedded tissue from Korean 
patients. Lung cancer 64, 66-70. 
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A.J., Barradas, M., Benguria, A., 
Zaballos, A., Flores, J.M., Barbacid, M., et al. (2005). Tumour biology: senescence in 
premalignant tumours. Nature 436, 642. 
Crasta, K., Ganem, N.J., Dagher, R., Lantermann, A.B., Ivanova, E.V., Pan, Y., Nezi, L., 
Protopopov, A., Chowdhury, D., and Pellman, D. (2012). DNA breaks and chromosome 
pulverization from errors in mitosis. Nature 482, 53-58. 
Deng, C., Zhang, P., Harper, J.W., Elledge, S.J., and Leder, P. (1995). Mice lacking 
p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 
82, 675-684. 
Der, C.J., Krontiris, T.G., and Cooper, G.M. (1982). Transforming genes of human bladder and 
lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma 
viruses. Proc Natl Acad Sci U S A 79, 3637-3640. 
Diaz-Rodriguez, E., Sotillo, R., Schvartzman, J.M., and Benezra, R. (2008). Hec1 
overexpression hyperactivates the mitotic checkpoint and induces tumor formation in vivo. Proc 
Natl Acad Sci U S A 105, 16719-16724. 
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A.K., Moore, M., Finlay, C., and Levine, 
A.J. (1993). Gain of function mutations in p53. Nat Genet 4, 42-46. 
Dryja, T.P., Friend, S., and Weinberg, R.A. (1986). Genetic sequences that predispose to 
retinoblastoma and osteosarcoma. Symposium on Fundamental Cancer Research 39, 115-119. 
Duijf, P.H., and Benezra, R. (2013). The cancer biology of whole-chromosome instability. 
Oncogene 32, 4727-4736. 
Duijf, P.H., Schultz, N., and Benezra, R. (2012). Cancer cells preferentially lose small 
chromosomes. Int J Cancer. 
Dulbecco, R. (1967). The induction of cancer by viruses. Scientific American 216, 28-37. 
Duncan, A.W., Taylor, M.H., Hickey, R.D., Hanlon Newell, A.E., Lenzi, M.L., Olson, S.B., 
Finegold, M.J., and Grompe, M. (2010). The ploidy conveyor of mature hepatocytes as a source 
of genetic variation. Nature 467, 707-710. 
	   90	  
Ellegren, H. (2004). Microsatellites: simple sequences with complex evolution. Nature reviews 
Genetics 5, 435-445. 
Evans, T., Rosenthal, E.T., Youngblom, J., Distel, D., and Hunt, T. (1983). Cyclin: a protein 
specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell 
33, 389-396. 
Fearon, E.R., and Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. Cell 61, 
759-767. 
Fisher, G.H., Wellen, S.L., Klimstra, D., Lenczowski, J.M., Tichelaar, J.W., Lizak, M.J., 
Whitsett, J.A., Koretsky, A., and Varmus, H.E. (2001). Induction and apoptotic regression of 
lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor 
suppressor genes. Genes Dev 15, 3249-3262. 
Flemming, W. (1878). Zur Kenntniss der Zelle und ihrer Theilungs-Erscheinungen. Schriften 
des Naturwissenschaftlichen Vereins für Schleswig-Holstein 3: 23–27. 
Foster, D.A., Yellen, P., Xu, L., and Saqcena, M. (2010). Regulation of G1 Cell Cycle 
Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth 
Checkpoint(s). Genes & cancer 1, 1124-1131. 
Galdiero, M.R., Garlanda, C., Jaillon, S., Marone, G., and Mantovani, A. (2013). Tumor 
associated macrophages and neutrophils in tumor progression. Journal of cellular physiology 
228, 1404-1412. 
Gandarillas, A., and Freije, A. (2014). Cycling up the epidermis: reconciling 100 years of 
debate. Experimental dermatology 23, 87-91. 
Gao, C., Furge, K., Koeman, J., Dykema, K., Su, Y., Cutler, M.L., Werts, A., Haak, P., and 
Vande Woude, G.F. (2007). Chromosome instability, chromosome transcriptome, and clonal 
evolution of tumor cell populations. Proc Natl Acad Sci U S A 104, 8995-9000. 
Garcia-Cao, I., Garcia-Cao, M., Martin-Caballero, J., Criado, L.M., Klatt, P., Flores, J.M., 
Weill, J.C., Blasco, M.A., and Serrano, M. (2002). "Super p53" mice exhibit enhanced DNA 
damage response, are tumor resistant and age normally. Embo J 21, 6225-6235. 
Gartner, H.V., Seidl, C., Luckenbach, C., Schumm, G., Seifried, E., Ritter, H., and Bultmann, 
B. (1996). Genetic analysis of a sarcoma accidentally transplanted from a patient to a surgeon. 
N Engl J Med 335, 1494-1496. 
Gascoigne, K.E., and Taylor, S.S. (2008). Cancer cells display profound intra- and interline 
variation following prolonged exposure to antimitotic drugs. Cancer Cell 14, 111-122. 
Gey GO, C.W., Kubicek MT. (1952). Tissue culture studies of the proliferative capacity of 
cervical carcinoma and normal epithelium. Cancer Res 
 12, 264-265. 
Giannakakou, P., Robey, R., Fojo, T., and Blagosklonny, M.V. (2001). Low concentrations of 
paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: 
molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 20, 3806-3813. 
Glotzer, M., Murray, A.W., and Kirschner, M.W. (1991). Cyclin is degraded by the ubiquitin 
pathway. Nature 349, 132-138. 
	   91	  
Gossen, M., and Bujard, H. (1992). Tight control of gene expression in mammalian cells by 
tetracycline-responsive promoters. Proc Natl Acad Sci U S A 89, 5547-5551. 
Hajdu, S.I. (2011). A note from history: landmarks in history of cancer, part 1. Cancer 117, 
1097-1102. 
Hajdu, S.I. (2012). A note from history: landmarks in history of cancer, part 4. Cancer 118, 
4914-4928. 
Hajdu, S.I., and Darvishian, F. (2013). A note from history: landmarks in history of cancer, part 
5. Cancer 119, 1450-1466. 
Hajdu, S.I., and Vadmal, M.S. (2010). The use of tobacco. Ann Clin Lab Sci 40, 178-181. 
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70. 
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 
646-674. 
Harley, M.E., Allan, L.A., Sanderson, H.S., and Clarke, P.R. (2010). Phosphorylation of Mcl-1 
by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. Embo J 29, 
2407-2420. 
Harper, J.W., Elledge, S.J., Keyomarsi, K., Dynlacht, B., Tsai, L.H., Zhang, P., Dobrowolski, 
S., Bai, C., Connell-Crowley, L., Swindell, E., et al. (1995). Inhibition of cyclin-dependent 
kinases by p21. Molecular biology of the cell 6, 387-400. 
Hartwell, L.H., and Smith, D. (1985). Altered fidelity of mitotic chromosome transmission in 
cell cycle mutants of S. cerevisiae. Genetics 110, 381-395. 
Hartwell, L.H., and Weinert, T.A. (1989). Checkpoints: controls that ensure the order of cell 
cycle events. Science 246, 629-634. 
Haruki, N., Saito, H., Harano, T., Nomoto, S., Takahashi, T., Osada, H., Fujii, Y., and 
Takahashi, T. (2001). Molecular analysis of the mitotic checkpoint genes BUB1, BUBR1 and 
BUB3 in human lung cancers. Cancer letters 162, 201-205. 
Hassold, T., Hall, H., and Hunt, P. (2007). The origin of human aneuploidy: where we have 
been, where we are going. Hum Mol Genet 16 Spec No. 2, R203-208. 
Hatch, E.M., Fischer, A.H., Deerinck, T.J., and Hetzer, M.W. (2013). Catastrophic nuclear 
envelope collapse in cancer cell micronuclei. Cell 154, 47-60. 
Hoyt, M.A., Totis, L., and Roberts, B.T. (1991). S. cerevisiae genes required for cell cycle 
arrest in response to loss of microtubule function. Cell 66, 507-517. 
Imielinski, M., Berger, A.H., Hammerman, P.S., Hernandez, B., Pugh, T.J., Hodis, E., Cho, J., 
Suh, J., Capelletti, M., Sivachenko, A., et al. (2012). Mapping the hallmarks of lung 
adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120. 
Iwanaga, Y., Chi, Y.H., Miyazato, A., Sheleg, S., Haller, K., Peloponese, J.M., Jr., Li, Y., 
Ward, J.M., Benezra, R., and Jeang, K.T. (2007). Heterozygous deletion of mitotic arrest-
deficient protein 1 (MAD1) increases the incidence of tumors in mice. Cancer Res 67, 160-166. 
Jacks, T. (1996). Lessons from the p53 mutant mouse. J Cancer Res Clin Oncol 122, 319-327. 
	   92	  
Jacks, T., Remington, L., Williams, B.O., Schmitt, E.M., Halachmi, S., Bronson, R.T., and 
Weinberg, R.A. (1994). Tumor spectrum analysis in p53-mutant mice. Curr Biol 4, 1-7. 
Jackson, E.L., Willis, N., Mercer, K., Bronson, R.T., Crowley, D., Montoya, R., Jacks, T., and 
Tuveson, D.A. (2001). Analysis of lung tumor initiation and progression using conditional 
expression of oncogenic K-ras. Genes Dev 15, 3243-3248. 
Janssen, A., Beerling, E., Medema, R., and van Rheenen, J. (2013). Intravital FRET imaging of 
tumor cell viability and mitosis during chemotherapy. PLoS One 8, e64029. 
Janssen, A., and Medema, R.H. (2013). Genetic instability: tipping the balance. Oncogene 32, 
4459-4470. 
Jeganathan, K., Malureanu, L., Baker, D.J., Abraham, S.C., and van Deursen, J.M. (2007). 
Bub1 mediates cell death in response to chromosome missegregation and acts to suppress 
spontaneous tumorigenesis. The Journal of cell biology 179, 255-267. 
Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., and Forman, D. (2011). Global cancer 
statistics. CA: a cancer journal for clinicians 61, 69-90. 
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R.T., Crowley, D., Tuveson, D.A., and 
Jacks, T. (2001). Somatic activation of the K-ras oncogene causes early onset lung cancer in 
mice. Nature 410, 1111-1116. 
Kabeche, L., and Compton, D.A. (2012). Checkpoint-independent stabilization of kinetochore-
microtubule attachments by Mad2 in human cells. Curr Biol 22, 638-644. 
Kalitsis, P., Earle, E., Fowler, K.J., and Choo, K.H. (2000). Bub3 gene disruption in mice 
reveals essential mitotic spindle checkpoint function during early embryogenesis. Genes Dev 
14, 2277-2282. 
Kalitsis, P., Fowler, K.J., Griffiths, B., Earle, E., Chow, C.W., Jamsen, K., and Choo, K.H. 
(2005). Increased chromosome instability but not cancer predisposition in haploinsufficient 
Bub3 mice. Genes Chromosomes Cancer 44, 29-36. 
Kastan, M.B., Zhan, Q., el-Deiry, W.S., Carrier, F., Jacks, T., Walsh, W.V., Plunkett, B.S., 
Vogelstein, B., and Fornace, A.J., Jr. (1992). A mammalian cell cycle checkpoint pathway 
utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71, 587-597. 
Kazushi Inoue, E.F., Dejan Maglic and Sinan Zhu (2013). (2013). Genetically Engineered 
Mouse Models for Human Lung Cancer, Oncogenesis, Inflammatory and Parasitic Tropical 
Diseases of the Lung, Prof. Jean-Marie Kayembe (Ed.), ISBN: 978-953-51-0982-2, InTech, 
DOI: 10.5772/53721.  
Kerbel, R., and Folkman, J. (2002). Clinical translation of angiogenesis inhibitors. Nat Rev 
Cancer 2, 727-739. 
Kidokoro, T., Tanikawa, C., Furukawa, Y., Katagiri, T., Nakamura, Y., and Matsuda, K. (2008). 
CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 27, 
1562-1571. 
Kim, E.M., Park, J.K., Hwang, S.G., Kim, W.J., Liu, Z.G., Kang, S.W., and Um, H.D. (2014). 
Nuclear and cytoplasmic p53 suppress cell invasion by inhibiting respiratory Complex-I activity 
via Bcl-2 family proteins. Oncotarget. 
	   93	  
Kirby, A.C., Coles, M.C., and Kaye, P.M. (2009). Alveolar macrophages transport pathogens to 
lung draining lymph nodes. J Immunol 183, 1983-1989. 
Knouse, K.A., Wu, J., Whittaker, C.A., and Amon, A. (2014). Single cell sequencing reveals 
low levels of aneuploidy across mammalian tissues. Proc Natl Acad Sci U S A 111, 13409-
13414. 
Knudson, A.G., Jr. (1971). Mutation and cancer: statistical study of retinoblastoma. Proc Natl 
Acad Sci U S A 68, 820-823. 
Koshland, D.E., Jr. (1993). Molecule of the year. Science 262, 1953. 
Kuffer, C., Kuznetsova, A.Y., and Storchova, Z. (2013). Abnormal mitosis triggers p53-
dependent cell cycle arrest in human tetraploid cells. Chromosoma 122, 305-318. 
Kuukasjarvi, T., Karhu, R., Tanner, M., Kahkonen, M., Schaffer, A., Nupponen, N., Pennanen, 
S., Kallioniemi, A., Kallioniemi, O.P., and Isola, J. (1997). Genetic heterogeneity and clonal 
evolution underlying development of asynchronous metastasis in human breast cancer. Cancer 
Res 57, 1597-1604. 
Landry, J.J., Pyl, P.T., Rausch, T., Zichner, T., Tekkedil, M.M., Stutz, A.M., Jauch, A., Aiyar, 
R.S., Pau, G., Delhomme, N., et al. (2013). The genomic and transcriptomic landscape of a 
HeLa cell line. G3 3, 1213-1224. 
Lane, D.P. (1992). Worrying about p53. Curr Biol 2, 581-583. 
Lebert (1845). Physiologie Pathologique ou Récherches Clinique, Experimentales et 
Microscopiques. (Paris: Bailliére). 
Lengauer, C., Kinzler, K.W., and Vogelstein, B. (1997). Genetic instability in colorectal 
cancers. Nature 386, 623-627. 
Li, F.P., and Fraumeni, J.F., Jr. (1969). Soft-tissue sarcomas, breast cancer, and other 
neoplasms. A familial syndrome? Annals of internal medicine 71, 747-752. 
Li, M., Fang, X., Baker, D.J., Guo, L., Gao, X., Wei, Z., Han, S., van Deursen, J.M., and Zhang, 
P. (2010). The ATM-p53 pathway suppresses aneuploidy-induced tumorigenesis. Proc Natl 
Acad Sci U S A 107, 14188-14193. 
Li, R., and Murray, A.W. (1991). Feedback control of mitosis in budding yeast. Cell 66, 519-
531. 
Li, Y., and Benezra, R. (1996). Identification of a human mitotic checkpoint gene: hsMAD2. 
Science 274, 246-248. 
Liu, G., McDonnell, T.J., Montes de Oca Luna, R., Kapoor, M., Mims, B., El-Naggar, A.K., 
and Lozano, G. (2000). High metastatic potential in mice inheriting a targeted p53 missense 
mutation. Proc Natl Acad Sci U S A 97, 4174-4179. 
Liu, G., Parant, J.M., Lang, G., Chau, P., Chavez-Reyes, A., El-Naggar, A.K., Multani, A., 
Chang, S., and Lozano, G. (2004). Chromosome stability, in the absence of apoptosis, is critical 
for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 36, 63-68. 
Look, A.T. (1997). Oncogenic transcription factors in the human acute leukemias. Science 278, 
1059-1064. 
	   94	  
Luo, J., Emanuele, M.J., Li, D., Creighton, C.J., Schlabach, M.R., Westbrook, T.F., Wong, 
K.K., and Elledge, S.J. (2009). A genome-wide RNAi screen identifies multiple synthetic lethal 
interactions with the Ras oncogene. Cell 137, 835-848. 
Lynch, H.T., Shaw, M.W., Magnuson, C.W., Larsen, A.L., and Krush, A.J. (1966). Hereditary 
factors in cancer. Study of two large midwestern kindreds. Archives of internal medicine 117, 
206-212. 
Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., 
Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., et al. (2004). Activating mutations in 
the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to 
gefitinib. N Engl J Med 350, 2129-2139. 
Macleod, K.F., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kinzler, K., Vogelstein, B., and 
Jacks, T. (1995). p53-dependent and independent expression of p21 during cell growth, 
differentiation, and DNA damage. Genes Dev 9, 935-944. 
MacPherson, D., Kim, J., Kim, T., Rhee, B.K., Van Oostrom, C.T., DiTullio, R.A., Venere, M., 
Halazonetis, T.D., Bronson, R., De Vries, A., et al. (2004). Defective apoptosis and B-cell 
lymphomas in mice with p53 point mutation at Ser 23. Embo J 23, 3689-3699. 
Mallakin, A., Sugiyama, T., Taneja, P., Matise, L.A., Frazier, D.P., Choudhary, M., Hawkins, 
G.A., D'Agostino, R.B., Jr., Willingham, M.C., and Inoue, K. (2007). Mutually exclusive 
inactivation of DMP1 and ARF/p53 in lung cancer. Cancer Cell 12, 381-394. 
Malumbres, M. (2014). Cyclin-dependent kinases. Genome biology 15, 122. 
Mariotto, A.B., Yabroff, K.R., Shao, Y., Feuer, E.J., and Brown, M.L. (2011). Projections of the 
cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103, 117-128. 
Marxer, M., Ma, H.T., Man, W.Y., and Poon, R.Y. (2014). p53 deficiency enhances mitotic 
arrest and slippage induced by pharmacological inhibition of Aurora kinases. Oncogene 33, 
3550-3560. 
Meuwissen, R., and Berns, A. (2005). Mouse models for human lung cancer. Genes Dev 19, 
643-664. 
Michel, L., Diaz-Rodriguez, E., Narayan, G., Hernando, E., Murty, V.V., and Benezra, R. 
(2004). Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation 
and mitotic failure in human somatic cells. Proc Natl Acad Sci U S A 101, 4459-4464. 
Michel, L.S., Liberal, V., Chatterjee, A., Kirchwegger, R., Pasche, B., Gerald, W., Dobles, M., 
Sorger, P.K., Murty, V.V., and Benezra, R. (2001). MAD2 haplo-insufficiency causes 
premature anaphase and chromosome instability in mammalian cells. Nature 409, 355-359. 
Mills, N.E., Fishman, C.L., Rom, W.N., Dubin, N., and Jacobson, D.R. (1995). Increased 
prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res 55, 1444-1447. 
Mitelman, F., Johansson, B., Mandahl, N., and Mertens, F. (1997). Clinical significance of 
cytogenetic findings in solid tumors. Cancer genetics and cytogenetics 95, 1-8. 
Morgenbesser, S.D., Williams, B.O., Jacks, T., and DePinho, R.A. (1994). p53-dependent 
apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 371, 72-74. 
	   95	  
Moullan, N., Mouchiroud, L., Wang, X., Ryu, D., Williams, E.G., Mottis, A., Jovaisaite, V., 
Frochaux, M.V., Quiros, P.M., Deplancke, B., et al. (2015). Tetracyclines Disturb 
Mitochondrial Function across Eukaryotic Models: A Call for Caution in Biomedical Research. 
Cell Rep. 
Muller (1838). Ueber den feinern Bau und die Formen der 
krankhaften Geschwulste. 
Murchison, E.P., Schulz-Trieglaff, O.B., Ning, Z., Alexandrov, L.B., Bauer, M.J., Fu, B., Hims, 
M., Ding, Z., Ivakhno, S., Stewart, C., et al. (2012). Genome sequencing and analysis of the 
Tasmanian devil and its transmissible cancer. Cell 148, 780-791. 
Murga, M., Bunting, S., Montana, M.F., Soria, R., Mulero, F., Canamero, M., Lee, Y., 
McKinnon, P.J., Nussenzweig, A., and Fernandez-Capetillo, O. (2009). A mouse model of 
ATR-Seckel shows embryonic replicative stress and accelerated aging. Nat Genet 41, 891-898. 
Murgia, C., Pritchard, J.K., Kim, S.Y., Fassati, A., and Weiss, R.A. (2006). Clonal origin and 
evolution of a transmissible cancer. Cell 126, 477-487. 
Nam, H.J., and van Deursen, J.M. (2014). Cyclin B2 and p53 control proper timing of 
centrosome separation. Nature cell biology 16, 538-549. 
Nigg, E.A. (2002). Centrosome aberrations: cause or consequence of cancer progression? Nat 
Rev Cancer 2, 815-825. 
Nowell P, H.D. (1960).  
A minute chromosome in chronic granulocytic leukemia. Science 132 (3438): 1497. 
Nowell, P.C. (1976). The clonal evolution of tumor cell populations. Science 194, 23-28. 
Nurse, P.M. (December 9,2001). CYCLIN DEPENDENT KINASES AND CELL CYCLE 
CONTROL (Nobel Lecture). 
O'Farrell, P.H. (2011). Quiescence: early evolutionary origins and universality do not imply 
uniformity. Philosophical transactions of the Royal Society of London Series B, Biological 
sciences 366, 3498-3507. 
Pantoja, C., and Serrano, M. (1999). Murine fibroblasts lacking p21 undergo senescence and are 
resistant to transformation by oncogenic Ras. Oncogene 18, 4974-4982. 
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., 
Rusch, V., Fulton, L., et al. (2004). EGF receptor gene mutations are common in lung cancers 
from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. 
Proc Natl Acad Sci U S A 101, 13306-13311. 
Parada, L.F., Land, H., Weinberg, R.A., Wolf, D., and Rotter, V. (1984). Cooperation between 
gene encoding p53 tumour antigen and ras in cellular transformation. Nature 312, 649-651. 
Pardee, A.B. (1974). A restriction point for control of normal animal cell proliferation. Proc 
Natl Acad Sci U S A 71, 1286-1290. 
Pavelka, N., Rancati, G., Zhu, J., Bradford, W.D., Saraf, A., Florens, L., Sanderson, B.W., 
Hattem, G.L., and Li, R. (2010). Aneuploidy confers quantitative proteome changes and 
phenotypic variation in budding yeast. Nature 468, 321-325. 
	   96	  
Pavletich, N.P. (1999). Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, 
their cyclin activators, and Cip and INK4 inhibitors. Journal of molecular biology 287, 821-828. 
Perez de Castro, I., Aguirre-Portoles, C., Fernandez-Miranda, G., Canamero, M., Cowley, D.O., 
Van Dyke, T., and Malumbres, M. (2013). Requirements for Aurora-A in tissue regeneration 
and tumor development in adult mammals. Cancer Res 73, 6804-6815. 
Politi, K., Zakowski, M.F., Fan, P.D., Schonfeld, E.A., Pao, W., and Varmus, H.E. (2006). Lung 
adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers 
respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20, 
1496-1510. 
Pulciani, S., Santos, E., Lauver, A.V., Long, L.K., Robbins, K.C., and Barbacid, M. (1982). 
Oncogenes in human tumor cell lines: molecular cloning of a transforming gene from human 
bladder carcinoma cells. Proc Natl Acad Sci U S A 79, 2845-2849. 
Rao, C.V., Yang, Y.M., Swamy, M.V., Liu, T., Fang, Y., Mahmood, R., Jhanwar-Uniyal, M., 
and Dai, W. (2005). Colonic tumorigenesis in BubR1+/-ApcMin/+ compound mutant mice is 
linked to premature separation of sister chromatids and enhanced genomic instability. Proc Natl 
Acad Sci U S A 102, 4365-4370. 
Rausch, T., Jones, D.T., Zapatka, M., Stutz, A.M., Zichner, T., Weischenfeldt, J., Jager, N., 
Remke, M., Shih, D., Northcott, P.A., et al. (2012). Genome sequencing of pediatric 
medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148, 59-
71. 
Rehen, S.K., Yung, Y.C., McCreight, M.P., Kaushal, D., Yang, A.H., Almeida, B.S., 
Kingsbury, M.A., Cabral, K.M., McConnell, M.J., Anliker, B., et al. (2005). Constitutional 
aneuploidy in the normal human brain. J Neurosci 25, 2176-2180. 
Ricke, R.M., Jeganathan, K.B., and van Deursen, J.M. (2011). Bub1 overexpression induces 
aneuploidy and tumor formation through Aurora B kinase hyperactivation. The Journal of cell 
biology 193, 1049-1064. 
Rothschild, B.M., Witzke, B.J., and Hershkovitz, I. (1999). Metastatic cancer in the Jurassic. 
Lancet 354, 398. 
Schvartzman, J.M., Duijf, P.H., Sotillo, R., Coker, C., and Benezra, R. (2011). Mad2 is a critical 
mediator of the chromosome instability observed upon Rb and p53 pathway inhibition. Cancer 
Cell 19, 701-714. 
Schvartzman, J.M., Sotillo, R., and Benezra, R. (2010). Mitotic chromosomal instability and 
cancer: mouse modelling of the human disease. Nat Rev Cancer 10, 102-115. 
Sedivy, J.M. (1998). Can ends justify the means?: telomeres and the mechanisms of replicative 
senescence and immortalization in mammalian cells. Proc Natl Acad Sci U S A 95, 9078-9081. 
Segal, D.J., and McCoy, E.E. (1974). Studies on Down's syndrome in tissue culture. I. Growth 
rates and protein contents of fibroblast cultures. Journal of cellular physiology 83, 85-90. 
Senovilla, L., Vitale, I., Martins, I., Tailler, M., Pailleret, C., Michaud, M., Galluzzi, L., 
Adjemian, S., Kepp, O., Niso-Santano, M., et al. (2012). An immunosurveillance mechanism 
controls cancer cell ploidy. Science 337, 1678-1684. 
	   97	  
Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. (1997). Oncogenic ras 
provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 
88, 593-602. 
Shames, D.S., and Wistuba, II (2014). The evolving genomic classification of lung cancer. The 
Journal of pathology 232, 121-133. 
Shi, J., Zhou, Y., Huang, H.C., and Mitchison, T.J. (2011). Navitoclax (ABT-263) accelerates 
apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL. Cancer Res 71, 4518-
4526. 
Silk, A.D., Zasadil, L.M., Holland, A.J., Vitre, B., Cleveland, D.W., and Weaver, B.A. (2013). 
Chromosome missegregation rate predicts whether aneuploidy will promote or suppress tumors. 
Proc Natl Acad Sci U S A 110, E4134-4141. 
Sinnott, R., Winters, L., Larson, B., Mytsa, D., Taus, P., Cappell, K.M., and Whitehurst, A.W. 
(2014). Mechanisms promoting escape from mitotic stress-induced tumor cell death. Cancer 
Res 74, 3857-3869. 
Sotillo, R., Dubus, P., Martin, J., de la Cueva, E., Ortega, S., Malumbres, M., and Barbacid, M. 
(2001). Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 
inhibitors. Embo J 20, 6637-6647. 
Sotillo, R., Hernando, E., Diaz-Rodriguez, E., Teruya-Feldstein, J., Cordon-Cardo, C., Lowe, 
S.W., and Benezra, R. (2007). Mad2 overexpression promotes aneuploidy and tumorigenesis in 
mice. Cancer Cell 11, 9-23. 
Sotillo, R., Schvartzman, J.M., and Benezra, R. (2009). Very CIN-ful: whole chromosome 
instability promotes tumor suppressor loss of heterozygosity. Cancer Cell 16, 451-452. 
Sotillo, R., Schvartzman, J.M., Socci, N.D., and Benezra, R. (2010). Mad2-induced 
chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature 464, 
436-440. 
Soussi, T., and Beroud, C. (2001). Assessing TP53 status in human tumours to evaluate clinical 
outcome. Nat Rev Cancer 1, 233-240. 
Spencer, F., and Hieter, P. (1992). Centromere DNA mutations induce a mitotic delay in 
Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 89, 8908-8912. 
Stehelin, D., Varmus, H.E., Bishop, J.M., and Vogt, P.K. (1976). DNA related to the 
transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260, 
170-173. 
Stewart, B.W., Wild, C., International Agency for Research on Cancer, and World Health 
Organization (2014). World cancer report 2014 (Lyon, France 
Geneva, Switzerland: International Agency for Research on Cancer 
WHO Press). 
Storchova, Z., and Kuffer, C. (2008). The consequences of tetraploidy and aneuploidy. J Cell 
Sci 121, 3859-3866. 
Sullivan, B.A., Blower, M.D., and Karpen, G.H. (2001). Determining centromere identity: 
cyclical stories and forking paths. Nature reviews Genetics 2, 584-596. 
	   98	  
Tahara, H., Sato, E., Noda, A., and Ide, T. (1995). Increase in expression level of 
p21sdi1/cip1/waf1 with increasing division age in both normal and SV40-transformed human 
fibroblasts. Oncogene 10, 835-840. 
Tang, Y.C., Williams, B.R., Siegel, J.J., and Amon, A. (2011). Identification of aneuploidy-
selective antiproliferation compounds. Cell 144, 499-512. 
Tannous, B.A., Kerami, M., Van der Stoop, P.M., Kwiatkowski, N., Wang, J., Zhou, W., 
Kessler, A.F., Lewandrowski, G., Hiddingh, L., Sol, N., et al. (2013). Effects of the selective 
MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs. J Natl Cancer Inst 
105, 1322-1331. 
Temin, H.M., and Mizutani, S. (1970). RNA-dependent DNA polymerase in virions of Rous 
sarcoma virus. Nature 226, 1211-1213. 
Terradas, M., Martin, M., Tusell, L., and Genesca, A. (2010). Genetic activities in micronuclei: 
is the DNA entrapped in micronuclei lost for the cell? Mutation research 705, 60-67. 
Thompson, S.L., and Compton, D.A. (2008). Examining the link between chromosomal 
instability and aneuploidy in human cells. The Journal of cell biology 180, 665-672. 
Thompson, S.L., and Compton, D.A. (2010). Proliferation of aneuploid human cells is limited 
by a p53-dependent mechanism. The Journal of cell biology 188, 369-381. 
Thompson, S.L., and Compton, D.A. (2011). Chromosome missegregation in human cells arises 
through specific types of kinetochore-microtubule attachment errors. Proc Natl Acad Sci U S A 
108, 17974-17978. 
Torres, E.M., Sokolsky, T., Tucker, C.M., Chan, L.Y., Boselli, M., Dunham, M.J., and Amon, 
A. (2007). Effects of aneuploidy on cellular physiology and cell division in haploid yeast. 
Science 317, 916-924. 
Varetti, G., Pellman, D., and Gordon, D.J. (2014). Aurea Mediocritas: The Importance of a 
Balanced Genome. Cold Spring Harbor perspectives in biology. 
Walmsley, R.M., and Tate, M. (2012). The GADD45a-GFP GreenScreen HC assay. Methods in 
molecular biology 817, 231-250. 
Warburg, O. (1956). On the origin of cancer cells. Science 123, 309-314. 
Watson, J.D., and Crick, F.H. (1953). Molecular structure of nucleic acids; a structure for 
deoxyribose nucleic acid. Nature 171, 737-738. 
Weaver, B.A., Silk, A.D., Montagna, C., Verdier-Pinard, P., and Cleveland, D.W. (2007). 
Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11, 25-36. 
Weiss, E., and Winey, M. (1996). The Saccharomyces cerevisiae spindle pole body duplication 
gene MPS1 is part of a mitotic checkpoint. The Journal of cell biology 132, 111-123. 
Williams, B.R., Prabhu, V.R., Hunter, K.E., Glazier, C.M., Whittaker, C.A., Housman, D.E., 
and Amon, A. (2008). Aneuploidy affects proliferation and spontaneous immortalization in 
mammalian cells. Science 322, 703-709. 
Yamamoto, N., Jiang, P., Yang, M., Xu, M., Yamauchi, K., Tsuchiya, H., Tomita, K., Wahl, 
G.M., Moossa, A.R., and Hoffman, R.M. (2004). Cellular dynamics visualized in live cells in 
	   99	  
vitro and in vivo by differential dual-color nuclear-cytoplasmic fluorescent-protein expression. 
Cancer Res 64, 4251-4256. 
Zack, T.I., Schumacher, S.E., Carter, S.L., Cherniack, A.D., Saksena, G., Tabak, B., Lawrence, 
M.S., Zhang, C.Z., Wala, J., Mermel, C.H., et al. (2013). Pan-cancer patterns of somatic copy 
number alteration. Nat Genet 45, 1134-1140. 
Zasadil, L.M., Andersen, K.A., Yeum, D., Rocque, G.B., Wilke, L.G., Tevaarwerk, A.J., 
Raines, R.T., Burkard, M.E., and Weaver, B.A. (2014). Cytotoxicity of paclitaxel in breast 
cancer is due to chromosome missegregation on multipolar spindles. Science translational 
medicine 6, 229ra243. 
Zhivotovsky, B., and Kroemer, G. (2004). Apoptosis and genomic instability. Nature reviews 
Molecular cell biology 5, 752-762. 
Zienolddiny, S., Ryberg, D., Arab, M.O., Skaug, V., and Haugen, A. (2001). Loss of 
heterozygosity is related to p53 mutations and smoking in lung cancer. British journal of cancer 
84, 226-231. 	  
